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Abstract
The interactions between FGF and fibroblast growth factor receptors are responsible for the
regulation of key cellular processes. FGF is important in both germ cell and embryonic
developments.

FGF continues to play important roles during adulthood by regulating

embryogenesis, cell differentiation, and wound healing (1-7). The regulations of these cellular
events are initiated through FGF binding to the fibroblast growth factor receptors. The complex
formed by FGF and the receptor involves a key interaction with heparin. Through interactions
with heparin, the FGF, FGFR and Heparin form a 2:2:2 complex (8). This complex formation
results in autophosphorylation in the tyrosine kinase domain in the cytoplasm. The
autophosphorylation events lead to downstream signaling that result in the regulation of
previously mentioned cellular processes (9, 10). Mutations within the FGF or FGFR may
interfere with signaling or protein stability. Changes in the signaling efficiency by FGF or the
FGFR are shown to lead to disease states There exist many point mutations in the FGF receptor
that result in craniofacial, hypogonadotropic hypogonadism, anosmia, and tumor development.
Using site-directed mutagenesis we have shown non-covalent interactions formed by Kallmann
syndrome linked mutations result in a loss-of-binding between FGF and the FGF receptor. This
evidence has shown that the non-covalent ligand binding interactions lost are due to changes in
the D2 structure or binding site. Additionally, the R203C mutation, linked to breast cancer, was
tested and determined to break a D2 stabilizing cation-π bond. The cation-π stabilized the
binding interaction with heparin and provides stability to the D2 domain. Although the decreased
stability of the D2 domain supports a loss-of-function, we are currently investigating
intermolecular disulfide bond formation between adjacent receptor. This is a known mechanism
among FGF receptors that may lead to signaling in the absence of a ligand.
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Introduction
I. Fibroblast Growth Factor Receptor Structure
The fibroblast growth factor receptor signaling has been shown to play a critical role in
embryonic development, angiogenesis, wound healing, cell differentiation and migration (1114). The fibroblast growth factor receptors (FGFR) consist of 3 extracellular domains (D1, D2,
and D3), a single transmembrane helix, juxtamembrane domain and two cytoplasmic tyrosine
kinase domains. A total of four FGF receptors make up the human FGFR family. FGFR ligands,
FGF and heparin are the ligands that bind to and activate the FGF receptor. The FGF receptor is
activated when a 2: 2: 2 extracellular dimeric complex is formed containing two heparin
molecules and two FGF molecules bound to two FGF receptors (8). Following the binding of
heparin and FGF to the extracellular D2-D3 domains of the FGF receptor, autophosphorylation
of the cytoplasmic tyrosine kinase domains occurs. (9, 10) Autophosphorylation of the tyrosine
kinase domains is the mechanism by which signal transduction occurs in the FGFRs(15). The
role of D2 on the FGFR is critical for signal transduction following the binding of FGF.
Mutations that occur on the D2 domain have been associated with Kallmann syndrome, breast
cancer and colon cancer (16-18). Similarly, mutations on the D3 domain have been associated
with Pfeifer syndrome and Cruzon syndrome. Many of the disease-linked mutations occurring in
the FGF receptors are located in the extracellular D1, D2 and D3 domains.
The D1 domain is the first of three extracellular globular domains of the FGFR. The D1
domain is a β-sandwich structure composed of 99 residues forming 10 β-strands. The D1 domain
molecular weight is approximately 10.4 kDa (19). The D1 domain is linked to the D2 domain by
a 24 amino acid linker domain. The linker between the D1 and D2 domain contains a patch of
eleven residues formed by 9 residues that are aspartic acid or glutamic acid. This negatively
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charged region in the linker domain is termed the “acid box” and along with the D1 domain are
believed to play a role in an autoinhibition mechanism (20).
The D2 domain is a 13.7 kDa that consists of 12 beta strands. The beta strands of D2
form two β-sheets, which allows for a β-sandwich structure (21). Two cysteine residues form a
disulfide bond between the two beta sheets and are highly conserved in the FGFRs. The D2
domain is the binding site for ligands heparin and FGF. The heparin-binding site on the D2
domain is highly conserved among the FGF receptors. The heparin-binding site on the D2
domain is made of residues K160, K163, K172, K175, and K177 (figure 1.1) (8) The five-lysine
residues on the D2 domain form nine hydrogen bonds with the sulfate groups of heparin. The
active dimeric complex of FGF, FGFR and heparin is a 2: 2: 2 complex (8). The requirement of
heparin for FGFR signaling and autophosphorylation is highly debated and not fully understood.

Figure 1.1 - Shows the chimera representation of the x-ray structure of the D2 domain in
complex with heparin (pdb:1EV2) (8). The figure shows the dimeric structure with the heparin
molecules oriented between the two D2 domains.
FGF receptors 1-4 have been shown to interact with FGF. The structure of D2 forms a
hydrophobic pocket near the C-terminal to form the FGF binding site. The beta strands of D2
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making up the FGF binding site include: βA’ strand and βG strand at the C-terminal end of D2.
Residues located on the βA’ and

Figure 1.2 – Chimera representation of FGFR2 D2-D3 bound to FGF-2 (pdb: 1EV2). The
FGFR2 D2, D3 and linker domains are colored in green. Fibroblast growth factor 2 bound to the
FGFR is colored in red. The FGF binding site on the D2 domain is located at the βA’ and βG.
βG strands near the binding site are highly conserved. The D2 residues forming the binding
interaction with FGF include A167, H166 and V168 (8). Valine 248 and the aliphatic portion of
arginine 250 in the D2-D3 linker domain form a hydrophobic interaction with FGF.
Additionally, Asp 282 in the D3 domain forms a hydrogen bond with Arg-250 further stabilizing
3

the FGFR-FGF interaction (8). The D2 receptor is capable of binding FGF without the D3 or
linker domains (21). The FGF binding site on the D3 domain includes the βB’-βC, βC’-βE and
βF-βG. Asp-320 located on the D3 domain forms a hydrogen bond with FGF. Additionally,
proline 285, His 286 and Gly 315 of the D3 domain form hydrophobic interactions FGF (22).
Splice variants in the FGFR’s allows for variations in the binding site found on the D3 domain.
The D3 domain is the third extracellular domain located nearest to the cell membrane. A
13-residue linker domain connects the D2 domain with the D3 domain. The D3 domain is
composed of 97 amino acids forming 9 beta-strands. The 9 beta strands form a beta sandwich
structure containing one disulfide bond. The binding site of FGF is primarily located on the D2
domain. However, there are additional non-covalent interactions formed between FGF and the
D3 domain.

Figure 1.3 – Splice variants that occur in FGFR’s 1 – 4. FGFR’s 1 and 2 are shown to exist with
and without the D1 domain. Additionally, FGFR-2 variants may have an alternate c-terminus.
The “acid-box” is present in all four of the FGF receptors, but may be absent one of the FGFR2
variants.
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FGFR splice variants allow for an increased binding selectivity among the 22 FGF
proteins expressed in humans. The possible splice variants are shown in figure 1.3. The D1
domain and the acid-box have been suggested to be required in an auto regulation mechanism.
Cleavage of the D1 domain or removal of the acid-box may be a mechanism to increase
signaling of the FGFR. FGF receptors 1 and 2 splice variants to include and remove the D1
domain and the acid-box. The D3 domain of FGFR-1, FGFR-2 and FGFR-3 encoded by the exon
Ig IIIa is spliced to form the Ig IIIb or Ig IIIc variants. Exon splice variants of the FGFR includes
exons a, b and c. Exon 7 (denoted exon “a”) encodes from the N-terminal region of the D3
domain. Exons 8 (denoted exon “b”) and exon 9 (denoted “c”)
FGF Receptor Isoform

Ligand Specificity

FGFR1b

FGF1, FGF2, FGF3, FGF10

FGFR1c

FGF1, FGF2, FGF4, FGF5, FGF6

FGFR2b

FGF1, FGF3, FGF7, FGF10, FGF22

FGFR2c

FGF1, FGF2, FGF4, FGF6, FGF9, FGF17, FGF18

FGFR3b

FGF1, FGF9

FGFR3c

FGF1, FGF2, FGF4, FGF8, FGF9, FGF17, FGF18, FGF23

FGFR4

FGF1, FGF2, FGF4, FGF6, FGF8, FGF8, FGF9, FGF16,
FGF17, FGF18, FGF19

Table 1.4 - Ligands capable of binding to each of the FGFR isoforms. The table provides
evidence that FGF1 acts as a universal binding ligand (23, 24).
encode for the c- terminal segment of the D3 domain. These isoforms are denoted by the “b” or
“c” nomenclature following the FGFR. These variations allow varied specificity for the 22 FGFs
as it altars the residues that form interactions with FGF.
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Splice variants in the D3 domain occur in FGFRs 1, 2 and 3 but not in FGFR 4. Table 1.4
indicates the receptor – ligand specificities created by the b and c isoforms of the FGFR. Each of
the receptor forms is expressed in specific tissues. The FGFR2b form is exclusively expressed in
epithelial tissue. The FGFR2c isoform is exclusively found in mesenchyme tissue (25-27).The
developmental roles of the FGFRs have been shown to be widely varied for specific tissue types
and stages of development.
The use of knockout mice has been used to identify the roles of the FGFRs during
development. The FGFR1 defect mice resulted in a disruption of cell migration through the
primitive streak and ultimately embryonic death. The FGFR1c isoform disruption also results in
embryonic death (28). The FGFR1b isoform disruption does not reflect the FGFR1c results –
producing no identifiable changes in the phenotype {{;941 Bellusci,S. 1997;}}. Similar to the
FGFR1 - the FGFR2 defect mice also resulted in embryonic death. Mice containing the
disruption of the FGFR2b isoform resulted in phenotypes reflecting impaired development of the
lungs and limbs. The disruption of the FGFR2c isoform resulted in a phenotype reflecting
impaired skull and bone development. The FGFR2c isoform did not produce lethality in the
mice. Disruption of FGFR3 and FGFR4 in mice resulted in minor phenotypic changes, but was
not lethal (29-31).

B. FGF
FGF Family and Structural Conservation
Fibroblast growth factor research was initiated following the discovery of FGF1 (acidic
fgf) in 1974(32). The fibroblast growth factor family consists of a total of 23 polypeptides.
Twenty-two fibroblast growth factors have been identified and studied in mammals. The
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fibroblast growth factors consist of 3 exons and combine to form an approximately 16 kDa
protein of 150-250 amino acids (33). Variation occurs within the start codon including the
placement of secondary CUG start codons(34, 35). The location of this CUG sequence is able to
increase the typical size of the FGF protein from 16 kDa (FGF-1) to as many as 100 kDa (FGF12). The FGF structures are composed of beta sheets arranged in tre-foil formation (36). The
trefoil structure is composed of 12 antiparallel beta-strands. The core of the structure contains a
sequence of 28 conserved amino acids. Among the 28 conserved amino acids 6 residues are
identical. Conservation of these residues helps to provide only small variations to the FGFR
binding site located within the 28 amino acids (37). The fibroblast growth factors are typically
secreted proteins so they may act on the cell surface FGFR.
Many FGF’s contain a cleavable N-terminal signal peptide (1). The N-terminal signal
peptide allows for classical secretion mechanism. However, there exists a number of FGF’s that
are found in the extracellular space that do not contain N-terminal signal sequences. FGF1,
FGF2, FGF11-FGF14 lack an N-terminal signal sequence for secretion. These FGF’s have
shown specific activity related to the nucleus or may be secreted via a mechanism independent of
the reticulum-Golgi pathway (38, 39).The secretion mechanism of each FGF will be further
discussed.
The fibroblast growth factors all bind to heparin sulfate. Within the beta barrel structure of
FGF, lysine and arginine residues on beta strands -10 and -11 contribute to the heparin
binding site of FGF (40, 41). Heparin sulfate is the side chain of cell surface proteoglycans. The
binding of FGF’s to HS helps to reduce proteolytic degredation of FGF. It is unclear if heparin
sulfate is required for FGF to induce signaling through the FGFR (32, 42). Heparin knockout
cells in proliferation studies suggest that heparin is a requirement for signaling (40). Heparin
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sulfate supports dimerization of the FGFR as well as binding of FGF to the FGF receptor (43).

General FGF Interactions
The fibroblast growth factors each bind to FGFR1, FGFR2, FGFR3 and/or FGFR4 with
varying affinities. The FGF-FGFR interface is composed largely of hydrophobic interactions.
The FGF protein residues interacting with the receptor are located on the β1-strand, β1-β2 turn,
β2-strand, β3-β4 loop, β8-β9 turn, β9-strand and β12-strand (8). The FGF receptor binding
residues of FGF are largely hydrophobic and conserved to these locations. Only the Y24-X-X
sequence motif of β1-strand is consistent in the FGF sequences (8). The binding site of FGFFGFR is conserved on the D2 domain.

Figure 1.5 - Group 1 FGF’s were the first to be identified of the Fibroblast growth factors and
consists of FGF-1 and FGF-2. The group-1 FGF’s were first purified from bovine pituitary
extracts (32, 44).
8

Fibroblast growth factors are sub grouped into 6 families (figure 1.5). (Group 1: FGF1 and
FGF2; Group 2: FGF3, FGF7, FGF10 and FGF22; Group 3: FGF4, FGF5 and FGF6; Group 4:
FGF8, FGF17 and FGF18; Group 5: FGF9, FGF16 and FGF20; Group 6: FGF19, FGF21 and
FGF23) (1 - 3).
Acidic fibroblast growth factor or FGF-1 is named as such for its acidic isolectric point.
Basic fibroblast growth factor or FGF-2 was given the name basic as a result of it basic isolectric
point. The roles that FGF-1 and FGF-2 play in multicellular organisms has been documented as
critical functions for the development of tissues. One unique character of the group-1 FGF’s is
they do not have a signaling peptide to allow protein delivery through classical secretion (44).
The two proposed non-classical secretion pathway for group-1 FGF’s include cell damage
and novel secretion methods. McNeil et. al. have shown cell damage results in the release of
FGF-2(45). The types of cell damage studies include cell death, chemical injury or wound
healing. FGF-2 release has also been observed in cells subjected to irradiation. Additionally,
Kathir et. al have shown a novel FGF secretion mechanism involving an interaction with
S100A13. Previous studies have shown S100A13 to act as a peptide transporter for secretion
across the membrane. S100A13 was shown to bind to FGF-1 allowing for S100A13 to transport
FGF’s across the membrane (39).

Ras/MAPK Signaling Pathway
Binding fibroblast growth factors to the FGF receptors results in the autophosphorylation
in the tyrosine kinase domain of the receptor. PLC-γ and Src bind to the kinase domain of the
FGFR (46). Upon binding, PLC-γ and Src become phosphorylated (47). Adaptor proteins Grb2
and Shc bind to the autophosphorlyed sites. The SH3 domain of Grb2 binds to Sos (Ras guanine
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nucleotide releasing factor). The Grb2-Sos complex recruits Ras in the plasma membrane. The
complex is also activated by the exchange of GDP for GTP by Sos. Ras activation of a signaling
cascade involving the ser/thr kinase Raf, the dual specificity MAP kinase (MEK), and MAP
kinase (48). The Ras/MAP kinase pathway further regulates activities in the cell including
proliferation, migration and apoptosis (49).

Figure 1.6 - Shows the signaling cascade of the phosphorylated FGFR through the MAP kinase
pathway. The activation of this pathway occurs through the phosphorylation of tyrosine 766 in
the tyrosine kinase domain of the FGFR.
PLCγ/Ca2+ Signaling Pathway
Autophosphorylation of the kinase domains of the FGFR 2 and FGFR4 are able to activate
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phosphatidyl inositol (Pt Ins) hydrolysis through interactions with the phosphorylated tyrosine
766 on the FGFR. Activation of PLCγ results in the hydrolysis of phophatidylinositol-4,5diphosphate to diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). Both DAG and IP3
modulate the release of Ca2+ into the cell(50). Mutations at Y766 on the FGFR’s show a little
impact on the changes in mitogenic activity of a cell(51, 52). The existence of other signaling
pathways that result in mitogenic activity helps to reduce the possibility of a catastrophic
mutation at a single site.

PI3 Kinase/ AKT Pathway
The Phosphoinositol-3 Kinase pathway may be set into motion by serine-threonine kinase
receptors, tyrosine kinase receptors and exchange factors that regulate heterotrimeric guanosine
triphosphate binding proteins (figure 1.7). The three mechanisms by which the PI3 pathway may
be induced include: P13K may bind directly to the phosphorylated tyrosine kinase domain in the
FGFR, Ras may induce membrane localization as well as activation PI3K, and Gab1 may bind to
FRS2 through interaction with Grb2 leading to the phosphorylation and activation of the PI3K
pathway (53-56).. The binding interaction between Ras and the P110 subunit of the PI3K protein
stimulates PI3K activity. Activated PI3 kinase converts the plasma membrane lipid
phosphatidylinositol-4,5- bisphosphate (PI(4,5)P2) to phosphatidylinositol-3,4,5-trisphosphate
(PI(3,4,5)P3) (57). The phosphatidylinositol-3-4-5 trisphosphate recruits signaling proteins
containing Pleckstrin-homology domains. The recruited signaling proteins result in the
phosphorylation of AKT by PDKI. Anti-apoptotic protein kinase AKT and phosphoinositidedependent kinases are activated downstream of the PI3 kinase (58). This protein interaction
pathway results in events that may control protein synthesis, actin polymerization, cell survival
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and cell cycle entry.

Figure 1.7 – Intarcellular signaling pathway activated through FGFR autophosphorylation. The
intracellular signaling activation results in a cascade activating the PI3 K / AKT pathway.
Binding of Grb2 and p85 to the phosphorylated tyrosine kinase domain results in the recruitment
of PIP3 and activation of PI3 kinase. Activated PI3 Kinase phosphorylates phosphatidylinositol3,4,5-trisphosphate (PIP3) which recruits a subset of signaling proteins with pleckstrin homology
(PH). This phospoorylation of PIP3 recruits signaling proteins that result in the activation protein
synthesis, cell cycle entry and actin polymerzation.

Regulation of the FGFR signaling pathway
The FGF and FGFR activate signaling cascades including: MAPK pathway,
phosphoinositol-3 kinase (PI3 kinase)/ AKT pathway and the phospholipase C gamma (PLC)
pathway. Both up and down regulation of the FGFR signaling are important to maintain normal
cellular function. The FGFR may be regulated by intercellular, extracellular and by auto
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inhibition mechanisms.
The auto inhibition mechanisms of the FGFR include alternate splicing of the FGFR,
selective expression of FGF, FGFR and HSPG. Heparin is a component of the extracellular
matrix that is anchored to membrane bound proteins. FGFR 1 and FGFR 4 require heparin to
contain 2-O-sulfates and 6-O-sulfates in order to form a binding interaction. This characteristic is
not shared by FGFR2 and FGFR3 (59, 60).

Alternate splicing of the receptors allows for

varied affinities to the FGF’s. The FGFR’s may be expressed in multiple forms (61).The
common splicing consists of FGFR2b or FGFR2c. The intron coding for the FGF binding site on
the receptor may consist of the 2b or 2c form. In turn this provides varied affinity for FGF
depending on the splice variant selected. The regions on the FGFR that are modified exist in the
linker region between D2 and D3 and include residue changes in the D3 domain. The cellspecific expression of exon IIIb is largely controlled by regulatory elements IAS2 and ISAR.
These elements selectively activate exonIIIb and may repress exon IIIc. Alternatively elements
UISS, ESS and DISS silence exon IIIb and express exon IIIc. The associated affinities between
FGF’s and the isoforms of the FGF receptors are shown in figure 1.8(62-65).
This figure suggests splicing variants as mechanism of control for the affinity the FGFR may
have for the various FGF families. This form of control over FGF signaling is also observed in
splicing variants that occur in the D1 domain and the linker between D1- D2.
The splicing variations that occur on the FGFR result in the presence and absence of the
D1 domain and the “acid box” domain located between D1 – D2. The isoforms that lack the D1
occur on FGFR1c, FGFR1b and FGFR2c. Isoforms of the FGFR that lack the “acid box” include
FGFR3c.
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FGFR1b

FGFR1c

FGFR2b

FGFR2c

FGFR3b

FGFR3c

FGFR4

FGF1

+++

+++

+++

+++

+++

+++

+++

FGF2

+

+++

NB

+

NB

+++

+++

FGF3

+

NB

+

NB

NB

NB

NB

FGF4

NB

+++

NB

+++

NB

+++

NB

FGF5

NB

+

NB

+

NB

NB

NB

FGF6

NB

+

NB

+

NB

NB

NB

FGF7

NB

NB

++

NB

NB

NB

NB

FGF8

NB

NB

NB

NB

NB

+

NB

FGF9

NB

+

UNK

+++

+

+++

NB

FGF10

++

NB

++

NB

UNK

UNK

NB
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NB

NB

NB

NB

NB

NB

NB

FGF16

UNK

NB

UNK

NB

UNK

UNK

NB

FGF17

UNK

++

UNK

++

UNK

UNK

NB

FGF18

NB

NB

NB

++

NB

++

NB

FGF19

NB

NB

NB

NB

NB

NB

NB

FGF20

UNK

++

UNK

UNK

UNK

UNK

UNK

FGF11-

Table 1.8 - “+” quantifies the mitogenic effect of FGF1-9 on BaF3 cells transfected with the
respective FGF isoform. “NB“ indicates no binding interaction. For the other FGF’s, “+”, “++“
and “+++” respectively indicate the relative strength of the interaction. (66-68).
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Fibroblast growth factor receptors that may lack both the D1 domain and the “acid box” include
FGFR2b (27, 69, 70). The use of splicing variants as a mechanism to control FGFR activity was
first demonstrated in 1993. In this study the affinity of FGF1 vs. FGFR1 with and without the D1
domain was examined. FGFR1 lacking the D1 domain showed a higher affinity for FGF-1 (71,
72).
The auto inhibition role of the “acid box” and D1 on the FGFR has been tested using both
surface plasmon resonance and nuclear magnetic resonance experiments. Kalinina et. al. have
shown that a positively charged patch of residues on the D2 domain bind to the negatively
charged residues making up the acid box (73). The acid box – D2 interaction blocks the
interaction of D2 with heparin. A secondary effect of this interaction is the decreased interaction
of the FGFR with FGF. In this manner the expression of the splice variant of FGFR with D1 –
AB may act to auto inhibit signaling of the FGFR.

FGF Roles in Development
Gastrulation is a process by which FGF signaling is essential in order to modulate cell migration
and growth. The signaling pathways components of FGF and the FGFR including adaptor
proteins FRS2/SNT-1(74, 75), Nck and Grb , Ras(76)Map kinase(77-80)Src-kinase laloo, protein
tyrosine phosphatases(81, 82)MEK, ERK and transcription factors AP1 and Ets2 have shown
critical for mesoderm development(83). Gastrulation defects have been the result of the
inhibition of any of these pathways. Gastrulation is a process regulated by FGF by both direct
and indirect signaling mechanisms. XSprouty2 has been determined to be an antagonist of FGFdependent calcium signaling (84). Nutt et. al. showed that the overexpression of XSprouty2
inhibited convergent extension during gastrulation. The over expression of XSprouty2 did not
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inhibit MAP kinase activity, mesoderm induction or mesoderm patterning (84).
FGF has also been show to indirectly regulate gastrulation. FGF has been shown to be a
regulator of Xbra induction. Convergent extension is promoted by the expression of Xbra. The
expression of Xbra also acts to inhibit cell migration through the inhibition of adhesion
molecules on cells allowing them to bind to fibronectin (85, 86).Xbra induces the expression of
Xwnt1 and prickle. These two proteins act as regulators of the Wnt-pathway, which in turn
regulates convergent extension (84).
Knock-out mice have played a pivotal role in understanding the importance of FGFR
signaling during gastrulation. FGFR1

-/-

mutant mice embryos display defects in cell migration,

cell specification and cell patterning resulting in embryo death (30, 87).First evidence of this
appears during gastrulation in which the cells fail to make an epithelial to mesenchymal
transition(88). The epithelial to mesenchymal transition is regulated by the increased expression
of mSnail. Increased FGF results in higher expression of mSnail, which down regulates the
expression of E-cadherin. The accumulation of E-cadherin may prevent the epithelial to
mesenchymal transition. Arrest of the epithelial to mesenchymal transition may occur as a result
of continued Wnt signaling. Continued expression of E-cadherin sequesters cytoplasmic βcatenin at the plasma membrane leading to the attenuation of Wnt signaling (30).

Neural Induction
Following gastrulation the ectodermal cells adopt a neural fate during a process termed
neural induction. Ectodermal cells have two possible fates: signaling from BMP results in cells
forming the epidermis or cells receive no signaling resulting in a neural fate. This process by
which cells adopt a neural fate is termed the “default model”(89). The default model is
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oversimplified for the process of neural induction. Several conserved proteins have shown to
play a role in cell fate leading to neural induction including FGF (90).
The importance of FGF signaling during neural induction has been observed in chick
embryos. Following neural induction the chick embryo undergoes the formation of a line of cells
termed Hensen’s node(91, 92).Using chick embryos, FGF’s soaked beads are capable of
inducing the formation of Hensen’s node. Inhibition of FGF signaling results in the cell arrest
and prevents the formation of Hensen’s node (93-96). Epidermal cell fate may be indirectly
controlled by the expression of FGFs. Fibroblast growth factors are shown to slowly induce the
expression of Churchill (ChCh). Churchill activates the protein Sman-interacting-protein-1
(Sip1). Sip1 binds to inhibit Smad1/5, which is responsible for activating target genes – blocking
BMP signaling (97). BMP signaling is capable of directing cellular development toward
epidermal formation neural formation.

Anterior/Posterior Development of the Neural Plate
FGF signaling plays a crucial role in the anterior posterior patterning of the neural plate.
The conversion of anterior neural tissue to posterior tissue is capable by FGF signaling (80,
98).The anterior to posterior patterning is observed when FGF soaked beads are imbedded within
anterior neural tissue(99).The conversion of anterior to posterior neural tissue is postulated to be
the result of cross talk of FGF with Wnt signaling(100-102).The overexpression of FGF3 in
zebrafish continues the expansion of the posterior neural tissue while reducing the anterior neural
tissue(103).The patterning of the anterior and posterior neural tissue has been shown to be
related to the expression of FGF as well the expression of Hox genes.
Caudals are genes that respond to signaling by FGF’s. These same genes are responsible
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for regulating Hox gene expression(99, 104, 105).The overexpression of FGF in mouse, chick
and Xenopus embryos resulted in the increased expression of Hox genes.

Endoderm Formation
FGFR knockout mice have provided evidence to the function of receptor signaling
during endoderm formation. The overexpression of dominant negative FGFR2 leads to the
inhibition of α-feoprotein, HNF4 and Evx1 – three endodermal markers (106). The FGF4-/embryos failed to develop a mesoderm or endoderm (107). The phenotype of the FGF4-/represented the phenotype observed for the embryo containing dominant negative FGFR2. FGF
and the receptor are not the sole growth factors required for endoderm formation. Inhibition of
other fibroblast growth factors showed no significant change in embryos. FGF’s have not shown
to induce the expression of endoderm genes in animal caps (108, 109).This data suggests the
FGFs may be required for patterning of the endoderm and not development.

Signaling and Angiogenesis
The functions that FGF-1 and FGF-2 in development have been heavily studied. FGF-2 has
shown to be important in the development and maintenance of the nervous system, angiogenesis,
lung development, muscle, skeletal system, skin and digestive system. Angiogenesis is a key
cellular process that has been the focus of novel tumor treatments (110). Angiogenesis is among
the most notable processes mediated by both FGF-1 and FGF-2.
Angiogenesis is a process that must be preceded by key cellular events in order to prepare
the endothelial cells for branching into new blood vessels. First, the basement membrane
degradation must occur. Second, the endothelial cells begin migration and proliferation. The
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endothelial cells will begin to sprout into the stromal space during proliferation. Finally, vascular
loops are formed and capillary tubes develop as tight junctions bind endothelial cells to form a
new basement membrane (111-113).

Figure 1.9 – Schematic representation of the interactions formed following autophosphorylation
events of the FGFR cytoplasmic tyrosine kinase domains. In this figure signaling through the
MAPK pathway is initiated through interactions of CRK with the phosphorylated Y463. The
PLC-γ activation is mediated through interactions with phosphorylated Y766. This interaction
leads to the activation of PKC, which regulates the mitogenic response. The mechanism of
activation of Grb-14, Src, P70 S67, P38 and PI3K is unknown. The mechanism of the SHP-2
pathway to activate Ras, which induced by FGFR1 and FGFR2 is still unknown.
FGF is a potent inducer of angiogenesis, but interactions formed by vascular endothelial growth
factors (VEGF), angiopoietins, tranformaing growth factors α and β (TGFα and β), interleukins
and chemokines are required for the formation of blood vessels.
Signaling through the MAPK pathway will induce cell proliferation. Activation of the
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protein kinase C (PKC) pathway is required for FGF -2 to induce a full mitogenic effect. Loss of
mitogenic activity as a result of reduced PKC activation may be overcome by the upregulation of
the urokinase-type plasminogen activator (uPA)(115). Urokinase-type plasminogen activator
upregulation is induced by FGF-2 activation of FGFR1. Following cell proliferation, it is
important for extracellular matrix degradation to occur for the formation of new blood vessels.
FGF-1, FGF-2 and FGF-4 are responsible for the upregulation of uPA. These FGF’s are
also responsible for the upregulation of uPA receptors at the endothelial cell surface (38). In
return uPA converts plasminogen into plasmin. Plasmin is a serine protease that degrades matrixforming proteins such as fibrin (116) .uPA also activates matrix metalloproteinases MMP1(collagenase-1), MMP-2 , MMP-3 and MMP-9 (type IV collagenase) in order to further
degrade the matrix(117).The increased expression of uPA receptors induced by FGF’s results in
matrix degradation in a focused direction. FGF-2 has shown to stimulate surface membrane
vesicle shedding. The vesicles typically contain MMP-2, MMP-9 and MMP inhibitors TIMP-1
and TIMP-2. Tarabouletti et al. have shown that vesicles shed stimulate capillary-like structure
formation within endothelial cells (118). Extracellular matrix degradation must be followed by
endothelial cell migration.
Endothelial cell migration is induced following chemotaxis and chemokinesis stimulated
by FGF-1, FGF-2, FGF-8b and FGF10 (119-121). The chemotactic influence on endothelial cells
has been mimicked in vitro by culturing endothelial cells within a 3D permissive matrix
substrate. Using this matrix substrate, the addition of FGF-2 results in the invasion of endothelial
cells into the substratum. Endothelial cells organize into capillary like structures with a hollow
lumen (122). Similar results have been observed by the addition of FGF-2 to 3D fibrin gels
containing endothelial cells (123). Endothelial cell migration may only lead to angiogenic

20

growth if lateral cell-cell adhesions and extracellular matrix interactions are formed.
Cadherin and integrin receptors direct the formation of cell-cell adhesion and extracellular
matrix interactions. Cadherin and integrin (αv β3) expression is mediated by FGF-2 (124-126).
Prolonged expression of FGF-2 has shown to influence the redistribution of junctional adhesion
proteins, vascular and endothelial cadherins, and plakoglobin. This redistribution and cell-cell
interactions formed by endothelial cell is a key step in vessel formation. Following these key
interactions FGF’s have been shown to be important in the development of the extracellular
matrix.
Vascular endothelial growth factors (VEGF) and their receptors are required for
angiogenesis development following extracellular matrix degradation. There are six VEGF’s that
interact with their membrane surface tyrosine kinase receptors (VEGFR). The interactions of
VEGF-A with VEGFR-2 are essential in the formation of blood vessels (127). VEGF is a critical
protein required for tubal formation of endothelial cells. FGF-2 interacts with vascular
endothelial growth factors (VEGF) in order to modulate the induction of angiogenesis,
vasculogenesis and lymphangiogenesis. The interactions between VEGF/VEGFR and FGF-2
have shown to regulate processes involved in angiogenesis. FGF-2 expressed by the cell or
added to the cell has shown to induce the expression of VEGF (128). FGF-2 also plays a role
with inducing VEGF receptors (129). The roles of FGF-2 and VEGF with the development of
endothelial cells have been suggested to be synergistic (123, 130). This effect is observed by the
differences in expression patterns observed in cells induced with FGF-2 or VEGF. Endothelial
cells show an increased expression of telomerase activity and a reported induction of senescence
for the cell. These modulated expressions controlled in part by FGF suggest there to be a role for
fibroblasts throughout the angiogenesis process.
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Limb and Bud Formation
Limb developments are a process by which the lateral plate mesoderm (LPM) and the
ectoderm protrude in order to form a bud. From this bud cell proliferation gives rise to skeletal
structures. Muscular and connective tissue are the result of the cell proliferation of mesenchymal
tissue (131, 132). Cell proliferation first proceeds in a proximal to distal formation. This
development forms a flattened structure along the dorsal-ventral and anterior-posterior planes.
The first recognizable elements of differentiation are apparent by the development of skeletal
tissue. The stylopod, found at the distal end of the limb, is among the first tissues showing
development and is followed by the differentiation of other distal structures.
Initiation of limb bud outgrowth originates with the bulge of the lateral wall. Fibroblast
growth factors have shown to play an important role in the initiation of the bud and outgrowth
development. Induction of ectopic limb formation has been observed by the addition of FGF1,
FGF2, FGF4, FGF8 and FGF10 (133-136). The method of FGF addition to the mesoderm has
shown to be critical for limb formation. FGF added in a non-focal method results in the limb
outgrowth in multiple locations. Each of the outgrowths eventually regresses and limb formation
is not completed (136). Additionally the ectopic addition of FGF’s has resulted in deletions,
reductions and fusions of the proximal bones (136). Successful outgrowths and bud formations
are only observed by a focused insertion of FGF. The addition of FGF by a soaked bead or pellet
has been shown to lead to limb formation. Many FGF’s have been shown to induce limb
formation, but it is rare that induced limbs result in a functioning limb. The expression pattern in
the nephronic mesoderm is has been suggested FGF 10 may be required to induce limb
formation. The roles that FGF 10 plays in the induction are the result of three observations.
FGF10 expression precedes the expression of FGF8 within the mesoderm.

Following the
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expression of FGF 10 within the mesoderm, FGF8 is subsequently expressed within the limb
ectoderm. Limbs ectopically induced through the usage of FGF8 result in the expression of
FGF10 rna within the mesenchyme before FGF8 rna is detected within the ectoderm (135). This
data suggests that the role of FGF10 may be to act as an inducing agent for other FGF’s.
The role of FGF10 has been suggested to induce the expression of FGF8 within the
ectoderm. Embryos that are FGFR2

ΔIgIII

homozygous provide evidence for the importance of

FGF 10 requirement to induce FGF 8. FGFR2 ΔIgIII homozygous embryos express FGF 10 within
the mesoderm. However, FGF8 fails to be expressed within the prospective limb ectoderm, as it
would be in wild-type examples. Xu et al. have suggested that the decreased FGF8 expression is
the result of a loss-of-signal transduction resulting from the FGFR2

ΔIgIII

homozygous embryos

(27). This model proposes FGF10 expressed in the mesoderm induces the expression of FGF8
within the ectoderm through FGFR2. The expression of FGF8 is proposed to act as a positive
feedback inducing FGF10. FGF8 may also act to induce Shh expression that is also required for
limb formation and tissue patterning.
Tissue patterning and outgrowth originates from three distinct locations. The first limbsignaling center is the apical ectodermal ridge (AER). The apical ectodermal ridge runs from the
anterior to the posterior near the distal region of the bud. FGF’s originating from the AER has
been shown to be required for pattern regulation along the proximal - distal axis (137, 138).The
second signaling center is identified as the zone of polarizing activity (ZPA). The zpa is located
posterior to the bud. Signaling from the zpa has been suggested to regulate patterning along the
anterior – posterior axis (139, 140). The third signaling center is the nonridge ectoderm of the
bud. FGF signaling and sonic hedgehog gene induced expression is largely responsible for acting
on undifferentiated mesenchymal cells located in are region known as the “progress zone” (140).
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The “progress zone” is located near the distal tip of the limb bud. Elongation of the limb is the
result of cellular proliferation in the progress zone. Fibroblast growth factors perform a number
of functions in the apical ectodermal ridge.
Many of the advances in our understanding of the apical ectodermal ridge have come from
the study of chick limb development in ovo. The importance of FGF during limb development
was observed by the addition of FGF soaked beads added to bud formation following the
removal of the apical ectodermal region. Normal limb formation was observed in the chicks
containing the fgf soaked beads (141, 142). The AER tissue patterning may be replaced by the
addition of FGF-2, FGF-4 and FGF-8(136, 141, 142).The requirement of FGF4 and FGF8 for
limb development may not be studied by null mutations because of their requirement for chick
development.
Early limb development proceeds in anterior, posterior and distally from the site origin.
This early development is considered to be the apical ectodermal ridge. There exists differential
expression of FGF across the regions of bud formation. Tissue specific inactivation of FGF8 has
been used to study the importance of FGF8 in the AER. The mutant mice skeletal abnormalaties
include are observed in forelimbs, hind limbs and a lack of limb development (143). Further
evidence suggests FGF’s play a significant role at the apical ectodermal ridge through the
stimulation of cellular proliferation and increased expression of sonic hedgehog at the AER.
Cell proliferation has been observed as a result FGF signaling in the AER (144-146). The
ectopic expression of FGF-2 results in the excess proliferation of mesenchymal cells. The
increased expression results in the splitting of the skeletal primordial (147). Further evidence
suggests FGF’s are required for the continued expression of Hox genes and Bmp2 (144, 148).
The increased expression of Hox genes and Bmp2 may activate cell proliferation within the
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mesenchymal tissue (149, 150).
The second proposed major function of FGF in the AER is to maintain the expression of
Shh in the zone of polarizing activity (ZPA). Removal of the apical ectodermal ridge results in
the inhibition of polarizing activity in the AER (136).Shh has been shown to be a mediator of
polarizing activity in the ZPA. FGF is able to substitute the absence of an AER resulting in the
continued polarizing activity. This is believed to result from the induced expression of Shh that
allows for the increase polarizing activity (136, 151, 152).
Limb growth that is induced through the expression of both FGF and Shh requires an
inhibitor to moderate signaling within the limb. The protein moderating FGF and Shh signaling
is the Gremlin1 (Grem1) protein. Signals from FGF4, FGF8, FGF9 and FGF17 originate from
the apical ectodermal ridge. The Shh and Grem 1 proteins are expressed in the underlying
mesenchyme tissue (142, 144, 153-155). FGF acts to induce Shh and the Shh in turn induces the
expression of FGF. The progress of limb growth and termination has been proposed by
Verheyden et. al (156).
Verheyden et al. propose that in phase I (limb growth) and phase II (inhibitory growth)
occur by two different mechanisms (156). In the growth phase FGF from expressed in the apical
ectodermal ridge is too low to inhibit Grem1 efficiency. Instead FGF leads to an increased
expression of Shh and BMP. In turn, higher concentration of Shh and BMP lead to an increase in
the concentration of Grem1 within the distal mesenchyme tissue (157, 158). Within phase I the
increased Gremlin1 protein induces the expression of FGF in the AER (159-161). The positive
FGF/Shh feedback loop continues to lead to an increased expression of the two proteins.
The phase I to phase II transition occurs when the FGF expression and signaling increases
to a concentration that begins to inhibit FGF signaling through an FGF/Germ1-negative
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inhibitory loop. Phase II is initiated by separation of the mesenchyme tissue and apical
ectodermal ridge. The mesenchyme tissue proceeds to expand distally and posteriorly (156). The
mesenchyme expansion occurs until Germ1-negative diffuses past the expressed Germ1 protein.
The Germ-1 negative leads to a decreased concentration of FGF, which in turn decreases the Shh
expression. The decreased FGF and Shh expression is expected to result in a termination of the
limb development and the end of phase II (156).

Fibroblast Growth Factors and Disease
Fibroblast growth factor signaling is critical for a variety of developmental, processes.
Fibroblast growth factors have not been associated with disease until a mutation found in FGF 23
was determined to cause hypophosphatemic rickets in 2000. Since 2000 numerous FGF have
been associated with diseases including: FGF3 in Michel aplasia; FGF 8 in hypogonadotropic
hypogonadism; FGF9 in carcinoma; FGF10 in carimal/salivary aplasia; FGF14 in
spinocerebellar ataxia; FGF20 in Parkinsons disease; and FGF23 in tumoral calcinosis and
hypophosphatemic rickets (72, 162-164). The diseases related to the mutations across the FGF
family are evidence to the variety of their functions.

FGF3 and Michel Aplasia
Michel aplasia is defined by an absence of developed inner ear structures including the
cochlea, vestibule and semicircular canals. The loss of these structures result in hearing loss.
Sometimes associated with Michel aplasia is microtia and microdentia. Microtia is defined by
anteverted ears and microdentia defined by widely spaced teeth. The mutations in FGF3 that
have been associated with this disease include L6P, G66C, I85M R104X, S156P and V206S
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(162, 163). FGF3 and FGF10 have been inferred as important for inner ear development through
knockout mice. Mice lacking FGF3 and FGF10 lack development of the cochleavestibular
ganglion, impaired otic vesicles and a reduction or absence of expressed otic marker genes Pax,
Dlx4 and Sox9 (93, 165). Similar defects have been identified in FGFR2b null chicks(166).

Kallmann Sydrome and FGF8
Kallmann’s syndrome (KS) or idiopathic hypogonadotropic hypogonadism (IHH) with is
the result of absent or delayed puberty. Kallmann’s syndrome is also paired with anosmia – loss
of the sense of smell. Kallmann’s syndrome has also been identified to occur as a result of
mutations occurring in FGFR1. FGF8 mutations H14N, P26L, K100E, R127G and T229M are
associated with IHH or KS (164). Structural analysis suggests these mutations may impair the
interactions of FGF8 with heparin. The decreased interactions may result in a decreased signal
transduction. This analysis is consistent with proposes loss-of-function mechanisms determined
for the FGFr1 mutations.

FGF8 and FGF10 in Nonsdromatic Cleft lip and/or Palate
Cleft lip or palate is a disease by which the two halves of the craniofacies fail to fuse to
complete the hard palate and/or lip. The FGF8 mutation that results in this disease is D73H. The
mutation is located at the N-terminal region of FGF8 and important in the binding interactions
with the D3 domain of the FGFR (147). FGF8 hypomorphic mice develop impaired survival of
the neural crest cells. The neural crest cells populate the pharyngeal arches, which are required
for the development of many facial structures (147).
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Spinocerebellar Ataxia and FGF14
Spinocerebellar ataxia (SCA) is characterized by tremors, low cognitive performance and
memory impairment (167). Two mutations in FGF14 have been identified to be associated with
SCA. FGF14 F145S was the first mutation determined in FGF14 to be associated with SCA. A
second mutation associated with SCA was determined to be a single-nucleotide deletion
mutation at nucleotide 487. The result of the deletion mutation is a truncation of the FGF14
protein (167, 168). The F145S mutation is buried within the hydrophobic core of the structure.
The large aromatic residue replaced by a serine results in the loss of hydrophobic interactions
with surrounding residues. The significant decrease residue in volume may result in the
destabilization of the FGF structure. The mutation is believed to result in a loss-of-function of
FGF 14. The loss-of-function assessment is consistent with the phenotype observed in FGF 14
null mice. FGF 14 null mice develop ataxia, paroxysmal movement disorder and cognitive
defects. The development of such cognitive defects is predicted to originate from neural
structures where FGF14 is expressed including: hippocampal neurons, Purkinje cells and
cerebellar granular neurons (169). The FGF 14-/- mice show granular neuron morphology
believed to result in ataxia and paroxysmal movement disorder (169). Additionally, FGF 14
colocalizes with voltage-gated sodium channels in the soma and beginning segment of the
neuron. The colocalization is attributed through interactions of the cytoplasmic C-terminal tail of
the channels α-subunit (170, 171). The source of the loss-of-function may occur through a loss of
interactions formed with the C-terminal tail of the channels α-subunit. The loss of this interaction
may result in the decreased neuronal excitability in the FGF 14-/- mice.
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Parkinson’s Disease and FGF20
Parkinson disease (PD) is defined by the manifestation of a resting tremor, bradykinesia
and a loss of dopaminergic neurons resulting in rigidity. FGF20 is associated with PD as a result
of a single nucleotide polymorphism (SNP) at the 3’ untranslated portion of the gene. The SNP
located in the untranslated portion of FGF20 has been shown to increase the expression of the
protein (72).The association of the increase expression FGF20 with PD is the result of both its
location of expression and the resulting induction of other proteins.
FGF20 is preferentially expressed in the substantia nigra and within dopaminergic neurons
(67, 172). The increased expression of FGF20 has been shown to increase the expression of αsynuclein, which is a key component in filamentous lewis bodies (173). The increased αsynuclein resulting from elevated FGF20 may be a key contributor to the deterioration of
dopaminergic neurons in aging individuals.

Hypophosphatemic Rickets and FGF23
Autosomal dominant

hypophosphatemic rickets is a disease characterized by

hypophosphatemia, rickets, osteomalacia, bone pain, dental abscesses and low levels of 1,25dihydroxyvitamine D3 – resulting in renal phosphate wasting. Missense mutations R176Q,
R179Q and R179W in FGF23 have been associated with ADHR (174). These mutations are
expected to confer increased stability of FGF23. The increased stability in turn is inferred to
result in a gain-of-function. The three mutations disrupt the RHTR amino acid sequence in
FGF23. This sequence is a targeted cleavage site location for subtilisin-like protein convertase or
PHEX endopeptidase (175). Increased expression of FGF23 downregulates phosphate through
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the inhibition of reabsorption in renal proximal tubes. Phosphate regulation may be the result of
FGF23 inhibition of Na/Pi cotransporters. Therefore the expression of Npt1, Npt2a and Npt2c by
the kidney is inhibited by FGF23 (176-179).

Tumoral Calcinosis and FGF23
Tumoral calcinosis is the result of the deposition of basic calcium phosphate crystals in the
periarticular spaces including hip, elbow and shoulder (180). Within these tissues ulcerations,
bone infections and contractures result in painful calcifications. Mutations H41Q, Q54K, S71G,
M96T and S129F occurring in FGF23 have been associated with the tumoral calcinosis disease
(181-184). FGF23-/- mice result in increased 1,25(OH)2D3 and hyperphosphatemia – phenotypes
reflected by patients with tumoral calcinosis(185). Additionally, the FGF23-/- mice suggest
tumoral calcinosis may result from a loss-of-function mechanism. The loss-of-function may be
the result of mutated FGF23 retention and lack of secretion from the golgi complex (182).

Tumor Development and FGF Signaling
FGF signaling has been identified as a key component in tumor pathogenesis. There exist
several mechanisms by which FGF receptors are considered to encourage tumoral growth
including: single-nucleotide polymorphisms (SNP); chromosomal translocation; differential
expression; impaired down-regulation of FGF signaling; and mutations within the FGFR.
Single nucleotide polymorphisms (SNP) within the FGFR are related to increased
malignant phenotype and increased risk of some specific types of cancer. SNP have been
identified to exist adjacent to and within the FGFR2 gene. SNP adjacent to the FGFR2 gene are
associated with an increased risk of breast cancer (186, 187). SNP found adjacent to the FGFR2
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gene may act to alter the binding affinity for transcription factors for the FGFR2 gene. FGF
receptor 2 shows increased expression in both breast cancer cell lines and breast cancer tumors
(187). Current data suggests the SNP adjacent to the FGFR2 gene are related to increased
expression of FGFR2 leading to sustained signal transduction (188-190). The sustained signal
transduction may cause increased cell proliferation. In mice, FGFR2 acts to increase the
proliferation and invasiveness of terminal end buds of developing breasts in mice (191). SNP
adjacent to the FGFR2 gene provide evidence associating the SNP with increased expression and
increased risk for patients with BC. Additionally SNP adjacent to FGFRs are linked to lung, skin,
colon and prostate cancers (192-195).
Impaired down-regulation of the FGFR is associated with the attenuation of FGF-FGFR
signaling. Following the FGF binding to the receptor and autophosphorylation, the FGFR is
endocytosed and transported to lysosomes for degradation. Impairment of this down-regulation
mechanism of the FGFR may occur through; alterations of the negative regulators of the FGFR
and mutations preventing efficient internalization and degradation and splice variants of the
FGFR that resist internalization.
The negative regulators of the FGFR include Cbl and ubiquitin ligase. Mutations or
expression alterations of these proteins involved in the endocytic pathways may be related to
increased lifetimes of the FGFRs. Mutations within the FGFR’s may also act to prevent the
endocytosis mechanisms.
Prevention of degradation and endocytosis mechanisms may also be the result of mutations
within the FGFR. The FGFR3 G380R mutation is associated with bladder cancer. Analysis of
this mutations shows the mutation promotes dimerization of the receptor. Additionally the
FGFR3 G380R mutant avoids degradation, which is associated with prolonged signaling (195).
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One component required for efficient endocytosis is the C-terminal endo of the FGFR.
FGFR2 is expressed in some tissue with a truncated C-terminal end. The endocytic motif
of the FGFR is located within the C-terminal end. Truncation is shown to result in continued
signaling and is related to several cancer cell lines (196).
A screen of more than 1000 somatic mutations determined exons of more than 500 kinase
genes associated with 200 different forms of human cancer (197). FGF signaling pathways are
the most common non-synonymous signaling pathways containing mutations (197). Fibroblast
growth factors 1, 2, and 4 have been associated with cellular proliferation, differentiation,
invasiveness and motility of tumor developments.
Cell survival is an important tumor defense mechanism that plays a role in the efficiency of
drug treatments. Antiapoptotic proteins XIAP and Bcl-X(L) are increased in expression in small
cell lung cancer cells by FGF-2(198). Additionally FGF-2 expression may form an interaction
with Akt and factor κB activation, which is linked to antiapoptotic effects in breast cancer (199).

Breast Cancer and FGFR
Human breast cancer tissue shows an increased amplification of the 8p11-12 chromosomal
regions containing the FGFR1 gene. Amplification of the 8p11-12 chromosomal regions occurs
in 10% of human breast cancers. The increased expression of the 8p11-12 chromosomal regions
is associated with breast cancer with a poor prognosis (200-202). FGFR1 activation in mouse
and human mammary cell lines resulted in increased cell proliferation, survival and invasion
(203). Although FGFR1 is associated with cell proliferation, other proteins found in the 8p11-12
regions may be capable or also required for cellular proliferation.
The ectopic expression of FGFR2 and FGFR4 is present in some breast cancer cases.
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FGFR2 has been found in tumors negative for estrogen receptor, progesterone receptor and
human EGFR 2/ErbB2 (HER2)(204). The FGFR2 related triple negative breast cancer tumors do
not show a response to current cancer treatments. The cells showing increased expression of
FGFR4 have shown increased sensitivity to chemotherapy upon the addition of antagonistic
FGFR4 antibodies (205). The role of FGF receptors in the progression of breast cancer has
shown to be important, but the changes induced by FGFR mutations has not yet been fully
studied and will be discussed in further detail.

Bladder Cancer and FGFR
Fibroblast growth factor receptor 3 is found to overexpress within non-invasive urothelial
cell carcinoma (UCC). UCC that initiates in the urothelial lining of the bladder and express
FGFR3 account for 70% of bladder cancer types and are considered non-invasive.
Approximately 70% FGFR3 found in non-invasive bladder cancer patients contain mutations
(206). Common mutations in FGFR3 include R248C, S249C, G370/372C and Y373/375C. The
locations of these mutants occur in the extracellular, transmembrane and cytoplasmic domain.
The cysteine mutation common to each of the mutants allows for disulfide bond formation
between FGFR3 dimers. Dimerization of FGFR3 would account for continued signaling (207).
FGFR3 targeted therapies are centered on antibodies for the receptor to prevent
autodimerization. The SU5402 antibody inhibiting FGFR activation has shown in mice to reduce
tumoral properties (208). An advance in antibody design has resulted in the development of
antibodies selective for specific mutations within the FGFR. Antibody specific for FGFR3
PD173074 mutants inhibit tumor growth in mouse xenografts (209). The relative specificity of
FGFR3 allows for the development of tests specific for bladder cancer by determining the
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presence of FGFR3.

Lung Cancer and FGFR
Fibroblast growth factors and FGF receptors have been identified as playing a role in lung
cancer. Mutations associated with lung cancer have been identified to occur in each of the FGF
receptors. FGFR1 (G70R, T141R, P252T, P252S, P576H), FGFR2 (N211I, D283N, W290C,
T370R, I380V, D530V, H544Q, R612T), FGFR3 (T79S) and FGFR4 (R183S, S232I, G388R,
R616K, E681K, P712T, A729G and S772N) are suggested to play a role in lung cancer
development (210-219). Normal lung development requires the expression and signaling of
FGFR2, FGF7 and FGF10 (220, 221). FGFR2 W290C is a mutation associated with lung
carcinomas. The W290C mutation is also found in Pfeiffer syndrome. The mutation results in
ligand-independent signaling (222). The gain-of-function mechanism of action for the FGFR2
W290C accounts for increased tumoral growth. The expression of FGFR1, FGFR3 and FGFR4
and mutations occurring in these receptors are associated with lung carcinomas. The mechanism
of action for each of the FGF receptors has not been clearly determined.

Multiple Myeloma and FGFR
Fibroblast growth factor receptor mutations associated with multiple myeloma consistently
occur in FGFR3. The mutations that have been associated with multiple myeloma occurring in
FGF3 include G197S, Y241C, R248C, P250R, Y373C, G380R, G382D, F384L/C, S433C,
A441T, A452S, K650E, K650M, A717T and I726F (223-230). Additionally, FGFR3 is
overexpressed in multiple myeloma mouse models(231). FGFR3 acts to enhance multiple
myeloma cell survival and increases cell proliferation. Mutations R248C, G382D, K650M and
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Y373C are associated with other disorders and result in increased kinase activity. Increased
kinase activity is often the result of ligand independent signaling. The increased kinase activity is
further mitigated by the increased expression of FGFR3.
Approximately 20% of multiple myeloma patients have increased FGFR3 expression.
Overexpression of FGFR3 is the result of t(4:14)(p16.3;q32) translocation(232).The
translocation of t(4:14)(p16.3;q32) results in the FGFR3 expression regulated by a strong IgH
enhancer(233).The t(4:14) translocation is associated with a poor response to treatments(233).

Disease States and FGFR
Mutations in fibroblast growth factor receptors have been associated with numerous
diseases related to gain-of-function and loss-of-function signaling. Among the diseases FGFRs
are attributed to include: various forms of cancer, developmental disorders and skeletal disorders.

Cancer Type
Bladder

Brain

Breast

Cervix
Colon
Head and neck

Receptor
FGFR1
FGFR2
FGFR3
FGFR1
FGFR2
FGFR4
FGFR1
FGFR2
FGFR3
FGFR4
FGFR2
FGFR1
FGFR3
FGFR1
FGFR2

Up-regulated
(references)
(234-238).
(234, 235).
(240-244).
(87, 245-248).
(249).
(252).
60-76(253-269).
(253, 257, 263, 266, 267,
269).
(270-272).
(267, 273, 274).
(275-277).
(278).
(281-287).
(287-292).

Down-regulated
(references)
(239).

(250, 251).

(279).
(280).
(293).
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FGFR3
FGFR4

(290, 291, 294, 295).
(91).
Up-regulated
Down-regulated
Cancer Type
Receptor (references)
(references)
Liver
FGFR2
(297).
(298).
FGFR3
(297, 299).
FGFR4
(297, 300, 301).
Leukeamia/MPD/Lymphoma FGFR1
(302, 303, 303-306).
FGFR3
(307-310).
Lung
FGFR1
(311-321).
FGFR2
(313-316, 322-324).
FGFR3
(313, 314, 325, 326).
FGFR4
(313).
(327).
Multiple myeloma
FGFR3
(328-343).
Ovary
FGFR1
(344-346).
FGFR2
(347).
FGFR4
(274).
Pancreas
FGFR1
(348-352).
FGFR2
(353-355).
FGFR3
(356).
FGFR4
(356, 357).
Prostate
FGFR1
(358-365).
FGFR2
(366-368).
FGFR4
(358, 369, 370).
Sarcoma
FGFR1
(7, 371, 372).
FGFR2
(7).
FGFR3
(7).
Skin
FGFR1
(373, 374).
FGFR3
(375, 376).
FGFR4
(377).
Soft tissue sarcoma
FGFR1
(378).(379, 380).
FGFR2
(381, 382).
FGFR3
(7).
FGFR4
(382-386).
Stomach
FGFR1
(387, 388).
FGFR2
(387, 389-398).
FGFR4
(387).
Testis
FGFR1
(399).
Thyroid
FGFR1
(400, 401).
FGFR2
(402).
FGFR3
(403).
FGFR4
(403).
Uterus
FGFR1
(404, 405).
FGFR2
(406-408).
Table 1.11 – Identifies the myoproliferative disorders to which FGF receptors have been
associated. Adjacent to each identified FGFR are the citations identifying each receptor showing
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increased or decreased regulation. It is evident that the overall trend for cancer-linked mutations
suggests FGFRs show up-regulation.

Receptor Mutation
G70R(409,
410).
FGFR1
R78H(411).
S125L(412,
413).
T141R(414).
P252T(413).
P252S(411).
A268S(411).
A429S(415).
N546K(416).
R576W(416).
P576H
K656E(413).
V664L(413).
S24F(417).
FGFR2
M71T(411).
V77M(417).
A97T(418).
D101Y(418).
E160A(417).
R203C(413).
Q212K(419).
H213Y(417).
E219K(417).
G227E(417).
V248D(417).
R251Q(417).
S252W(418).
S252W(415).
P253R(418).
S267P(420).
G271E(417).
G272V(413).
D283N(413).
W290C(413).
G305R(417).
K310R(418).
A314D(418).

Cancer Type

Consequence

Lung
Prostate
Breast, Skin
Lung
Lung
Skin
Stomach, Colon
Colon
Brain
Brain
Lung
Brain
Lung
Skin
Bladder,
lymphoma
Skin
Cervix
Endometrial
Skin
Breast
Brain
Skin
Skin
Skin
Skin
Skin
Endometrial
Ovary
Endometrial
Stomach
Skin
Ovary
Lung
Lung
Skin
Endometrial
Endometrial

Altered ligand specificity

Increased kinase activity
Increased kinase activity (in silico)
Increased kinase activity

Decreased HSPG interaction (in silico)

Decreased HSPG interaction (in silico)
Reduced receptor dimerization (in silico)
Destabilization of the D2 domain (in silico)
Destabilization of the D2 domain (in silico)
Loss of ligand binding
Altered ligand specificity
Altered ligand specificity
Ligand-independent dimerization
Destabilization of the D3 domain (in silico)

Ligand-independent dimerization
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A315T(421).
G462E(422).
W474(417).
Receptor Mutation
D530N(417).
H544Q(423).
I547V(421).
N549K(418).
E574K(417).
P582L(424).
R612T(413).
E636K(417).
M640I(417).
I642V(417).
A648T(417).
K659M(418).
K659N(418).
K659E(421).
S688F(417).
G701S(417).
P708S(417).
R759X/Q(417).
L770V(417).
T79S(413).
FGFR3
G197S(425).
C228R(413).
Y241C(426,
427).
R248C(428).
R248C(429).
S249C(430).
S249C(431433).
S249C(434).
S249C(435).
P250R(425).
E322K(420).
G370C(427).
S371C(427).
Y373C(427).
Y373C
I376C
G380R(427).

Endometrial
Brain
Skin
Cancer Type
Skin
Lung
Endometrial
Endometrial
Skin
Colon
Lung
Skin
Skin
Skin
Skin
Endometrial
Endometrial
Endometrial
Skin
Skin
Skin
Skin
Skin
Lung
multiple myeloma
Colon

Consequence
Reduced kinase activity

Enhanced kinase activity

Decreased kinase activity (in silico)
Decreased kinase activity
Decreased kinase activity
Increased kinase activity

Decreased kinase activity (ins silico)

Inhibition of phosphorylation of Y769

multiple myeloma
Head and neck
multiple myeloma
Cervix
Ligand-independent dimerization
Bladder
Head and neck
Prostate
Multiple
myeloma
Colon
Bladder
Bladder
Bladder
Multiple
myeloma
Bladder
Bladder

Ligand-independent dimerization
Ligand-independent dimerization
Ligand-independent dimerization

Enhanced kinase activity
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G380R
G382D
Receptor Mutation
Receptor Mutation
F384L/C(425).
A391E(427).
A391E(435).
S433C(425).
A441T(425).
A452S(425).
E466K
D617G(428).
V630M(428).
D646Y
K650E(413,
427).
K650E
K650E
K650Q(427).
K650M
K650M
K650M(425).
K650T
K650T
E686K(428).
G697C

FGFR4

A717T(425).
I726F(425,
426).
C56S
R72L
T122A
A175T
R183S(414).
S232I(414).
R234H
Y367C(411).
G388R
G388R

Multiple
myeloma
Mult. Myeloma
Cancer Type
Cancer Type
multiple myeloma
Bladder
Prostate
Multiple
Myeloma
Multiple
Myeloma
Multiple
Myeloma
Brain
Head and neck
Head and neck
Bladder
Bladder
Testis
Multiple
myeloma
Bladder
Bladder
Testis
MM
Bladder
Testis
Head and neck
Head and neck
Multiple
Myeloma
Multiple
Myeloma
RMS
RMS
RMS
RMS
Lung
Lung
RMS
Breast
Lung
Liver

Enhanced kinase activity
Consequence
Consequence
Dimer stabilization

Enhanced kinase activity

Enhanced kinase activity
Enhanced kinase activity

Enhanced kinase activity

Enhanced kinase activity

Common SNP that occurs in 50% of the
population

39

G388R
G388R
G388R

Head and neck
RMS
Sarcoma

G388R
Colon
G388R
Breast
G388R(411).
Brain
G388R(417).
Skin
G388R
Stomach
N535D
RMS
N535K
RMS
Enhanced kinase activity
V550E
RMS
Enhanced kinase activity
V550L
RMS
V550M
Breast
Receptor Mutation
Cancer Type
Consequence
G576D
RMS
R616G
Lung
E681K
Lung
P712T
Lung
P716R(417).
Skin
A729G(414).
Lung
S772N
Lung
Table 1.12 – Mutations found in the FGF receptors and the disease for which they are
associated.

Skeletal disorders and FGFR mutations
The study of mutations within the FGFR started with the determination of a common
mutation in FGFR3 found among 34 individuals with achondroplasia. Since 1994 and the
discovery of the FGFR3 G380R mutation associated with short-limbed dwarfism, additional
developmental disorders have been associated with mutations in FGF receptors. Pfeiffer
syndrome, Apert, Crouzon, Beare-Stevenson, Jackson-Weiss, Meunke and Kallmann syndrome
are all found to result from mutations occurring in the FGF receptors. The location of the
mutations associated with theses diseases occur in the D1, D2, D3, juxtamembrane and tyrosine
kinase domains.
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Apert Syndrome
Apert syndrome (AS) is characterized by midface hypoplasia, syndactyly and visceral
abnormalaties and craniosynostosis (436 - 438). Craniosynostosis is the result of premature
fusion of the cranial suture. The cranial suture is composed of the periosteum, intervening
mesenchyme and underlying dura matter.
The periosteum located at the surface of the cranial suture is important in cranial bone
formation, wound healing and regeneration. The periosteum tissue contains fibroblast cells,
mesenchymal stem cells, differentiated osteogenic progenitor cells, osteoblasts and skeletal stem
cells (439-441). The stem cells and fibroblast cells found in the periosteum allows this tissue to
be capable of driving the cranial fusion observed in patients with craniosynostosis (439, 440).
Fibrobast growth factor receptor 2 mutations have been associated with AS FGFR2
mutations S252W and P253R have been found in each of 40 patients analyzed for diseases and
account for approximately 65% of the mutations resulting in AS (442). The FGFR2 S252W is
typically expressed phenotypically with cleft palate. The FGFR2 P253R differs from the S252W
phenotypes by increased syndactyly. The biological mechanism associating the S252W and
P253R mutations with the phenotypes of AS are tied to their influences on cellular proliferation
and differentiation. Models containing the FGFR2 S252W mutant have been shown to both
increase and decrease cellular proliferation (436 - 444). The contradictory cellular proliferation
studies were conducted using murine cells. More recent studies using human cell lines gathered
from patients harboring the FGFR2 S252W mutation have been conducted. Mesenchymal stem
cells (MSC) and fibroblast cells containing the FGFR2 S252W mutation has shown an increase
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in cell proliferation activity in fibroblast cells, but not in the mesenchymal stem cells. The rate of
osteogenic differentiation was increased in both MSC and fibroblast cells. Additionally,
fibroblast cells were able to induce osteogenic differentiation in periosteal MSCs. Fibroblast
cells do not result in osteogenic differentiation in MSC’s derived from other tissue. The FGFR2
S252W mutation significantly changes the osteogenic differentiation potential in cells found in
the cranial suture.

Pfeiffer Syndrome and FGFR
Pfeiffer syndrome is characterized by the premature fusion of the cranial sutures
(craniosynostosis) during development. The cranial suture premature fusion often results in
impaired cerebral blood flow, airway obstruction, impaired vision and hearing, learning
difficulties and raised intracranial pressure. The rate of occurrence of Pfeiffer syndrome is
approximately 1 in 2500(445). The most common mutations have been determined to result in
the craniosynostosis include FGFR3 (32%), FGFR4 (25%), TWIST1 (19%) and EFNB1
(7%)(446).
Cranial suture development and morphogenesis is a cellular role postulated to be
modulated by FGFR2, msx2 and transforming growth factor  1-3. The full details of cranial
suture cellular differentiation and proliferation have yet to be determined. The expression of
FGFR2 has been observed in increased amounts within the cranial sutures. The presence of
FGFR2 is also observed to be mutually exclusive with the increased expression of ostopontin.
Osteopontin is an indicator of bone differentiation (447-449). The expression of FGR2 acts to
mark cells that have not yet been differentially committed within the suture. Osteopontin acts to
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commit FGFR2 expressing cells to osteogeneic differentiation. The role of the Msx2 and
transforming growth factor beta 1-3 during suture development has not been fully elucidated.
Mammalian mutant studies have shed light on the mechanism of action resulting from
select Pfeiffer syndrome mutations. The first Pfeiffer syndrome mutation studies were conducted
using Xenopus oocytes/embryos. An injection of FGFR2 mutant C332Y mRNA was added to the
blastomere. The resulting phenotype was an elongation of the pole ectoderm and induction of
Xbra. Xbra is a marker of mesodermal expression, which acts to mimic FGF1. An
antiphosphotyrosine antibody was used to determine the degree of phosphorylation of the mutant
and wild-type FGFR. The FGFR C332Y mutants showed an increased phosphorylation of
tyrosines when compared to FGFR (wt)(447). Additionally it was determined that the C332Y
mutant was unable to bind to FGF-1. The resulting conclusion finds the PS related FGFR mutant
C332Y caused a blockage of the FGF-1 binding site as well as ligand independent activation of
the FGFR. The ligand independent activation is postulated to result from the disulfide
dimerization of adjacent FGFR. The dimerization is the result of an opening of the FGFR,
exposing additional cysteine residues (447). Pfeiffer syndrome related FGFR mutants Y349H,
C342Y and S354C were transfected into NIH 3T3 cells. The findings from this study reflected
the FGFR C322Y finding. Ligand independent dimerization resulted from each of the mutations
(447, 448).

Kallmann Syndrome (KS) and FGFR
Kallmann syndrome is a human developmental disorder characterized by underdevelopment of
olfactory bulbs (anosmia) and hypogonadotrophic hypogonadism. Additionally KS results
(GnRH) – resulting in puberty delay. Additional phenotypes are observed in patients with
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alternate mutations associated with KS. Phenotypes may include cleft palate dental agenesis and
additional reproductive malformations. Mutations identified in FGFR1 have been associated with
patients with the disease.
The FGF receptor mutations related to KS are attributed to loss-of-function mechanisms
(1). The loss-of-function is consistent with experiments of mice containing disrupted FGFR 1
genes. The disruption of FGFR 1 in mice results in persistent cell proliferation, olfactory bulb
dysplasia and decreased GnRH neurons (450). Interestingly patients containing the same FGFR1
mutations have been observed with a wide variability in phenotypes. Two Patients with identical
mutations show varied phenotypes: one with isolated hyposmia without hypogonadism and the
other patient with normosmic idiopathic hypogonadotrophic hypogonadism not observed in the
previous patient (451). The phenotype variability observed in patients with the same mutation
suggests epigenetic mechanisms or interactions with modifier genes may result in KS
phenotypes. The roles of FGFR1 during development and cellular events also require
interactions with both FGF proteins and FGFR regulators proteins.
Twenty-two different FGFs are found in the human genome. The mutations associated
KS occur in the receptor FGFR1 IIIc. Binding specificity varies between FGF receptors. FGFR1
IIIc is capable of interacting with FGF1, FGF2, FGF8, FGF9, FGF17, FGF18 and FGF23.
FGF’s show tissue specific differential expression and regulate the different cellular processes.
FGF8 hypomorphic mice result in a decreased number of GnRH neurons and a disruption of
olfactory bulb formation (452, 453). The phenotype resulting from the FGF8 hypomorphic mice
reflects the phenotype of Kallmann syndrome patients. The FGFR1 mutation L342S is found at
the FGF binding site on the D3 domain. This mutation does very little to change the binding
affinity of FGFR1 to FGF1 or FGF2. However, the FGF8 – FGFR1 IIIc L342S interactions is
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significantly inhibited by the mutation (454). Additional mutations on the FGF8 domain have not
yet been described. The interactions between FGF and the FGFR1 protein are not the single
location for mutations related to KS. Although signaling requires a 2:2:2 complex of
FGFR/FGF/heparin, mutations in regulating proteins are capable of producing KS.
Anosmin-1 directly interacts with FGFR1 IIIc on the cytoplasmic Ig domains II and III
(455, 456). Expression of anosmin-1 is associated with FGFR1 expression as it similarly located
on the KAL-1 gene associated with x-linked KS (fig. 1.13). Anosmin-1 is composed of eight
domains including; cysteine rich domain (CR), whey acidic protein-like domain (WAP), four
repeating domains (FnIII) and a histidine rich domain. The WAP and CR domains are the
domains responsible for interacting with the D2 and D3 domains of FGFR1. The FnIII domain 1
is required to form the conformation required of the WAP and CR domains to bind to the FGFR.
Surface Plasmon resonance experiments show anosmin-1 binds to the FGFR1 IIIc at 7nM
affinity (457). Anosmin-1 is capable of interacting with FGFR1 IIIc with much higher affinity
than the FGFR2 IIIc or FGFR3 IIIc. Additionally, anosmin-1 is induces cell proliferation in
BaF3 lymphoid cells expressing FGFR1 IIIc (458). However, anosmin-1 does not increase
proliferation in the same cells expressing FGFR2 IIIc or FGFR3 IIIc.

Figure 1.13 – Cartoon representation of the domains of anosmin-1. Listed above each domain is
the abbreviation of each domain including: signal peptide (sp), cystiene box (Cys Box), whey
acidic protein-like (WAP), FnIII-1, FnIII-2, FnIII-3, FnIII-4 and the histidine rich domain.
Below each domain is the amino acid numbering for each of the protein domains.

45

Missense mutations occurring in the FnIII domain of anosmin-1 results in KS
phenotypes. The mutations occurring in the FnIII domain include N267K, E514K and F517L
(457). The Anosmin-1 N267K mutation inhibits the interactions with FGFR1. However,
mutations E514K and F517L also found in the FnIII domain result in increased interactions with
the FGFR1 domain (457). Additionally, mutations found in the WAP domain are associated with
KS. Mutation anosmin-1 C172R located in the WAP domain results in the disruption of a
conserved disulfide bond. The disruption of the disulfide bond has shown to decrease the
protein-protein interaction of anosmin-1 with FGFR. The decreased interaction of anosmin-1
C172R with FGFR1 may be the result of the increased flexibility resulting from the disrupted
disulfide bond.

Non-covalent cation-π bonds
The FGFR’s are stabilized by a variety of noncovalent interactions. The twelve beta-strands
making up the FGFR D2 domain is maintained by a network of hydrogen bonds. Additionally,
the beta-sandwich structure of the D2 domain allows hydrophobic interactions to stabilize the
structure. In addition to the more common noncovalent interactions, cation-pi interactions have
been suggested to contribute to the stability of globular proteins. Cation-π interactions may be
formed from pi residue tryptophan, phenylalanine or tyrosine with cation residues lysine,
arginine, or histidine. The interaction distance of cation-π interactions are limited to a distance
of 3 – 8 angstroms (459). Additionally the optimum angle of interaction of the cation relative to
the center of the pi residue is 90°. Cation-π interactions have been shown to stabilize beta sheets,
alpha helices, protein-protein interactions and beta-hairpin structures (459-462). The energetic
significance of the cation-π interaction has been exhibited in model peptide systems as well as in
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protein structures through site directed mutagenesis (463). The energetic contributions of cationπ interactions are shown to contribute to -sheet formation, -strand interactions, turn
propensity, and proper folding (464-467). Cation- interactions involving lysine and arginine
range from -3.3 ± 1.5 kcal/mol to -2.9 ± 1.4 kcal/mol (468). Typically proteins are stabilized by
5-10 kcal/mol (469). As a result it is possible that cation-pi interactions contribute significantly
to the stability and functionality of a protein. However, there has been some discussion regarding
the overestimation of the stabilizing potential of a cation-π interaction. One significant
contributing factor to the strength of a cation-π interaction is related to the distance and
orientation of the interaction.

Characterization of cation-π interactions
Typical cation-π interactions may be formed in a variety of angles and distances. However,
there are optimal angles as well as distances to maximize the cation-π interaction. The most
common cation orientations relative to the plane of the pi residue are “t-shaped” and “parallel”
(468). The t-shaped interaction places the cation residue to a 90º angle relative to the aromatic pi
residue. The parallel type interaction is 0º relative to the pi residue. The interaction energies
determined for cation-π interaction that fall between 0º - 90º are found to have lower van der
Waals and electrostatic interactions (470). Although van der Waals and electrostatic stabilizing
forces are used to characterize the cation-π interaction, additional interactions have been
considered.
The electrostatic contribution to the interaction between cation and π residues is supported by
numerous experiments and is believed to be the major energetic factor stabilizing the interaction.
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The electrostatic interactions formed between a cation and π residue is supported by: alkali metal
interactions with aromatic residues, and changes in the aromatic residue.
The contribution of electrostatic energy to the cation-π bond interaction has been analyzed
using alkali metals interacting with aromatic pi molecules. If electrostatics is a driving force then
it is expected that the greater electrostatic potential placed over a pi residue, the stronger the
cation-π bond. The cation-π energetic trend follows the electrostatic potentials in the order of Li+
> Na+ > K+ > Rb+(471). This trend would also be followed if the aromatic pi residue were
replaced with a negatively charged residue.

Figure 1.14 – Structures studied by ab initio calculations to determine the strength of cation-π
interactions formed. Binding energies are shown for each of the cation-π complexes calculated
(Kcal/mol)(473).
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Additional forces that must be considered are polarizability, dispersion forces and charge transfer
effects (472). The contribution of electrostatic binding forces has also been established by the
analysis of the aromatic residue.
The electrostatic interactions formed by a cation with an aromatic residue may be better
understood by considering the cation-π bond strength through modifying the aromatic residue
(figure 1.13). The electrostatic interactions of a cation-π bond formed by each of the benzene
molecules clearly represent a trend. The strongest cation-π bond formed for the benzene
molecules shown in figure 1.13 begins 14 > 4 > 13 > 1 > 3. This trend also suggests electron-rich
heterocycles result in poor cation-π binding interactions. This trend has been observed in 1,3,5
trifluorobenze that is not capable of forming cation-π interactions and provides support for the
electrostatic model (473). Although there is ample evidence for the electrostatic component in
cation-π interaction, additional interactions have evidence supporting their contributions
stabilizing the noncovalent bond.
Additional forces stabilizing cation-π bonds that have been included are charge-quadrupole,
charge-dipole, charge-induced dipole, charge-transfer, dispersion forces and hydrophobic forces
(474, 475). Benzene molecules lack a permanent dipole, but do have a permanent quadrupole.
The quadrupole of benzene is the result of two dipoles aligned on the structure (476). The result
is a non-spherical charge distribution allowing for a negative charge in the z plane of the benzene
ring and small positive charge distributed to the hydrogen atoms of the benzene ring. The
quadrupole interaction is still an electrostatic bond with a nearby cation residue. Theoretical
calculations have shown point charge – quadrupolar interactions of benzene and point charges
are comparable in strength to dipolar – point charge interactions (477, 478). However, the cationπ interactions that are commonly observed occur at a distance allowing for van der Waals
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contacts. Additionally, distance dependence of a quadrupole – ion interaction is 1/r3. The
distance dependence of a cation-π interaction shows a distance dependence of 1/rn (n < 2 Å).
This proximity makes it unlikely that quadrupole – cation interactions contribute significantly to
the strength of the cation-π interaction (475). The complexity of protein structures allows for
cation-π interactions to occur in both solvent exposed, buried locations, hydrophobic and highly
electrostatic locations. Each of these variations may contribute or detract from the strength of a
cation-π interaction.
Solvation of cation-π bonds
The peptide models used to determine the contribution a cation-π interaction provides to
the stability of the peptide is most often solvent exposed. The degree of solvent exposure of the
cation or the pi residue can change the strength of the interaction by at least 0.9 kcal/mol (479).
Recent studies tuning the degree of solvent exposure identifies the role that solvent plays in
reducing the cation-π interaction. Peptide models show a cation-π pair’s allowing the aromatic pi
residue to remain buried while the cation is partially solvated estimate the cation-π interaction at
0.9 kcal/mol. In contrast, solvating both the cation and pi residues results in a cation-π interaction
of 0.06 kcal/mol (479). This data suggests the solvent exposed cation-π interactions are
significantly less stabilized than what is observed for a buried cation-π interaction. Additionally,
cation-π ineractions require that the solvated cation must undergo desolvation to bind in a
hydrophobic pocket.
Desolvation of the cationic residue is considered to be a large energetic penalty of cation-π
interactions. The CAPTURE program was used to determine the relative location of cationπ interactions in proteins. Roughly 60% of cation-π interactions show partial solvation (480).
The strength of a cation-π interaction is energetically compared to salt bridge interactions.
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However, the energetic desolvation penalty of a salt bridge interaction is double that of a cationπ interaction. The aromatic residue of a cation-π interaction shows little energetic desolvation
penalties. The cation-π interaction is not strong enough to overcome the desolvation of the
cationic residue. However, it is typically the summation of the non-covalent interactions provide
the desolvation energy needed for the burial of cationic residues. The desolvation penalties of a
lysine and arginine residue are unequal (480, 481).
The two probable interaction geometries of a cation include parallel and t-shaped
orientations. The stacked orientation of arginine relative to tryptophan allows for preferential
hydrogen bonding of the NH groups adjacent residues. The preferential interaction of the argnine
sidechain places the epsilon carbon superficially to the indole ring. The stacked interaction of the
arginine residue also provides additional van der Waals contacts with the pi residue. The van der
Waals contacts of an arginine residue are not possible by any orientation of lysine over a pi
residue (480, 481).

Figure 1.15 – Shows the two major conformations of a cation relative to a pi residue. The left
structure shows the arginine residue in parallel or stacked orientation relative to the plane of the
tryptophan residue. The right structure shows the argnine in t-shaped orientation relative to the
plane of the tryptophan.
The desolvation penalties of a lysine residue is higher that arginine. These interactions are
observed in small molecule cation-π bonds. The cation-π interaction of ammonium with benzene
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is stonger than the interaction of guanidinium with benzene under the same conditions (480,
481). The difference is considered to be the result of desolvation required for a cationπ interaction to form (480, 481). The van der Waals interactions as well as the electrostatic
interactions are the two main parameters considered when determining the strength of a cation-π
interaction.
In silico determination of cation-π interactions
The in silico determination of a cation-π interaction must take into consideration the
contribution of several non-covalent forces contributing to a cation-π bond. The most agreed
upon component of a cation-π interaction is the electrostatic force. However, the electrostatic
interaction of the cationic residue is formed with an aromatic residue having no net negative.
Additionally, the strength of a cation-π interaction has shown to be both distance and angle
dependent. Coulombic charge interaction calculations typically used for charged interactions are
only distance dependent. The second most agreed upon parameter of a cation-π interaction is the
van der Waals interaction.
The van der Waals interaction is considered to contribute significantly to the cationπ interaction. The calculation required for van der Waals interactions must take into account
electron correlation effects. Calculation accounting for electron correlation effects include ab
initio – Møller-Plesset perturbation (MP2), coupled-cluster with singles, doubles and
perturbative triples (CCSD(T)) or quantum Monte Carlo calculations. Additional calculations
such as density functional theory (DFT) have also been used to determine van der Waals
interactions. Local density approximations and generalized gradient approximations used for
DFT calculations have been shown to fail in the estimation of van der Waals interactions. The
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most commonly used calculation to determine cation-π interactions in a protein have been
developed by Dougherty et al. (475).
The program cation-π trends using realistic electrostatics (CaPTURE Program) was
developed by Dougherty et al. This program uses ab initio calculations as well as modified
optimized potential for liquid surface (OPLS) calculations. Using the OPLS force field subsets,
the capture program is able to estimate both electrostatic and van der Waals interactions (482).
Additionally, the CaPTURE program sets distance constraints of 6Å for the determined cationπ interactions.
There are additional physical characteristics of a cation-π interaction that must be taken into
account. Cation-π bonds may also be contributed to by hydrogen bonds occurring between –OH
groups on tyrosine and the amino groups of lysine and arginine. Energetic penalties resulting
from the solvation of cationic residues have been taken into consideration from other prediction
models, but not in the CaPTURE program.
The chemical environment of a cation-pi interaction may significantly change in the
strength of the interaction. Traditional gas phase studies of cation-π interactions fail to account
for changes in the noncovalent interaction resulting from solvation. The chemical environment
can significantly reduce or increase the cation-pi interaction. Chemical environment altering
cation-π interactions include the solvent exposure of the cation or pi residue, anion coordination
to the cation or pi residue and the hydrophobic environment surrounding the cation or pi residue.

Intrinsic Fluorescence of Proteins
The intrinsic fluorescence of proteins has served as a probe to monitor the stability of
proteins through thermal denaturation, pH titrations and chemical denaturants. Additionally,
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intrinsic fluorescence may be used to observed structural changes upon protein-protein or
protein-ligand binding interactions. The intrinsic fluorescent probes common in proteins include
amino acids tyrosine, phenylalanine and tryptophan. Although proteins are often abundant in
these residues, the low quantum yields of tyrosine and phenylalanine make these intrinsic
fluorophores undesirable. The high quantum yield of tryptophan has made this residue one of the
most studied residues in protein fluorescence. However, there remain unique characteristics of
tryptophan fluorescence that complicate the fluorescence spectrum acquired from tryptophan
containing proteins. Single tryptophan containing proteins have shown unique and unpredictable
characteristics that are not common among multi-tryptophan containing proteins. Tryptophan
fluorescence is strongly sensitive to the local environment that may significantly influence the
quantum yield (ϕf), excited state lifetime (τf) and wavelength (λmax) (483). The most significant
contributor to the irregularity of a fluorescence spectrum is the electrostatic landscape
surrounding the tryptophan side chain. Placement of charged residues around tryptophan side
chains may result in the maximum wavelength to shift to the red or blue. The major
considerations that must be taken into account for tryptophan fluorescence intensity and lifetime
include: electrostatic environment, charged residues and fluorescence quenching side chains.
Tryptophan fluorescence is initiated by the excitation of the electrons in the pyrole ring of the
tryptophan side chain. The wavelength of light required for tryptophan fluorescence is 280 nm.
The excited state electrons in the pyrole ring then transfer to the benzene ring of the tryptophan
residue. Stabilization of the electron density shift from the pyrole to the benzene ring (ground
state to the excited state 1La) may determine the degree of red shift of the wavelength maximum
(483). Additionally, the intensity of the fluorescence observed for tryptophan residues is
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proportional to the stabilization of the electron density shift from the indole ring as a whole to
the electron acceptor during photoinduced electron transfer.

Fluorescence lifetime
Excited state fluorophores are able to undergo a variety of transformations that may include
electron redistribution, structural changes and chemical reactions. Commonly fluorophores
undergo a nonradiative loss of photoinduced energy in a process called quenching. Quenching is
a process that results in a loss or decrease in the fluorescence lifetime. Quenching is a process by
which energy is transferred and may occur internally by molecular vibrations or rotations or
externally by transferring the energy outside the molecule. Fluorescence quenching mechanisms
include internal rotation, temperature, viscosity, polarity and excited state electron transfer.

Temperature
The temperature of a solution may have defined effects on the observed fluorescence from the
fluorophore. The solvent is among the contributors to fluorescence quenching and fluorescence
lifetime as the temperature increases (106). The temperature dependence of the fluorescence
lifetime is approximated by the Arrhenius equation:

Figure 1.16 - Arrhenius eq. depicting the approximation temperature has on the rate of solvent
quenching (K). Additional parameters include the pree-exponential factor (A ~ 1015 – 1017 sec-1),
energy of activation (Ea ~ 11-13 kcal*mol-1), gas constant (R), and the temperature in Kelvin (T).
Increasing temperature is capable of varying the Ksol. by ~ 107 sec-1.
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Electron Transfer to the Peptide Backbone
The peptide backbone can also be a potential quenching agent of tryptophan residues.
The mechanism proposed for the tryptophan to backbone electron transfer is from the Cε of the
tryptophan residue to the carbonyl carbon of the peptide backbone (484). Additional
considerations that may alter the efficiency of the tryptohan to backbone electron transfer include
the rotameric state and the medium between the side chain and carbonyl (485-487). The electron
transfer has been described by Marcus and Sutin:

kET(R)=k0 exp(−β(R−R0))
Figure 1.17 - Marcus and Sutin equation for the rate of electron transfer from a sidechain to the
peptide carbonyl. In the Marcus and Sutin equation the rate of electron transfer (K et) is
determined by rate constant for electron transfer from van der Waals distance of 3 Å (K0), the
distance between the donor and acceptor (R) and the sharpness of the distance dependence (β).

The Marcus and Sutin equation requires a series of parameters including the distance between
the tryptophan and carbonyl. However, additional parameters including the rotameric states of
the tryptophan side chain are required to understand the quenching mechanism.
Goldman et al have determined the possible rotameric states during electron transfer from
the tryptophan residue to the carbonyl side chain (487). Classical molecular mechanics
calculations were used to determine six rotameric conformations for the tryptophan side chain
for electron transfer to the backbone.
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Figure 1.18 - Structure of the tryptophan residue showing the indole and benzene rings involved
in electron transfer (Cε2).
The semi-empirical calculations were used to determine the charge distribution and ionization
potentials for each rotameric state. The two possible electron donors from the tryptophan side
chain were determined to be Cε3 and Cξ2. When Cξ2 is the electron donor the lifetimes were
between 0.1 – 10 ps, which is unrealistic slow for lifetimes (483). However, when Cε3 is the
electron donor lifetimes were 0.11ns – 0.1ps. This is a more reasonable value that makes the Cε3
the more likely electron donor (487).

Fluorescence quenching side chains
The ability for side chains to quench tryptophan residues has been thoroughly studied.
Quenching rate constants have been determined for side chains containing protonated amino
groups (Lys or α-amino groups). Glutamine and asparagine are considered to be weak
fluorescence quenching agents (4 x 107 and 2.4 x 107 M-1 sec-1) (488). Protonated histidine
residue side chains also serve as a strong electron acceptor (Kq – 2.9 x 109 M-1 sec-1)(489, 489491). Additionally, amino acid cysteine (including disulfide bonds) is the most efficient
fluorescence quenching side chain (Kq – 4 x 109 M-1 sec-1) Disufide bound cysteine residues is
also efficient fluorescence quencher (Kq ->1010 M-1 sec-1) (492, 493). Additionally there are
residues that have historically been mistakenly considered as fluorescent quenching residues.
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There are several residues with little evidence supporting the ability to be considered to
be fluorescence quenching residues. Residues that are mistakenly considered to be fluorescent
quencher include glutamate, aspartate and phenylalanine. The negative charge of glutamate and
aspartate make unlikely electron acceptors (494). However, the proximity of a negatively
charged near a tryptophan is able to significantly increase the rate of tryptophan fluorescence
without being the electron acceptor. Phenylalanine side chains have also been mistakenly
considered to be a fluorescence quencher. However, the highest occupied molecular orbital of
tryptophan is too low in energy and the lowest unoccupied molecular orbital is too high in energy
to allow an exited state electron transfer from tryptophan (494).

Electrostatic interactions and tryptophan quenching
Stabilizing electrostatic interactions allow for an increase electron transfer rates that
increase the quenching rate. Electron transfer from the tryptophan side chain to the electron
acceptor requires the charge transfer state to be equal to the electron acceptor. The charge
transfer energy may be adjusted by the location of charged residues surrounding both the
tryptophan side chain and the electron acceptor. Placement of a negatively charged residue
(asapartic acid or glutamic acid) near the tryptophan side chain and a positively charged residue
(lysine or arginine) near the electron acceptor acts to stabilize the electron transfer (495).
Stabilizing the electron transfer from the tryptophan side chain to the electron acceptor acts to
significantly reduce the fluorescence intensity. Conversely, the charge transfer may be hindered
by the placement of charged residues around the tryptophan side chain. Insertion of a positively
charged residue (lysine or arginine) near the tryptophan side chain and a negatively charged
residue (aspartic acid or glutamic acid) near the electron acceptor will hinder the charge transfer.
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Inhibition of the charge transfer results in a build up of overall electron density on the benzene
ring of tryptophan resulting in increased fluorescence (495). The effect of the placement of
charged residues residing near the fluorescing residue to alter the charge transfer state is
considered to be the internal Stark effect.

Single tryptophan proteins
Single tryptophan proteins show unique fluorescence lifetimes when compared to
multiple tryptophan proteins. Single tryptophan proteins often show multiple fluorescence
lifetimes. The two major considerations explaining single tryptophan fluorescence include: the
existence of different states that do not interconvert on the fluorescent time scale (ground state
heterogeneity) and the existence of reversible excited state dynamics of the tryptophan residue.
Ground state heterogeneity occurs as a result of multiple rotameric states of the
tryptophan side chain. Each of the rotameric states possible for tryptophan do not interconvert on
the nanosecond timescale (496-498). Single tryptophan protein experimental evidence has
suggested the overall protein fold is unchanged while microstates for the tryptophan residues
continues to change. Additionally, the different microstates possible for a single tryptophan
residue allows for different quenching constants (Kq). The different quenching constants may be
determined for a single tryptophan with as single electron acceptor. Examples of this have been
observed in the single tryptophan protein colocin (499). Importantly, the timescale of the
heterogenic states of tryptophan also play a significant role fluorescence lifetime observed for
single tryptophan proteins. A number of case studies suggest the microstates to be on a
nanosecond timescale (bacteriophage T4 lysozyme, hemoglobin and phsophofructokinase)(500-
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502). The microstates determined have been suggested to be the result of rotation of the
tryptophan residues about the Cα - Cβ and the Cβ - Cγ bond.
Tryptophan rotameric states about the Cα - Cβ interconvert rapidly within protein (503).
However, rotamers of tryptophan residue resulting from interconversions about the Cβ - Cγ bond
occur on a much slower timescale (504). Interconversion data suggests the rotameric states of
tryptophan residues buried in proteins occur on a timescale from 0.04 ns – 0.5 ns (505). The
slower predicted rotation about the Cβ - Cγ bond was expected to contribute to the most to the
multiple fluorescence lifetimes. However, experimental studies of a cyclic hexapeptide suggest
the interconversion about the Cα - Cβ to be the major axis of rotation. Additionally, there are
many structural rotameric states that complicate the possible electron acceptor – tryptophan
interactions. As a result the number of unique fluorescent lifetimes may be unique to the protein
and the microenvironment of the tryptophan.
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Abstract
Activation of the Fibroblast growth factor receptors (FGFR) is a key step in important cellular
processes such as, angiogenesis, cell differentiation and tumor growth. The extracellular D2
domain of the FGFR is the binding site for both FGF and heparin. CaPTURE prediction program
identified a cation-π interaction in both the crystal and NMR solution structure of the D2 domain
of FGFR2.

Interestingly, the CapTURE predicted lone cation-π interaction is located in

distinctly different locations in the crystal (R152-Tyr155) and solution (Trp191-Arg203)
structures of the D2 domain. The significance of the lone cation-π interaction, in terms of
stability and heparin affinity, was studied by site-directed mutagenesis and in conjunction with a
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variety of biophysical studies. Results of the far-UV, steady-state fluorescence, and 1-anilino
naphthalene 8-sulfonate binding suggest that the mutations which are designed to potentially
disrupt the predicted cation-π interaction only cause subtle conformational changes in the D2
domain. Limited trypsin digestion data show that disruption of the predicted cation-π interaction
increases the backbone flexibility of the protein. Differential scanning calorimetry (DSC) data
show that loss of the predicted cation-π interaction causes a significant decrease in the
thermodynamic stability of the D2 domain. DSC data unambiguously support the existence of a
cation-π interaction between Trp191 and Arg203 predicted in the NMR solution structures.
However, DSC results conclusively show that the electrostatic interaction, observed in the crystal
structures of the D2 domain, between the positively charged guanido group of Arg203 and the
negatively charged -carboxyl of Asp225 is irrelevant in solution.

Isothermal titration

calorimetry data show that disruption of the cation-π interaction (Arg152-Tyr155) predicted in
the crystal structure does not significantly affect the binding affinity of the D2 domain to
heparin. In the contrary, loss of the predicted Trp191-Arg203 cation-π interaction in solution
causes a ~ 20-fold decrease in the heparin-D2 domain binding interaction. 1H-15N chemical shift
perturbation data suggest that disruption of the predicted Trp191-Arg203 cation-π interaction
causes subtle but clear long-range structural effects resulting in increase in the overall flexibility
of the backbone of the D2 domain. The results of this study, for the first time, demonstrate the
presence of cation-π interaction between Trp191 and Arg203 and also show that it plays an
important role in the thermodynamic stability and in ligand binding affinity of the D2 domain of
FGFR2.
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Introduction
Protein structures are stabilized by non-covalent forces such as electrostatic interactions,
hydrogen bonds, hydrophobic forces, and cation-π interactions (1). The least understood of these
forces are the cation-π interactions. Cation-π interactions are a subset of electrostatic attractions
between positively charged amino acids, such as lysine and arginine, and the quadrupole moment
generated by the π-cloud of aromatic amino acids (2). A survey of X-ray structures of proteins
deposited in the Protein Data Bank (PDB, http://www.pdb.org) revealed that cation-π
interactions are a common feature of protein structures and occur at an average of one in 77
residues (3). In recent years, cation-π interactions have garnered considerable interest due to their
role in structure, stability, folding and interactions of proteins (4-9). For example, cation-π
energy has been demonstrated to be correlated with the gating efficiency of the nicotinic
acetylcholine receptor (10-20). In addition, cation-π interactions are implicated as an important
structural force in DNA-protein complex formation, oligomerization of transmembrane helices,
self-assembly of collagen peptides, enzyme catalysis, enhancement of stability of thermophilic
proteins, ligand recognition, and enzyme catalysis (21, 22). The energetic significance of the
cation-π interaction(s) has been demonstrated in model peptide systems as well as in protein
structures by site-directed mutagenesis studies (4, 23-26). Cation- interaction energy involving
lysine and arginine range from -3.3 ± 1.5 kcal/mol to -2.9 ± 1.4 kcal/mol (3, 27-37).
CaPTURE (Cation-π Trends Using Realistic Electrostatics) has been successfully used to
predict cation- interactions in proteins (3). Studies have shown occurrence of cation-π
interactions in a number of protein structures deposited in the Protein Data Bank (3). In
particular, cation-π interactions are more prevalent in membrane proteins and thermophilic
proteins. (21, 22)The accuracy of prediction of cation-π interaction in crystal structures using the
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CapTURE algorithm is well documented (38). However, the studies focused on examination of
accuracy of CaPTURE prediction(s) based on the three-dimensional solution structures of
proteins determined by NMR spectroscopy is sparse. In this context, it will be interesting to
compare the strength of the cation-π interactions predicted in the X-ray and NMR solution
structures of proteins by the CaPTURE algorithm. This is important because the strength of the
cation-π interactions have been shown to be significantly influenced by the presence of aqueous
solvents (39-43). The conformational distributions in the ensemble of NMR structures allow for
flexible snapshots of a protein’s allowed conformations. In this context, it is possible that flexible
conformations determined by NMR involve important stabilizing interactions which are not
observed by the more rigid x-ray structures.
Fibroblast growth factors (FGFs) are approximately 16 kDa heparin-binding proteins that
regulate key cellular processes such as angiogenesis, cell differentiation, morphogenesis, wound
healing and tumor growth.(44-50). FGF receptors consist of three extracellular ligand binding
domains (D1, D2, D3), a single transmembrane helix, and cytoplasmic tyrosine kinase domain.
Cell surface-bound heparan sulfate proteoglycans (HSPG) that support dimerization or
oligomerization of the FGFRs are thought to be crucial for activation of the signaling pathway
(51, 52). The D2 domain is suggested to bind to both HSPGs and FGFs to form a ternary
complex. 4 The structure of the FGF binding complex of the FGFR has been well characterized
by Platnikov et. al to include FGF: FGFR: heparin in a 2: 2: 2 complex (53). Within the D2
domain there exist non-covalent interactions that stabilize the structure enabling it to interact
with FGF and heparin. In this context, it will be interesting to examine if the 3D structure of the
D2 domain contains potential cation-π interactions and also the role these interactions play in the
stability and ligand binding interactions.
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In this study, cation-π interactions in the D2 domain of x-ray and NMR solution structures were
identified using the CAPTURE program (54). Interstingly, both the x-ray and NMR structures of
the D2 domain predict a potential cation-π interaction. However, interestingly, the residues
participating in the cation-π interaction are diferent in the crystal and solution structures. The
authenticity of the prediction of cation-π interaction in the crystal and solution structures of the
D2 domain was verified using site-directed mutagenesis and a variety of biophysical studies,
including multidimensional NMR. Results of this study clearly suggest that the cation-π
interaction, W191-R203, observed in the solution structure of the D2 domain is accurate.
Comparison of ligand binding affinity and stability of wild type and mutants of the D2 domain
indicate that W191-R203 Cation-π interaction is important for both heparin and FGF.

Material and Methods
Mutagenesis, Expression and Protein Purification
All mutations on the FGFR D2 were made using the Quikchange protocol (Stratagene). The
designed mutations were confirmed by DNA sequencing. The mutations were all made to the
D2 domain contained in the pET20b vector.
BL-21(DE3) pLysS E. coli strain was used to overexpress the wild type and mutants of the D2
domain. Bacteria were grown under controlled shaking conditions (270 rpm) at 37 C in LB
medium containing 100mg/ml ampicillin and 100mg/ml chloramphenicol. Bacterial cells were
induced using IPTG at a O.D.600 value of 0.6. After induction the bacterial cells were allowed to
grow incubated at 37 C for another 5 hours. The cell culture was centrifuged at 6000 rpm to
pellet the cells. Cell samples were sonicated using a Microson XL unit with the power setting
adjusted to 12. The samples were sonicated 60 times at 1-second interval. The cell lysate was
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centrifuged at 16K rpm to pellet the cell debris. Following centrifugation, the pellet was
resuspended in 5M NaCl and centrifuged at 10K rpm. The pellet was then resuspended using 1M
urea and centrifuged at 10K rpm. Finally, the pellet was resuspended using 8M urea and
centrifuged at 10K rpm. The supernatant was dialyzed against 10mM phosphate buffer, 100mM
NaCl and 50mM ammonium sulfate (pH 6.5) in order to refold the protein. Dialysis was carried
out multiple rounds of buffer with a minimum of 3 hours per exchange. The dialyzed sample
was loaded onto a heparin sepharose column and eluted using a salt gradient between 0.3 – 1.5
M NaCl. The purity of each fraction was assessed by 10% SDS gel electrophoresis.

Cation-π Binding Interactions
The CaPTURE program was used to predict cation-π interactions in the available crystal (PDB
codes -1EV2, 1DJS and 1E0o) and solution (PDB code – 1WVZ) of D2 domain of the FGF
receptor-2 (FGFR2). The CaPTURE program identifies the potential cation-π (aromatic) sidechain interactions. The cation- π interaction energetic potentials were determined using OPLS
(optimized potentials for liquid simulations) force fields. The methodology for execution of the
CaPTURE calculation has been previously reported (55).

Circular Dichroism
Far UV CD measurements on the wild type and mutants of the D2 domain were acquired in
10mM phosphate buffer containing 100 mM NaCl and 50 mM ammonium sulfate (pH 6.5). All
CD spectra were acquired on a Jasco J-710 spectrometer at room 25 C. Wavelength scans were
set to 250-190 nm. Samples were approximately 90- 100 M in concentration and a 0.1 cm path
length cuvette was used for data acquisition. Each spectrum is an average of 10 scans.
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Steady-state Fluorescence
All steady state fluorescence measurements were made using a Hitachi F2500 fluorimeter. A 1.0
cm path length cell was used and concentration of each sample was adjusted to ~50 uM. The
excitation wavelength was set to 280 nm and acquisition from 300 to 450 nm. For the ANS
binding experiments, excitation wavelength was set at 390 nm and the emission was monitored
from 450 nm to 600 nm. ANS titration was carried out by addition of 3 l. aliquots of 10mM
ANS to a fixed volume of protein in 10mM phosphate buffer containing 100 mM NaCl and 50
mM ammonium sulfate at a pH of 6.5.

Differential Scanning Calorimetry
Differential scanning calorimetric measurements were performed using a DASM-1M
calorimeter. The concentration of the protein was was between 1.0 – 1.5 mg/ml in 10 mM
phosphate buffer containing 50 mM ammonium sulfate and 100 mM NaCl (pH ~6.5). All
samples were degassed prior to loading into the microcalorimeter. The temperature scanning rate
was set to 1 °C/min and the protein melting profiles were monitored scanned from 10 °C - 90°C.
The Tm values were determined using Origin DSC software provided by Microcal Inc. The
entropic or enthalpic energies are not reported because D2 domain does not completely refold
back to its native conformation on cooling the sample from 90C to 10C.

Isothermal Titration Calorimetry
Isothermal titration calorimetry measurements were performed using a Microcal VP titration
calorimeter (Northhampton, MA, USA). The concentration of the D2 domain used was 50 M in
10 mM phosphate buffer containing 50 mM ammonium sulfate and 100 mM NaCl (pH ~6.5).
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Titrations consisted of 5-10μl injections of 0.5 mM sucrose octasulfate (heparin analog)/FGF-1
delivered into 0.050 mM concentration of D2. Injections were delayed 3.5 minutes to allow the
titration peak to return to a baseline prior to additional injections. All titrations were corrected for
background heat changes. The raw data was fit using the available (Origin software supplied by
the vendor) binding models and the 2 values were used as a guide to decide on the accuracy of
the fitting model.

NMR Spectroscopy
1H-15N HSQC experiments were acquired using

15

N isotope enriched D2 domain sample. The

concentration of the protein(s) was in the range of 0.15 – 0.5 mM. in 10 mM phosphate buffer
(95% H2O + 5 %D2O, pH 6.5) containing 50 mM ammonium sulfate and 100 mM NaCl. All
NMR experiments were conducted at 298°K. All experiments were conducted using Bruker
Avance 700 mHz or Bruker Avance 500 mHz NMR. All NMR data were referenced to the 1H
resonance frequency of DSS.

Results and discussion

Prediction of cation- interactions- 3D structures of the ternary FGF signaling complex,
consisting of, FGF (ligand), heparin/SOS, and FGFR, shows that the D2 domain contributes
significantly to the binding of heparin as well as FGF (56) Deletion of the D2 domain completely
abolishes the FGF signaling process. To-date, multiple crystal structures of the extracellular
domains of FGFR, D2-D3, are available available (57-59)However, only one NMR solution
structure of the D2 domain has been reported (60). The 3D structure of the D2 domain of FGFR2
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has an immunoglobulin-like fold consisting of 10 antiparallel -strands arranged in a -sandwich
structure. Potential cation-π interactions in the D2 domain of FGFRs using the CaPTURE
program (http://capture.caltech.edu/) (3). Table-1 shows the cation-π interactions predicted in the
crystal and solution structures of the D2 domain of FGFR. The CaPTURE program predicts one
cation-π in the crystal and solution structures of D2 domain. However, interestingly, the location
of the predicted lone cation-π interaction is different in the crystal and solution structures of the
D2 domain (Fig. 2.1). The crystal structures consistently show a cation-π interaction between
Arg152 (located in -strand A) and Tyr155 (located in -strand A). The center of the phenolic
ring of Tyr155 is separted from the alpha-carbon atom of Arg152 by a spatial distance of 3.7-4.2
Å and planes of disposition of their side-chain subtend an angle of ~91°. The predcited average
electrostatic and van der Waals energies of the Arg152-Tyr155 cation-π interaction are quite
favorable and are ~ -3.8 kcal.mol.-1 and -3.5 kcal.mol.-1 , respectively. These predicted energies
values are in good aggreement with the experimentally determined values reported for different
types of cation-π interactions (3, 27, 28).

The R152-Y155 interaction site occurs in the x-ray

structures of the D2 domain. The W191-R203 cation- interaction is observed in the D2 NMR
structure. Interestingly, the CaPTURE program does not predict the presence of the Arg152Tyr155 cation-π interaction in any of the structures constituting the ensemble of the NMR
solution structures of the D2 domain. In the contrary, a cation-π interaction between Trp191
(located in -strand C) and Arg203 (located in -strand D) is predicted in the ensemble of the
solution structures of the D2 domain determined by multidimensional NMR spectroscopy (60).
The average distance between the center of the indole ring of Trp191 and the alpha-carbon atom
of Arg203 ~3.5 – 5.4 Å in the NMR structures of the D2 domain. It should be mentioned that
due to lack of sufficient side-chain NOE distance constraints, the spatial distance between
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Trp191 and Arg203 in the individual structures (constituting the ensemble of NMR structures)
was observed to show significant variation. The angle subtended by the side-chains of Trp191
and R203, involved in the cation-π interaction, is ~ 94 - 99 . The average electrostatic energy
for the Trp191-Arg203 cation-π interaction is ~ 3.87 kcal. mol.-1 (Table 2.2)
To our knowledge, cation-π interactions predicted in the crystal and solution structures of
a protein have not been directly compared. In this context, the observed disparity in the cation-π
interactions predicted in the crystal and solution structures of the D2 domain of FGFR2 is
interesting.

A.

B.
R152

Y155

W191

R203

D225

Figure-2.1. Depiction of the x-ray (Panel A, PDB: 1EV2) and NMR solution structures (PanelB, PDB: 1WVZ) of the D2 domain of FGFR2. The residues labeled indicate sites that are
predicted to form cation-pi interactions.
Therefore, we verified the authenticity of the predicted cation-π interactions in the 3D structure
of the D2 domain by mutating specific residues and monitoring the consequence of the site-
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specific mutations on the structure, stability, and ligand binding properties. In this context,
several site-specific mutations (K151E, K151L, K151R, R152E, R152L, R152K, F198A, R203E,
R203L, Y155A, W191A, and R203L/W191L, D225A), which can potentially disrupt the
predicted cation-π interactions in the crystal and solution structures of the D2 domain of FGFR,
were generated.
FGFR2 Pi
Cation ES
VDW
D2 PDB residue residue (kcal/mol) (kcal/mol)
1WVZ
#5

W191

R203

-6.28

-0.12

1WVZ
#7

W191

R203

-1.2

-1.78

1WVZ
#10

W191

R203

-4.14

-2.04

1EV2

Y155

R152

-4.64

-3.86

1DJS

Y155

R152

-2.98

-3.04

1E0o

Y155

R152

-3.73

-3.04

Table 2.2. Cation- interactions predicted by the CAPTURE program in the 3D structures of the
D2 domain of FGFR2. ES and VDW refer to the electrostatic (ES) and van der Waals energies
for each cation –π interaction. The NMR solution structures of FGFR2 D2 are represented by the
pdb code 1WVZ and the and the crystal structures of the D2 domain of FGFR2 are represented
by the pdb codes 1EV2, 1DJS and 1E0o.
Secondary structure is not perturbed by the disruption of the predicted cation-π interactions
It is important to assess if disruption of potential cation-π interactions would cause significant
changes in the backbone conformation of the D2 domain.

Far UV CD provides useful

information on the backbone conformation of proteins (61). The far-UV circular dichroism
spectra of the wild type and the designed mutants of the D2 domain are shown in Figure 2.2. The
far UV CD spectra show a positive and negative ellipticity bands centered at around 205 nm and
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225 nm, respectively. These spectral features are reminiscent of a protein with beta-sandwich
architecture (60). Interestingly, the far UV CD spectra of the wild type and the designed mutants
of the D2 domain superimpose quite well suggesting the disruption of the potential cation-π
interactions, caused due to the designed mutations, does not have significant effect(s) on the
backbone conformation of the protein.

Figure-2.3 Panel A - shows the circular dicroism spectra of the mutants shown to have
significant changes in flexibility or stability. Panel B shows the steady state fluorescence of wild
type and selected mutants of the D2 domain. The mutant proteins only minor red shift in their
wavelength of maximum emission.

Disruption of cation-π interactions only causes minor tertiary structural changes: Monitoring
changes in the intrinsic steady state tryptophan fluorescence spectrum of a protein yields
valuable information on the tertiary structural changes that can potentially occur as a result of
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site-specific mutation(s). The D2 domain contains three tryptophan residues at positions W156,
W214 and W191. Trp191 is buried in the interior of the structure of the D2 domain and the other
two tryptophans, Trp156 and Trp214, are moderately exposed at the surface of the protein.
Steady state fluorescence spectrum of the wild type D2 domain shows an emission maximum of
~ 339 nm and is reflective of the presence of partially buried indole chains in the protein (Figure2.3). The fluorescence spectra of all the designed mutations show a minor red-shift in the
wavelength of emission maximum (Figure-2.3). The W191L/R203E shows a maximum red shift
of ~ 5 nm (Figure-2.3). These results indicate that only subtle changes in the tertiary structure
occur when the predicted cation-π interaction(s) in the D2 domain are disrupted.

Subtle conformational change leads to increase in solvent- exposed non-polar surface: ANS
(8-anilino-1-napthalene sulfonate) is a hydrophobic dye that exhibits weak emission in aqueous
solutions. However, the emission of ANS increases significantly when it binds to solventexposed non-polar pockets in the protein. Therefore, ANS is an useful probe to monitor subtle
conformational changes which lead to increased exposure of solvent-exposed non-polar
surface(s) in proteins. In this context, we performed ANS binding studies to probe the potential
tertiary structural changes caused due to mutations disrupting the cation-π interaction. Titration
of wild type D2 domain with ANS shows an emission maximum at around 510nm. The emission
intensity (at 510 nm) increases very moderately when wild type D2 domain is titrated with ANS
in the concentration range of 0 – 250 M (Figure-2.4). All the mutations which potentially
disrupt the predicted cation-π interaction(s), such as, Y155A, R203E, R203L, R203K and
W191A, consistently show higher emission intensity than wild type D2 domain suggesting that
the designed mutations cause a subtle conformational change resulting in greater solvent122

exposure of the hydrophobic surface(s) in the protein. ANS emission intensity changes are most
pronounced for the mutations, which potentially disrupt the Trp191-Arg203 cation – π
interaction than those, which cause loss of the R152-Y155 interaction. These results plausibly
suggest that loss of the Trp191-Arg203 cation-π interaction predicted in the NMR structure(s) of
the D2 domain causes more discernible changes in the tertiary structure than the R152-Y155
cation-π interaction predicted in the crystal structures.

Figure 2.4: Panel A - ANS titration of the mutants and the wild type D2 domain monitored at
490 nm. Mutants D2 Y155A, W191A and R203E, L and K showed significant increases in
fluorescence when titrated with ANS. The D2 K151 is an example of an insignificant change in
the fluorescence when titrated with ANS. Panel B – Steady-state fluorescence titration of D2
(wt) with ANS.
Loss of cation-π interaction increases the conformational flexibility of the D2 domain: Limited
trypsin digestion is a common method to evaluate the flexibility of a protein (62, 63). There are
nine lysines and six arginines in the D2 domain making trypsin an apt choice for monitoring the
effect of the designed mutations on the conformational flexibility of the D2 domain.
Densitometric scan of the intact ~12 kDa D2 domain band on SDS-PAGE shows about ~50% of
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the D2 domain band is digested in the first five minutes of incubation with the enzyme (Figure2.5). Interestingly, R203E, W191A and Y155A mutants of the D2 domain are completely
digested within the first five minutes (Figure-2.5). These results suggest that designed mutations
cause a subtle conformational chain, which increases the flexibility of the protein backbone and
consequently rendering it more susceptible to trypsin cleavage. Therefore, the results of the
limited trypsin digestion corroborate the ANS fluorescence data that indicate a subtle tertiary
structural change in the R203E, W191A and Y155A mutants.
A.

B.

Figure 2.5 - Panel A shows the 15% SDS PAGE of the limited-trypsin digestion of the wild type, R152E, Y155A,
W191A and R203E mutants of the D2 domain after 0, 2, 4, 6, 8, 10, 15, 20, 30 and 40 min of incubation of the
protein domain with trypsin. Panel B shows the densitometric plot of the limited-trypsin digestion of wild type
(black), R203E (red), Y155A (blue), W191A (orange) and R152E (green).

flexibility of the D2 domain. Densitometric scan of the intact ~12 kDa D2 domain band on SDS
PAGE shows about ~50% of the D2 domain band is digested in the first five minutes of
incubation with the enzyme (Figure-2.5). Interestingly, the designed mutants of the D2 domain
are completely digested within the first five minutes (Figure-2.5). These results suggest that
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designed mutations cause a subtle conformational chain, which increases the flexibility of the
protein backbone and consequently rendering it more susceptible to trypsin cleavage. Therefore,
the results of the limited trypsin digestion corroborate the fluorescence data, which indicate a
subtle tertiary structural change in the designed mutants.
Cation-π interactions contribute significantly to the thermodynamic stability of the D2
domain: Differential scanning calorimetry (DSC) is a popular technique for the direct
measurement of the thermodynamic stability of proteins (64, 65).

DSC facilitates the

measurement of melting temperatures (Tm), the temperature at which 50% of the population of
protein molecules are in the denatured state(s)]. Least-square fitting the individual DSC profiles
reveals that the Tm of wild type D2 domain is ~ 52.0  C. The Tm values of Y155A, R103E,
R203L, R203K, W191A and W191L/R203L mutants of the D2 domain are about 10C lower
than that of the wild type (Figure-2.6).

These results indicate that the predicted cation-π

interactions contribute significantly to the thermodynamic stability of the protein.
Pitteloud et al reported that D225-R203 mutations result in a loss-of-function (66). It
is believed that a mutation of D225 or R203 favors destabilization of the D2 domain, which
consequently results a loss-of-function. Interestingly, one of the notable differences between the
crystal and solution structures of the D2 domain is the interaction forged by Arg203 with residue
W191 (60). The aspartate group of D225 is projected in opposite directions in the crystal and
solution structures of the D2 domain. While in the solution structure(s), the positively charged
arginine side chain group is involved in a cation-π interaction with the indole side-chain of
Trp191, it is paired in an electrostatic interaction with the negatively charged -carboxyl group
of Asp225. We designed an Asp225Ala mutation to probe the presence of an electrostatic
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interaction between Arg203 and Asp225. Interestingly, results of the DSC experiments indicate
the Tm of the Asp225Ala mutant is in the same range (Tm ~ 51C) as that of the wild type D2
domain (Figure-2.6). These results clearly demonstrate that the electrostatic interaction which is
observed consistently in the crystal structures between Arg203 and Asp225 is not relevant in
solution. On the other hand, it appears that guanido group of Arg203 is only involved in a
cation-π interaction in solution.
D2 Mutation

Melting Temp. (~Tm)

D2 Mutation

Melting Temp.
(~Tm)

K151E

50 °C

Y155F

41 °C

K151L

51 °C

W191A

43 °C

K151R

52 °C

W191L/R203L

38 °C

R152E

48 °C

R203E

39 °C

R152L

51 °C

R203L

39 °C

R152K

52 °C

R203K

41 °C

R152A

51 °C

D225A

51 °C

Y155A

41 °C

Table 2.6: DSC melting temperature (Tm) for the wild type and mutants of the D2 domain.
Disruption of Trp191-Arg203 Cation-π interaction decreases heparin binding: Heparin is
crucial for the activation of FGFR (67). Both FGFR and FGF bind to heparin and form the active
FGF-heparin-FGFR ternary complex (68). Heparin is believed to increase the stability of the
FGF signaling complex (68). Crystal structure data of FGF signaling complex suggests that
heparin binds to a positively charged canyon formed through the dimerization of the D2 domain.
In this context, it is important to assess if the predicted cation-π interactions affect the binding
affinity of the D2 domain to heparin.
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Isothermal titration calorimetry (ITC) is a versatile technique, which can be used for direct
measurement of binding affinity (Kd) as well as the thermodynamics, which characterize proteinligand interactions. We used ITC to measure the binding affinity of the wild type and designed
mutants of the D2 domain and heparin/sucrose octasulfate (SOS). In our hands, commercially
available heparin (both low as well as high molecular weight heparin) was highly heterogeneous
both in terms of the length and the contaminants. In this context, we did not use heparin in our
ITC experiments because the accuracy of the binding affinity and stoichiometry measurements
significantly rely on the purity of both the ligand as well as the protein (69). We used sucrose
octasulfate (SOS) as a surrogate ligand for heparin in our ITC experiments. SOS is a good
structural and functional mimic of heparin. (70). SOS has been shown to support the cell
proliferation activity of FGF to the same extent as heparin (70). Isothermogram representing the
titration of SOS with wild type D2 domain is exothermic and sigmoidal (Figure-2.7, provides
raw ITC curves for wild type D2, R203E, W191A, Y155A and D225A)

The binding

stoichiometry between the D2 domain and SOS is 1:1 and the binding affinity to SOS is ~ 2.2
M (Figure-2.7). These values are consistent with those reported earlier for the FGFRheparin/SOS interaction(s). (60). In marked contrast, the mutations affecting the predicted
Trp191-Arg203 cation-π interaction show significant decrease in the binding affinity to SOS
(Table-2). These results clearly suggest that disruption of the Trp191-R203 cation-π interaction,
predicted in the solution structures of the D2 domain, affects the heparin binding of the D2
domain. On the other hand, ITC data show that the SOS binding affinity of the Arg152-Tyr155
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A.

D.

B.

E.

C.

F.

G.

Figure 2.7 - shows the isothermal titrations of each of the mutants of D2 with SOS. The
raw data was fitted to a one-site binding model. The lower panel depicts the raw data of the
μmol/s of heat release at various molar ratios of the lipid to protein. The binding affinity of D2
(wt) vs. SOS shows a moderate affinity (KD ~ 2.2 uM). The mutants showing the largest
decreases in binding affinity to SOS include W191L/R203L (KD ~ 38 uM), W191L (KD ~ 31
uM), R203E (KD ~ 30 uM) and R203L (KD ~ 33. uM). Minor decreases in binding affinity were
determined for mutants D2 Y155A (KD ~ 4 uM) and D2 D225A (KD ~ 3. uM).
mutant is not significantly affected (Kd ~ 4M, Table-2). These results indicate that the mutation
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A.

B.

C.

Figure 2.8 – Panel A – shows the 1H-15N HSQC of the D2 Y155A mutant of D2 (blue) overlaid
on wild type D2 (red). Panel B – is the chemical shift perturbation plot for D2 Y155A. Panel C is a structural representation highlighting the most perturbed residues on the D2 Y155A domain.
A.
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B.

C.

Figure 2.9 – Panel A – shows the 1H-15N HSQC of the D2 R203E mutant of D2 (blue) overlaid
on wild type D2 (red). Panel B – is the chemical shift perturbation plot for D2 R203E. Panel C is a structural representation highlighting the most perturbed residues on the D2 R203E domain.
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A.

B.

C.

Figure 2.10 – Panel A – shows the 1H-15N HSQC of the D2 R203E mutant of D2 (blue) overlaid
on wild type D2 (red). Panel B – is the chemical shift perturbation plot for D2 R203E. Panel C is a structural representation highlighting the most perturbed residues on the D2 R203E domain.
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(Y155A) potentially affecting the stability of the K151-Y155 cation-π interaction, predicted in
the crystal structures, does not affect heparin-binding affinity of the D2 domain.

Disruption of the Trp191-Arg203 interaction causes significant

1

H-15N chemical shift

perturbation: Two-dimensional 1H-15N heteronuclear spin quantum coherence (1H-15N HSQC)
is a finger-print of the backbone conformation of a protein. Each 1H-15N crosspeak in the HSQC
spectrum represents an amino acid in a particular backbone conformation of a protein.
Therefore, 1H-15N chemical shift perturbation provides atomic level information on the backbone
structural changes that occur in a protein due to mutation or ligand binding. In this context, we
monitored the potential conformational changes, which plausibly occur due to the disruption of
the predicted cation-π interactions. 1H-15N crosspeaks in the HSQC spectrum of the wild type D2
domain are spread-out suggesting that the protein is well structured (Figure-2.8, Panel-A).
Overlay of the HSQC spectra of the Tyr155Ala mutant on that of the wild D2 domain suggests
that most 1H-15N chemical shift perturbed residues are located in close spatial vicinity of the
mutation site. The most perturbed residues (R152, A153, G182, G183 and T157) are located in
beta-strands A and B. These results suggest that disruption of the Arg152-Tyr155 cation-π
interaction, predicted in the crystal structures of the D2 domain, does not result in a global
structural change(s).
It is important to understand the cause of the significant loss (Tm~ 10C) in the thermodynamic
stability of the Tyr1551Ala mutant as observed from the DSC data (Figure-2.6). 3D crystal
structures of the D2 domain show that Tyr155 is involved in a pi-pi stacking interaction with
Trp156. Therefore, substitution of Tyr with Ala (as in the Tyr155Ala mutation) appears to
weaken the pi-pi stacking interaction resulting in a significant loss in the thermodynamic
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stability of the protein.

Based on the DSC and HSQC data obtained on Tyr155Ala and

Arg152Glu it appears that the cation-π interaction predicted in the crystal structures of the D2
domain is either non-existent in solution or its presence makes no significant contribution to the
structural stability of the protein domain.
Overlay of the 1H-15N HSQC spectrum of the Trp191Ala on that of the wild type D2 domain
shows that several crosspeaks in the HSQC spectrum of the Trp191Ala mutant have shifted
significantly from their orginal position. Therefore, owing to large chemical shifts we could not
completely assign all the 1H-15N crosspeaks in the HSQC spectrum of the Trp191Ala mutant. In
addition, some regions are severely overlapped suggesting that the conformational flexibility of
certain portion(s) of the D2 domain are increased due to the mutation. In addition, the Trp191Ala
mutation appears to cause a mild conformational heterogeneity in D2 domain. This is obvious
from the presence of two/multiple sets of 1H-15N crosspeaks (15N chemical shift range from 127
ppm to 130 ppm & 1H chemical shift range from 9.75 ppm to 10.25 ppm) in the HSQC spectrum
(Figure-2.8, Panel-C).

These results are consistent those of steady state flurescence, ANS

binding and DSC experiments and support the prediction of the presence of a cation – π
interaction in the D2 domain involving Trp191 and Arg203.
Superimposition of the 1H-15N HSQC spectra of the Arg203Glu mutant and the wild
type D2 domain show that disruption of the predicted Trp191-Arg203 cation-π interaction causes
a significant change in the backbone folding of the protein (Figure-2.8, Panel-D). Despite the
prominent shift of the 1H-15N crosspeaks, the HSQC spectrum appears well-dispersed. These
results suggest that the Arg203Glu mutation does not disorganize the native -sandwich
architecture of the D2 domain. The conclusions drawn from the NMR data are in good
agreement with those obtained from other biophysical experiments.
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Significance of the predicted cation-π interactions in solution:

The results of this study

overwhelmingly support the presence of the Trp191-Arg203 cation-π interaction present in the
solution structures but not the one predicted in the crystal structures between Arg152 and
Tyr155. The experimental evidence against the presence of the Arg152-Tyr155 cation-π
interaction could imply, 1. The predicted Arg152-Tyr155 is non-existent under solution
conditions and its existence is an artifact of the crystallization conditions used, 2. the predicted
cation-pi interaction, even if present, does not contribute significantly to the stability of the
protein or 3. the cation-pi interaction is only induced when the D2 domain interacts with its
ligands (FGF/heparin), or it is only formed in the dimeric state of D2 domain. The latter two
possibilities are relevant because, in all the crystal structures, of FGFR (pdb code – 1EV2
)/FGFR-heparin binary complex (pdb code - 1EV2) the D2 domain is present with along with
the other extracellular domain (D3 domain) and exists as a dimer with direct structural contacts
between the D2 domains. In marked contrast the lone NMR solution structure reported of the
isolated D2 domain is a monomer. The solution structure of the FGF signaling complex is not yet
available. However, the results of this study clearly support the presence of the Trp191-Arg203
cation-π interaction in the D2 domain under solution conditions. In addition, this cation-π
interaction appears to confer thermodynamic stability to the D2 domain and also affects the
heparin binding affinity of the protein domain.
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Supplementary data:
A.

B.

Figure S2.11 – Panel A and B show the relative steady-state fluorescence of mutants of D2.
Each of the mutants showed very minor shifts in the maximum wavelength. Most mutants
exhibit 1-3 nm red shift in maximum wavelength.
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A.

B.

Figure S2.12 – Panels A and B show mutants ANS titration of mutants of D2. The relative
fluorescence of the mutants of D2 shown suggests only minor increases in hydrophobic residue
exposure.
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Figure S2.13 - Overlay of the far-UV circular dichroism spectra of the wild type (black) and
mutants of D2.

Figure S2.14 - Overlay of the far-UV circular dichroism spectra of the wild type (black) and
mutants of D2.

137

Figure S2.15 - Overlay of the far-UV circular dichroism spectra of the wild type (black) and
mutants of D2.
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Abstract: Kallmann syndrome (KS) is a developmental disease that expresses in patients as
hypogonadotropic hypogonadism and anosmia. KS is commonly associated with mutations in the
extracellular D2 domain of the fibroblast growth factor receptor (FGFR). In this study, for the
first time, the molecular basis for the FGFR associated KS mutation (A168S) is elucidated using
a variety of biophysical experiments, including multidimensional NMR spectroscopy. Secondary
and tertiary structural analysis using far UV circular dichroism, fluorescence and limited trypsin
digestion assays suggest that the KS mutation induces subtle tertiary structure change in the D2
domain of FGFR. Results of isothermal titration calorimetry experiments show the KS mutation
causes a 10-fold decrease in heparin binding affinity and also a complete loss in ligand (FGF-1)
binding. 1H-15N chemical perturbation data suggest that complete loss in the ligand (FGF)
binding affinity is triggered by a subtle conformational change that disrupts crucial structural
interactions in both the heparin and the FGF binding sites in the D2 domain of FGFR. The novel
findings reported in this study are expected to provide valuable clues toward a complete
understanding of the other genetic diseases linked to mutations in the FGFR.

Introduction: Kallmann syndrome (KS) is a form of idiopathic hypogonadotropic
hypogonadism (IHH) that expresses phenotypically with anosmia (1). Most commonly, KS is
expressed with synkinesia, hearing loss, labial or palentine cleft, dental anomalies and inhibited
puberty development. An estimated 10% of KS cases are attributed to mutations in the fibroblast
growth factor receptor 1 (FGFR1) (2).
Fibroblast growth factors (FGFs) are a family of heparin-binding proteins that regulate key
cellular processes such as angiogenesis, cell differentiation, morphogenesis, wound healing and
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tumor growth (3-10). FGF receptors consist of three extracellular ligand-binding domains (D1,
D2, and D3), a single transmembrane helix, and a cytoplasmic tyrosine kinase domain. Cell
surface-bound heparan sulfate proteoglycans (HSPGs) that support dimerization or
oligomerization of the FGF receptors (FGFRs) are believed to be required for the activation of
the FGF signaling pathway (11, 12).

The FGF signaling is shown to be modulated by anosmin-

1, a KAL-1 gene product underlying X-linked KS. (13). Anosmin-1 is a 680-amino acid
glycoslylated protein, which directly binds to HSPG and FGFR and regulates the assembly and
activity of the FGF signaling complex (13-16).
The extracellular D2 domain of FGFRs is suggested to bind with both HSPGs and FGFs
to form a ternary FGF signaling complex. Mutations in the D2 domain of FGFR1 have been
associated with families carrying Kallmann syndrome phenotypes (17). The A168S mutation in
the D2 domain of FGFR is one of the common KS mutations. Knockout mutational studies in
mice have established A168S as a loss-of-function mutation resulting in the inactivation of
FGFR. Inactivation of FGFR in mice telencephalon tissue results in the failure of olfactory bulb
formation- a phenotype manifestation commonly observed in KS (17). The molecular basis for
the observed loss-of-function associated with KS mutations is still unclear. It is believed that KS
mutations either disrupt the anosmin-1/FGFR interaction(s) or cause a drastic structural change
in FGFR leading to loss in the binding affinity to the ligand (FGF) (17). However, very little
experimental evidence exists in support or in contradiction of this proposal. In this study for the
first time the structural basis for the A168S associated KS is elucidated. The results of the
present study are expected to trigger intensive studies leading to a comprehensive understanding
of the molecular mechanism underlying the different FGFR mutation related diseases.

148

Materials and Methods
Mutagenesis, overexpression and protein purification: The A168S mutation on the FGFR2 D2
domain (residues, 145-255) was generated using the Quikchange kit (Stratagene). The mutation
was confirmed by automated DNA sequencing. Wild type and the A168S mutant of the D2
domain were overexpressed and purified from Escherichia coli [BL21 (pLysS) strain] according
to the method reported previously [18].
Far UV Circular Dichrosim (CD): Data on the wild type D2 and the A168S mutant were
acquired using a Jasco J-710 spectropolarimeter. Protein solutions (90-100 μM) were prepared in
10 mM phosphate buffer containing 100 mM NaCl and 50 mM ammonium sulfate (pH 6.5).
Wavelength scans were set to 250-190 nm. CD measurements were made using a 0.1 cm
pathlength cuvette. A total of 10 scans were averaged for each sample.
Fluorescence spectroscopy: Measurements were made using a Hitachi F-2500 fluorimeter.
Fluorescence measurements were made using a 1.0 cm path length and the concentration of each
protein sample was adjusted to ~50 µM. Excitation wavelength was set to 280 nm and intrinsic
tryptophan emission was measured from 300 nm to 450 nm. 8-anilino-1-napthalene sulphonate
(ANS) binding experiments were performed using an excitation wavelength of 390 nm and an
emission wavelength range of 450 nm - 600 nm. In the ANS titration experiments, protein
samples were titrated with 3 μl aliquots of 10 mM ANS in 10 mM phosphate buffer containing
100 mM NaCl and 50 mM ammonium sulfate at pH 6.5.
Differential scanning calorimetry (DSC): DSC measurements were performed using a N-DSC
III calorimeter. Protein concentration used was in the range of 1.0 – 1.5 mg/ml in 10 mM
phosphate buffer containing 50 mM ammonium sulfate and 100 mM NaCl (pH ~6.5). The scan
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rate was set to 1 °C/min and protein samples were heated from 10 °C - 90°C. Data were analyzed
using the CpCalc software provided by the manufacturer.
Isothermal titration caolorimetry (ITC): ITC measurements were performed using Microcal VP
titration calorimeter (Northhampton, MA, USA). Titrations consisted of 5-10 μl injections of 0.5
mM sucrose octasulfate (a heparin analog) delivered into 0.050 mM concentration of the D2
domain. Injections were delayed for 1.5 - 3.5 minutes to allow the titration peak to return to the
baseline prior to additional injections. The titrations curves were analyzed using Origin software
supplied by Microcal Inc.
NMR spectroscopy: 1H-15N HSQC data were acquired at 298 °K using 0.5 mM 15N labeled D2
domain in 10 mM phosphate buffer (prepared in 95% H2O + 5 %D2O, pH 6.5) containing 50
mM ammonium sulfate and 100 mM NaCl. All experiments were performed using Bruker
Avance 700 MHz and 500 MHz NMR spectrometers equipped with cryoprobes. NMR data were
referenced to the 1H resonance frequency of 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS).

Results
The secondary structure of the D2 domain of FGFR includes 12 antiparallel β-strands arranged in
a β-sandwich fold. A168 is well conserved in all four isoforms of the human FGF receptor.
Ala168 is located in the middle of a hydrophobic core of residues consisting of L165, P170,
V248 and V249 (Fig. 3.1). In addition, A168 along with L165 and V248 has been shown to
contribute to the binding of the ligand (FGF) (18).
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Figure 3.1: Panel-A, Depiction of the three-dimensional structure of the D2 domain Worldwide
Protein Data Bank (PDB ID: 1WVZ) of FGFR2. The residues forming hydrophobic interactions
with FGF include A168 (red), L166 (blue), P170 (blue) and V249 (blue). A168 of the D2 domain
contacts Tyr-24 and Met- 142 of FGF. Panel-B Amino acid sequence of the D2 domain of
FGFR2. The conserved residues in the D2 domain of FGFRs are indicated by an asterix. Ala168
is conserved in FGFRs and is highlighted in bold.
A168S mutation does not significantly perturb the backbone conformation of the D2 domain:
Far UV CD spectrum of the wild type D2 domain shows a strongly negative ellipticity band
around 220 nm and a positive ellipticity peak centered at 205 nm. These features of the far UV
CD spectrum are typical of β-sheets arranged in a β-sandwich structure. Interestingly, the far UV
CD spectrum of the A168S mutant superimposes quite well with that of the wild type of the D2
domain suggesting that the A168S mutation causes no or minimal perturbations in the secondary
structure of the receptor domain (Supplementary Fig. S3.1). These observations are quite
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surprising because introduction of a polar serine residue in a hydrophobic core can be expected
to significantly perturb the backbone conformation of the protein.
A168S mutation causes a subtle but crucial tertiary structural change in the receptor domain:
Intrinsic fluorescence serves as a useful and sensitive spectral probe to monitor tertiary structural
changes in proteins. D2 domain has three well-conserved tryptophan residues that are partially
buried in the interior of the protein (19). The 339 nm emission maximum suggests that the
tryptophan residues in the wild type D2 domain are partially exposed to the solvent
(Supplementary Fig. S3.1). The emission maximum of the A168S mutant shows a modest red
shift of 3 nm (339 nm to 342 nm) indicating that the mutation causes a subtle tertiary
conformational change (Supplementary Fig. S3.1) resulting in greater solvent exposure of the
indole rings of tryptophan residues in the receptor domain.

ANS is a popular fluorescent hydrophobic dye, which is commonly used to monitor
solvent-exposed hydrophobic surfaces in proteins (6). ANS in the presence of the wild type D2
domain shows weak emission with an emission maximum centered at 508 nm. (Fig. 3.2A)
However, the emission maximum of the dye when bound to the A168S mutant shows a red shift
of 4 nm (from 508 nm to 512 nm) with a very moderate increase in the emission intensity
relative to the wild type protein. These fluorescence characteristics suggest that substitution of
alanine with serine (A168S) causes a subtle conformational change resulting in increased solvent
exposure of hydrophobic surface(s) in the protein.
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Figure 3.2 – Panel A represents the ANS spectra in the presence of the wild type (black) and
theA168S mutant of the D2 domain (blue). The concentration of ANS is 150 μM. Panel B shows
the densitometric plot of the limited-trypsin digestion of wild type (black) and the A168S (blue)
mutant of D2 domain. Panel B insert shows the 15% SDS PAGE of the limited-trypsin digestion
of the wild type and A168S mutant of the D2 domain after 0, 2, 4, 6, 8, 10, 15, 20, 30 and 40
minutes of incubation of the protein domain with trypsin.

The A168S mutation does not significantly affect the thermodynamic stability but increases
the conformational flexibility of the D2 domain: Differential scanning calorimetry is a versatile
technique that can be used to directly probe the themodynamic stability of proteins.(20) The
melting thermogram of the wild type D2 domain shows a relatively sharp melting transition
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(Tm~52 ºC), from the folded to the unfolded state (Supplementary Fig. S3.5). The Tm value does
not appear to change due to the A168S mutation (Supplementary Fig. S3.5; Tm~51.5 ºC). These
results suggest that the thermodynamic stability of the receptor domain is not significantly
affected by the mutation.
Limited trypsin digestion is a useful technique to obtain information on the backbone
flexibility of proteins (21, 22). Lysine and arginine residues located in the flexible and solventaccessible regions of the protein are more susceptible to trypsin cleavage than when they are
located in the interior or the rigid portions of proteins. Therefore, differences in the susceptibility
to trypsin cleavage can be expected to provide valuable information on the changes in the
backbone flexibility caused by subtle conformational changes induced in the protein due to the
A168S mutation.

The D2 domain contains nine lysine residues and six arginine residues. The wild type
protein is rapidly cleaved by trypsin in the first few minutes of initiation of the cleavage reaction
(Fig. 3.2). About 40% of the band (Mr ~13.7 kDa) corresponding to the intact D2 domain
remains after 10 minutes of initiation of cleavage (Fig. 3.2). Interestingly more than 80% of the
A168S mutant protein is cleaved within the same time period (Fig. 3.2). These results in
conjunction with those obtained from the fluorescence data suggest that the alanine to serine
substitution at position 168 causes subtle conformational change, which significantly increases
the backbone flexibility and solvent-accessibility of the hydrophobic surface(s) in the protein.

A168S mutation decreases heparin-binding affinity and causes a complete loss of FGF
binding: D2 domain is the most important structural module of the fibroblast growth factor
receptor as it provides binding surface to both heparin and the ligand (FGF). Isothermal titration
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calorimetry (ITC) experiments were performed to examine the effect(s) of the Kallmann
mutation (A168S) on the heparin and FGF binding affinities of the D2 domain. ITC is a useful
technique to characterize the protein-protein/ligand interactions as it relies on the heat evolved or
absorbed during binding interactions.

Heparin is polydisperse and therefore it is challenging to obtain an accurate estimation of
its binding affinity to proteins. In this context, we used polyanionic sucrose octasulfate (SOS) to
represent heparin binding interactions with the D2 domain. Sucrose octasulfate, unlike heparin,
is monodisperse and can be obtained in the pure form (>99% purity). In addition, SOS has been
demonstrated to be a good structural and functional mimic for heparin.

The isothermogram representing the binding of wild type D2 domain to SOS is sigmoidal and
the binding constant (Kd) characterizing the SOS-D2 domain interaction(s) is ~ 2.2 µM (Fig.
3.3A). SOS and D2 domain bind to each other in a 1:1 stoichiometry. Interestingly, in marked
contrast, the A168S versus SOS titration curve is hyperbolic and the binding affinity between
A168S mutant and SOS is about 10 times (Kd ~22 µM) weaker than that of the wild type D2
domain (Fig. 3).

The lowering of the heparin binding affinity is unexpected because the mutation site
(A168S) is spatially remote from the heparin-binding site in the D2 domain. Wild type D2
domain binds strongly (Kd~ 2 µM) to FGF. The binding affinity (Kd) of the isolated D2 domain
is in the same range as that of the intact extracellular portion of FGFR suggesting that D2
domain is critical for FGF binding.
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Figure 3.3 – Binding isotherm representing the titration of the wild type and the A168S mutant
of the D2 domain with SOS and FGF. The top panel shows the raw data from the titration. The
bottom panel shows the integrated data derived from the raw data. Panels A and B show the
titration of the wild type and the A168S mutant of the D2 domain with SOS. Panels C and D
show the isothermogram of the wild type and A168S mutant of the D2 domain titrated with FGF.
Interestingly, the A168S mutant of the D2 domain exhibits no or very insignificant
binding to FGF. These results suggest that loss-of-function associated with the KS (A168S)
mutation is due to complete loss of interaction between the ligand and the receptor.
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Structural basis for Kallmann syndrome: A clear picture of the molecular basis for Kallmann
syndrome would only emerge when the effects of the mutation on the conformation are
understood at an atomic level.

In this context, multidimensional NMR experiments were

performed to assess the plausible structural changes induced by the KS mutation and also
understand the consequences of the conformational change on both heparin and FGF binding.
Two-dimensional 1H-15N HSQC spectrum is a finger-print of the backbone conformation
of proteins. Each crosspeak in the 1H-15N HSQC spectrum represents an amino acid in a
particular backbone conformation of the protein. In this context, we monitored the backbone
conformational changes induced due to the Kallmann mutation (A168S) using the 1H-15N
chemical shift perturbation () observed in the HSQC spectra (Fig. 3.4A).

Most of the perturbed residues are located in the vicinity of the mutated residue (A168).
Interestingly, residues located in the β-strand G (residues, H242 to V248) located at the Cterminal end of the D2 domain are also significantly perturbed (23). The observed 1H-15N
chemical shift perturbation of residues in β-strand G is plausibly because of their spatial
proximity to mutation site (A168) in the three-dimensional structure of the D2 domain (23). It
appears that the Kallmann mutation causes a subtle conformational change resulting in the
disruption of the structural topology of the FGF binding pocket, which consequently leads to
complete loss in ligand (FGF) binding. Although several residues in the D2 domain are involved
in the stabilization of the FGF-D2 domain complex, the intramolecular and intermolecular
structural interactions contributed by A168 appear to be quite critical for the formation and
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Figure 3.4: Structural changes induced due to the Kallmann (A168S) mutation. Panel A shows
an overlay of the 1H-15N HSQC spectra of the wild type (red) and the A168S (blue) mutant of the
D2 domain of FGFR.
Panel B shows the composite 1H-15N chemical shift perturbation ()
calculated from the data shown in Panel A. The horizontal bar represents an arbitrarily set
threshold to identify the residues, which show the most significant 1H-15N chemical shift
perturbation. Panel C depicts a structural of the D2 domain (PDB ID: 1WVZ) highlighting the
A168S mutation site (red) and the most perturbed residues (blue).[18] 1H-15N HSQC spectra of
the A168S mutant of the D2 domain in the presence (red) and absence (blue) of FGF is shown in
Panel D. Composite 1H-15N chemical perturbation of the A168S mutant calculated from the 1H15
N HSQC data (Panel E). The data suggest that the A168S mutant of the D2 domain does not
bind to FGF.

stabilization of the ligand-receptor complex. The complete loss in ligand binding affinity of the
Kallmann mutant is evident from the insignificant 1H-15N chemical shift perturbation [composite
1H-15N chemical shift ( <0.02 ppm)] of residues observed when 15N enriched A168S mutant of
the D2 domain is titrated with unlabeled FGF (Fig. 3.4D). The lack of binding affinity of the
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A168S mutant to the ligand is also corroborated by the ITC results discussed earlier (Figs. 3C &
3D).

ITC results, discussed earlier, revealed that the A168S mutant exhibits 10-fold lower
affinity to bind to heparin than wild type D2 domain (Figs. 3.3A & 3.3B). In this context, the
structural basis for the decrease in heparin binding of the Kallmann mutant was assessed by
comparing the composite 1H-15N chemical shift perturbation () of the A168S mutant and wild
type D2 domain on binding to heparin/SOS. Comparison of the composite 1H-15N chemical shift
perturbation plots of the wild type and A168S mutant in the presence of SOS show that residues
such as, K161, K174, K196, K208 and R210 in the wild type D2 domain show significant 1H-15N
chemical shift perturbation (Supplementary Fig. S3.3). 3D structures of the FGF-heparinreceptor complex show that these residues located in the D2 domain constitute the heparinbinding pocket (24). Interestingly, the extent of the composite 1H-15N chemical shift perturbation
for residues in the heparin binding pocket are significantly less in the A168S mutant than
observed in the wild type D2 domain (Supplementary Fig. S3.7). These results suggest that the
subtle conformational change caused due to the A168S mutation alters the orientation of sidechains of residues involved in electrostatic interaction with heparin and consequently causes the
decrease (~ 10-fold) in affinity to the polysulfated proteoglycan.

Discussion
Kallmann syndrome mutations have been detected in all major structural modules located
in the extracellular portion of the FGFR (25). KS mutations invariably cause a loss-of-function.
Several proposals are made to account for the loss-of-function observed in KS. Anosmin-1, a
glycosylated protein, encoded by the KAL-1 gene modulates FGF signaling by directly
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interacting with FGFR (25). It is believed that the KS mutations cause a disruption of the
putative anosmin-1 / FGFR interaction and consequently inhibits the FGF signaling process.
Alternatively, it is also believed that the loss-of-function of the KS mutations is due to a drastic
conformational change leading to the misfolding and plausibly aggregation of the receptor.
Contrary to these proposals, the results of the present study clearly suggest that the loss-offunction of the KS (A168S) mutation is due to a subtle conformational change that results in
complete disruption of binding interactions between FGF and the receptor. We believe that
structure-function studies in the future with other KS mutations can be expected to provide
valuable information to understand the general molecular mechanisms underlying FGFR-linked
genetic diseases.
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Supplementary Data:

Figure S3.5 Panel A, Overlay of the far-UV circular dichroism spectra of the wild type (black)
and the A168S (blue) mutant of D2. Panel B, The steady-state intrinsic fluorescence spectra of
wild type (black) and the A168S mutant of the D2 domain (blue). Panel C, Overlay of the DSC
scans of the D2 wild type (black) and A168S mutant of D2 (blue).
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Figure S3.6 - shows an overlay of the 1H-15N HSQC spectra of the A168S mutant in the
presence (red) and absence (blue) of SOS at protein to SOS ratio of 1:1.

Figure S3.7 - shows the 1H-15N chemical shift perturbation observed on titration of the wild type
(Panel –A) and the A168S mutant (Panel –B) of the D2 domain individually with SOS. The
decrease in the magnitude of the composite 1H-15N chemical shift perturbation observed in the
A168S mutant of the D2 domain (in the presence of SOS) appears to corroborate with the ITC
results which show a 10-fold loss in heparin binding affinity of the KS mutant.
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Characterization of a Kallmann Syndrome Mutations of the Fibroblast Growth Factor
Receptor D2 Domain
Ryan D. Thurman, Karuppanan Muthusamy Kathir and T.K.S Kumar

Abstract: Kallmann syndrome expresses in patients as hypogonadotrpic hypogonadism and
anosmia. Common symptoms of KS include cleft palate, corpus callosum agenesis, and fusion of
the fourth and fifth metacarpal bones. Fibroblast growth factor receptor 1 is a gene that mutations
commonly occur resulting in KS. Additionally, mutations found in the FGF receptor may also
result in Pfeiffer syndrome – a disease resulting in craniosynostosis, retardation and limb
abnormalities.

We have assessed the biophysical characteristics of both Kallmann syndrome

and Pfeiffer syndrome. Kallmann syndrome mutations in the D2 domain include C179S,
W214G, D225H, and G238D. The Pfeiffer syndrome mutation in the D2 domain includes
A172F. Isothermal titration calorimetry and 1H –

15

N HSQC experiments of the KS related

mutants of the D2 domain suggest a significant decreased FGF and heparin binding interaction
with the D2 domain and increased perturbation at the FGF binding site. Additionally, the Pfeiffer
syndrome mutation resulted in only moderately decreased interactions with FGF and heparin
with the D2 domain. This data combines to provide biophysical evidence that KS may result
from a loss of signaling from the FGFR1 protein.
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Introduction
Kallmann syndrome (KS) is a form of idiopathic hypogonadotrpic hypogonadism (IHH) that
expresses phenotypically with anosmia(1). Most commonly KS is expressed with synkinesia,
hearling loss, labial or palentine cleft, dental anomalies and inhibited puberty development (2, 2).
KS occurs in approximately 1:10,000 males and 1:50,000 females (3). An estimated 10% of KS
cases are attributed to mutations in fibroblast growth factor receptor 1 (FGFR1) (4). The
remaining cases are KS caused by mutations in KAL1 gene or sporadic mutations. KS cases
caused by FGFR1 mutations are an autosomal dominant form of KS. The mutations found in
FGFR1 include missense, nonsense, frameshift and deletion mutations (5-12)
Fibroblast growth factors (FGFs) are approximately 16 kDa heparin-binding proteins that
regulate key cellular processes such as angiogenesis, cell differentiation, morphogenesis, wound
healing and tumor growth (13, 14).

FGF receptors consist of three extracellular ligand-binding

domains (D1, D2, D3), a single transmembrane helix, and cytoplasmic tyrosine kinase domain.
Cell surface-bound HSPGs (heparan sulfate proteoglycans) that support dimerization or
polymerization of the FGFRs are thought to be required to activate the signaling pathway (15,
16). The D2 domain is suggested to bind both HSPGs and FGFs to form a ternary complex. The
dimerization complex of the FGFR has been well characterized by Platnikov et. al to include
FGF: FGFR: heparin in a 2: 2: 2 complex. Mutations found in FGFR1 in the D2 domain have
been associated with families carrying Kallmann syndrome phenotypes (17).
The FGFR D2 C179S, W214G, D225H and G238D mutations have been associated with
Kallmann syndrome (18, 19). The role of FGFR1 plays in the development of KS is postulated to
be the result of decreased signal transduction (18, 20-22)The decrease in FGFR1 signaling
resulting from KS linked mutations has been termed the loss-of-function mechanism. The loss-
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of-function mechanism has been established through structure analysis and through knockout
mice. FGFR1 inactivation in mice telencephalon tissue results in a failure of olfactory bulb
formation (22). Analysis of the structure of FGFR suggests either a decreased interaction of the
receptor with the ligand (FGF) or the destabilization of the structure caused due to mutations in a
diseased state. However, very little structural information is available to rationalize the results of
the knockout studies in mice. Kallmann syndrome linked mutations D2 G238D and D225H have
been characterized using structural analysis of x-ray structures of the D2 domain. The D2 G238D
has been postulated to destabilize the D2 domain. Glycine 238 occurs in a turn located between
β-strand F and β-strand G. Replacement of glycine 238 with aspartic acid is suggested to result in
unfavorable steric clashes with neighboring residues. Structural assessment using x-ray
crystallography structures of the D225H mutation has been postulated to disrupt a charge-charge
interaction with nearby R203 (23). This interaction is shown to occur in the x-ray crystal
structure solved by Plotinikov et. al.(24)However, the orientation of these residues in the D2
NMR solution structure suggests these interactions are not present. (25). The loss-of-function
theory and decrease structural competency as a result of KS mutations were both assessed. In this
study we use biophysical experiments to determine the structural changes in D2 and the changes
in D2-ligand interactions.
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Material and Methods

Mutagenesis, Expression and Protein Purification. All mutations on the FGFR2 D2 were made
using the quikchange protocol. (Stratagene).

The mutations were confirmed using DNA

sequencing. The mutations were all made to the D2 domain contained in the PET20b vector. All
experiments were conducted using only the D2 domain.

BL-21(DE3) pLysS E. coli strain was used to express the wild type and mutants of the D2
domain. The cells were grown in LB medium containing 100mg/ml ampicillin and 100mg/ml
chloramphenicol. The cells were grown and 37 C and induced using IPTG when the O.D.600
value was 0.6. After induction the cells were incubated at 37 C for 5 hours. The culture was
centrifuged at 6000 rpm to pellet the cells. Cell samples were sonicated using a Microson XL
unit with the power setting adjusted to 12. The samples were sonicated 60 times for 1-second
intervals. The cell lysate was centrifuged at 16K rpm to pellet the sample. Following
centrifugation the pellet was resuspended in 5M NaCl and centrifuged at 10K rpm. The pellet
was then resuspended using 1M urea and centrifuged at 10K rpm. Finally, the pellet was
resuspended using 8M urea and centrifuged at 10K rpm. The supernatant was dialyzed against
10mM phosphate buffer, 100mM NaCl and 50mM ammonium sulfate (pH 6.5) in order to refold
the protein. The buffer exchange was repeated four times with a minimum of 3 hours per
exchange. The dialyzed sample was loaded onto a heparin sepharose column and eluted using a
salt gradient between 0.3 – 1.5 M NaCl. The purity of each fraction was assessed using a 10%
SDS gel followed by Coomassie Brilliant Blue staining.
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Fluorescence and CD measurements of the D2 (wt) and mutants were acquired in a 10 mM
phosphate buffer containing 100 mM NaCl and 50 mM ammonium sulfate (pH 6.5). CD spectra
were acquired on a Jasco J-710 spectropolarimeter. Wavelength scans were set to 250-190 nm.
Samples were approximately 90- 100 uM in concentration and a 0.1 cm path length cuvette was
used for data acquisition. A total of 10 scans were averaged for each sample. Fluorescence
measurements were acquired using a Hitachi F2500 fluoremeter. A 1.0 cm path length quartz cell
was used and each sample was adjusted to ~50 uM. The excitation wavelength was set to 280 nm
and acquisition from 300 to 450 nm. The ANS titration excitation wavelength was 390 nm while
the acquisition was from 450 nm to 600 nm. During the ANS titration protein samples were
titrated with 3 ul. aliquots of 10mM ANS in 10mM phosphate buffer containing 100 mM NaCl
and 50 mM ammonium sulfate at a pH of 6.5.

Differential scanning calorimetric measurements were performed using a DASM-1M
calorimeter. Each sample concentration was between 1.0 – 1.5 mg/ml. The buffer used was 10
mM phosphate containing 50 mM ammonium sulfate and 100 mM NaCl (pH ~6.5) and degassed
prior to loading into the microcalorimeter. The scanning rate was set to 1 °C/min and scanned
from 10 °C - 90°C. The Tm values were determined using Origin DSC software provided by
Microcal Inc. The entropic or enthalpic energies were not reported because the D2 domain does
not undergo complete refolding by reducing the temperature.

Isothermal Titration Calorimetry measurements were performed using a Microcal VP titration
calorimeter (Northhampton, MA, USA). Titrations consisted of 5-10μl injections of 0.5 mM
sucrose octasulfate (heparin analog) delivered into 0.050 mM concentration of D2. Injections
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were delayed 3.5 minutes to allow the titration peak to return to a baseline prior to additional
injections.

NMR spectroscopy data on the D2 domain was acquired using a protein concentration of 0.150.5 mM concentrations in 10 mM phosphate buffer (95% H2O + 5 %D2O, pH 6.5) containing 50
mM ammonium sulfate and 100 mM NaCl. NMR experiments were conducted at 298°K. All
experiments were conducted using Bruker Avance 700 mHz or Bruker Avance 500 mHz NMR.
All NMR data were referenced to the 1H resonance frequency of DSS.

Results and Discussion

Structure Analysis of the D2 G238 mutation is located in the ßF-ßG turn of FGFR1.
G238 is highly conserved in each of the FGF receptors. The location of G238 stabilizes the ßFßG turn through hydrogen bonds formed from the backbone oxygen of G238 with the backbone
amide of N234. (Figure 4.1)

Figure 4.1 - shows a stereo view of the N-terminal region of FGFR1. Connecting black lines
highlight the hydrogen bonds formed in the ßF-ßG strands. The mutations site G237 is
highlighted in blue and contains one backbone hydrogen bond formed with N234.

Conservation of glycine 237 is critical for the FGF receptors. Gly234 is involved in interactions
with closely placed residues in ß-sheet ßA. Replacement of G237 with a bulky sidechain
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containing amino acid would result in the sidechain residue extending towards the ß-sheet ßA at
the N-terminal of D2. Side-chain containing mutations at G234 is postulated to destabilize the
D2 fold. Additionally, the expression of D2 G238D has been shown to result in a large
percentage of the protein entering into inclusion bodies. This change of expression of D2 G238D
suggests a decreased ability of D2 to properly fold. The expression of the G238D mutant is lower
than the expression of wild type D2. Pitteloud et al. suggest the lowered expression of the
G238D mutant of D2 results from the retention of the misfolded protein in the endoplasmic
reticulum(23).

Structural analysis of FGFR2 A172F: Ibrahami et al. studied the ligand binding characteristics
of A172F using surface plasmon resonance binding and xray crytallography (figure 4.2) (26-28).
A172 is located near the c-terminal end of the structure and is located at the ßA’-ßB loop.
Dimeric structures of the the D2 domain reveals that A172 is situated in hydrophobic contact
with the adjacent D2 A172 residue.

Figure 4.2 - shows FGFR1 D2 showing the A172F mutation. The model shown replaces A172
with phenylalanine to give a representation of the possible orientation of the aromatic
phenylalanine ring(29).
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A172 also forms hydrogen bond contacts with serine 220 of the adjacent D2 domain. The x-ray
structure of the D2 domain supports A172F forms a hyrophobic interactions with the A172F
residue of the adjacent D2. The xray structure places the A172F residue of interacting D2
molecules 3.3 Å apart(26). The addition of these hydrophobic contacts is believed to contribute
to the stability of the D2 dimeric structure required for FGF receptor signal transduction (26).

Structural analysis of FGF receptor C179S: The D2 domain is a ß-sandwich structure of two
layers of ß-sheets. One ß-sheet is composed of strands ßA, ßB, ßE and ßD and the second ßsheet formed by strands ßA’, ßG, ßF, ßC and ßC’. C179 is located between ßB and ßB’ and
forms a disulfde bond with C230 located on the ßF strand. C179 and C230 are highly conserved
residues found in FGF receptors 1-4. In each of the receptors these residues form a disulfide
bond that provides a stability to the ß-sandwich of D2. Although the C179S mutation is
associated with KS the pathogenic mechanism resulting from this mutation is unknown(30). The
disulfide bond is suggested to stabilize the D2 domain (29). It is likely that the C179S mutation
will destabilize the D2 domain and inhibit it interactions with heparin and/or FGF. This would
contribute to the proposed loss-of-function mechanis common in KS mutations.

Structural analysis of FGFR1 D225H was conducted by Pitteloud et. al through the analysis of
existing xray structures of the FGF receptor(31). The D225H mutation is located in a loop region
between ßE and ßF strands Pitteloud et.al. assert the mutation would result in the deformation of
a saltbridge formed between D225 and R203 (figure 4.3) (29). The x-ray structure of the D2
domain used to support this assertion places the D225 and R203 in close proximity.
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Figure 4.3 - Panel A is a stereo view of the x-ray structure of FGF receptor D2 (PDB – 1FQ9).
Highlighted is aspartic acid 225 and R203(15). Panel B is a stereo view of the NMR solution
structure (PDB – 1WVZ) of FGF receptor D2(25). Highlighted in this structure is the R203 and
aspartic acid 225.
However, FGFR2 D2 NMR solution structures provide a contradictory orientation of D225 and
R203. The D2 solution structure shows R203 in a vertical orientation placing it in close
proximity to W191. Additionally, D225 is rotated away from R203. Rotation of D225 places it in
a more solvent exposed orientation when compared to the x-ray structural models (25).

Structural analysis of W214G in the FGF receptor places the site of the mutation between
strands ßD – ßE (figure 4.4). W214 extends into a hydrophobic pocket formed by P180, A181,
P187, V233 and I 240. The size of the cavity formed allows for W214 to extend into the pocket
and stabilize the loop by hydrophobic interactions.
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Figure 4.4 - shows the stereo view of the xray structure of the D2 domain (PDB 1FQ9)(15). The
hydrogen bonds formed by strands ßD – ßE are shown in black. The residues forming a
hydrophobic pocked containg the W214 residue are include P180, A181, P187, M189, V233 and
I240.
The W214G mutation is expected to increase the the flexibility of the ßD – ßE strands and
decreae the stability of the D2 structure. Additionally, the heparin binding site extends across the
W214 location. As a result it is expected that the heparin binding interactions may be reduced as
a result of the increased flexibility caused by the W214G mutation.

The secondary structures of the mutants of D2 were assessed using far-UV CD. The far-UV
circular dichroism spectra are shown to overlay with the β-structure formed in D2 (wt). D2 wild
type shows a negative ellipticity band centered near 225 nm and a positive ellipticity peak near
205 nm. This profile is consistent with the  sheet formed by the nine -strands of the D2
domain (figure 4.5). The D2 G238D and D2 C179S mutations expected to show significant
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changes in the structure of the D2 domain, resulted in no significant changes in the CD spectra.
The CD spectra of the D2 D225H and W214G mutations were consistent with the wild type D2

CD spectra.

Figure 4.5 - Circular dichroism measurements from 200-250 nm suggests a ß-sheet structure for
each of the mutants. The spectrum overlay includes wild type (green), A172 (yellow), W214
(purple), D225H (red) and G238D (light blue) mutant of D2.
The D2 domain contains one tryptophan residue in a hydrophobic environment and two
tryptophan residues that are moderately exposed at the surface of the D2 domain. Using steadystate fluorescence the maximum fluorescence wavelength of the tryptophan residues in the D2
domain may indicate conformational changes in the domain. The fluorescence spectrum of wild
type D2 shows of a wavelength maximum at 339 nm (Figure 4.6). The wavelength maximum for
D2 C179S, D225H and D2 G238D exhibited a slight red shift to 342 nm. The D2 W214G
mutation exhibited the largest wavelength maximum shift. The D2 W214G fluorescence
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maximum shift is the result of the remaining two tryptophans, W156 and W191. The remaining
tryptophans are in buried environments resulting in a large blue shift for the maximum
wavelength of D2 W214G (λMax - 308 nm).

Figure 4.6 - Shows the steady-state fluorescence of each of the mutants of D2. The excitation
wavelength was 280nm. D2 W214G (green) shows the greatest shift in the maximum wavelength
(λmax-308 nm)
Differential scanning calorimetry (DSC) was used to determine changes in the melting
temperature (Tm) as a result the mutations in the D2 domain. The Tm values were determined for
each sample in the presence and absence of sucrose octasulphate (SOS). SOS is a heparin sulfate
proteoglycan used to mimic the binding of heparin to the D2 domain. The D2 (wt) melting
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temperature is 52.0  C and increased to 55.0 °C in the presence of SOS (figure 4.7). The melting
temperature for D2 D225H closely matched the Tm value of D2 (wt) at ~51°C and 52 °C in the
presence of SOS. This data suggests the aspartic acid to histidine mutation results in minor
decreases in the stability of the D2 domain. The greatest Tm value decrease resulted from the D2
C179S and G238D mutation. The D2 C179S Tm value was ~28 ºC without SOS (figure 4.8).
Additionally, the G238D mutation of D2 resulted in a significant destabilization of the D2
domain (Tm~34 ºC). This significant change in the structural stability was predicted by Plotnikov
et. al (17). The addition of SOS to the G238D mutant stabilized the D2 domain increasing the
melting temperature (Tm-40 ºC).

Figure 4.7 - Differential scanning calorimetry thermogram showing the thermal denaturation of
each of the mutants of D2. The mutants showing the greatest decrease in Tm is the G238D
(Tm~34 ºC) mutant of D2. Protein concentrations were 1-1.5 mg/ml in 10 mM phosphate buffer
containing 100 mM NaCl and 50 mM ammonium sulfate (pH – 6.5).
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Figure 4.8 - shows the differential scanning calorimetry thermogram of the KS and PS mutants
of D2 in the presence of SOS. The D2:SOS were added in a 1:1 molar ratios in 10 mM phosphate
buffer containing 100 mM NaCl and 50 mM ammonium sulfate (pH ~6.5).
The D2 W214G mutation also produced a moderate decrease in the Tm value ~45 ºC in
the absence of SOS and the melting temperature increased in the presence of SOS (Tm ~47 ºC) .
This data suggests the disulfide bond formed by C179-C230 plays a significant role in stabilizing
the D2 domain.

ANS (8-anilino-1-napthalene sulfonate) is a hydrophobic molecule that shows an increase
in fluorescence emission upon binding to hydrophobic surfaces on a protein. Mutants of D2 that
result in increased exposure of hydrophobic surfaces are expected show increased fluorescence
intensity when titrated with ANS. Figure 4.9 shows the relative fluorescence (RF) of each of the
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mutants of D2 when titrated with ANS. Titration of D2 C179S with ANS produced highest
relative fluorescence when compared to D2 (wt). The increase of fluorescence intensity suggests
a significant exposure of hydrophobic residues on the surface of the protein when compared to
D2 wild type (figure 4.9). W214G and G238D produced moderate increases in the RF upon
titration with ANS. The A172F and D225H mutants also showed minor increases in RF up
titration with ANS. These minor increases suggest only minor structural perturbations caused
due to these mutations. The relative increase in fluorescence also suggests an increased exposure
of hydrophobic residues as a result of the mutation.

Figure 4.9 – shows the ANS titration of each of the mutants of D2. This data suggests mutants
C179S, G238D and W214G posses significant exposure of hydrophobic residues.
Flexibility of the backbone: Limited trypsin digestion is a common method to evaluate
the flexibility of a protein. The D2 domain is abundant in both lysine (9) and arginine (6)
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residues, making trypsin an ideal proteolytic enzyme to probe the flexibility of wild type and
mutants of D2 (figure 4.10). The rate of the proteolytic digestion reflects the relative increased
backbone flexibility caused as a result of the mutation. Densitometric scan is representative of
the percentage of protein that remains uncleaved (Figure 4.11). Analysis of the SDS page of the
limited trypsin digestion of D2 D225H and D2 G238D suggest each of these mutants result in a

Figure 4.10 - Time dependent trypsin digestion of the wild type (A) and mutants of D2 include
C179S (E), A172F (B) W214G (C), D225H (D), and G238D (F). The D2 protein band is
indicated by the arrow. Lanes 1 through 10 represent the trypsin digestion products formed after
0 min. (lane 1), 2 min (lane 2), 4 min (lane 3), 6 min (lane 4), 8 min (lane 5), 10 min (lane 6), 15
min. (lane 7), 20 min (lane 8), 30 min (lane 9) and 40 min (lane 10)
significant increase in the backbone flexibility. Additionally the D2 W214G mutation also shows
a significantly-increased rate of proteolytic degradation. This data also suggests an increased
backbone flexibility resulting from this mutation. Additionally, the C179S mutant showed a
rapid cleavage rate suggesting a significant increase in the backbone flexibility of the protein.
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Figure 4.11 shows the densitometric plot of the limited-trypsin digestion of wild type (black)
and each of the disease mutations of D2.
Heparin and FGF receptor binding affinity: Isothermal titration calorimetry is a
technique used to measure the heat of binding events occurring during protein and ligand
interactions. Isothermogram also provides information on the binding affinity (KD) value
associated with the protein-ligand interactions. FGF-1 and sucrose octasulfate are both capable
of binding to the D2 domain. Sucrose octasulfate (SOS) is a heparin analog that binds to the D2
domain. Isothermogram characterizing the binding interactions of the wild type and mutants
with FGF-1 and SOS are shown in figure 4.12. The binding interactions of D2 W214G (51.35
μM ± 1.35), D2 D225H (13.0 μM) D2 G238D (47.14 ±2.01 μM) with SOS were significantly
reduced when compared to D2 wild type (0.97 μM ± 0.02). Additionally, the D2 C179S binding
interaction was most significantly inhibited of the mutants. The D2 C179S interaction was
reduced to Kd = 1.76 ±0.03 mM, suggesting there to be only minimal interactions formed with
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Figure 4.12 - shows the isothermal titration calorimetry data of each of wild type and the
mutants of D2 with SOS. The raw data was fitted to a two-site binding model. The lower panel
depicts the raw data of the μmol/s of heat release at various molar ratios of the lipid to protein.
The concentration of protein used was ~50 μM and the ligand was ~0.5 mM. 10mM phosphate
buffer containing 50 mM ammonium sulfate and 100 mM NaCl was used in each of the
titrations.
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SOS. The Pfeiffer syndrome (PS) mutation A172F of D2 showed a 7-fold decrease (KD) in the
interaction with heparin. The position of the A172F residue is not directly involved in the
binding of heparin. However, the binding pocket of heparin on the D2 domain stretches across
the β-strand wherein the A172F mutation site is located. Increased flexibility of residues around
A172 may result in higher flexibility of residues that interact with heparin. This result is
expected to reduce the signaling efficiency of the D2 domain as heparin contributes to the
stabilization of the 2: 2: 2 complex formed with FGF.
The isothermal titration calorimetry data of each of the D2 mutants with FGF was
also measured to determine changes in the binding interaction (fig. 4.13). FGF binds to wild type
D2 with a binding affinity 2.2 μM. The isothermograms shown in figure 4.12 suggests this
interaction is significantly decreased for each of the mutants of the D2 domain. The interaction
of C179S, W214G, D225H and G238D were reduced to insignificant binding. The PS mutation,
D2 A172F, showed a decreased binding interaction resulting in a moderate affinity for FGF-1
(KD ~91μM).

Monitoring the structural changes caused due to mutations in the D2 domain:
Superposition of the 1H-15N HSQC spectrum of C179S mutant overlaid on D2 (wt) shows
consistent with local structural changes caused at the mutation site. Crosspeaks show significant
1

H-15N chemical perturbations (>1ppm) and could not be unambiguously traced are highlighted

in blue.

This data suggests the disulfide bond formed between residues C179 and C230

significantly stabilize the D2 domain. The chemical perturbations of D2 C179S mapped onto the
structure of D2 shows a patch of perturbed residues near the c-terminal of the D2 domain.
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Figure 4.13 – Binding isotherm for the titration of D2 and the D2 mutants with FGF. The top
panel shows the raw data from the titration. The bottom panel shows the integrated data derived
from the raw data. Kallmann syndrome mutants of D2 (C179S, W214G, D225H and G238D)
exhibit typical isothermograms supporting a loss-of-binding with the FGF-1 ligand. The Pfeiffer
syndrome mutant (D2 A172F) showed a reduced interaction with FGF-1 (KD ~ 90 μM).
Hydrophobic c-terminal residues H166, A168, V170, L246 and V248 are required for
interactions with FGF-1. Residues H245, L246, D247 and V248 are significantly perturbed in the
1

H-15N HSQC of D2 C179S.
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Figure 4.16 shows the overlay of the 1H-15N HSQC spectra of the W214G mutant and
wild type D2 domain. Several 1H-15N crosspeaks in the HSQC spectrum of the W214G mutant
show significant chemical shift perturbations. Most of these correspond to residues located in the
β-strands βD and βE. Incidentally, several of these residues constitute the binding site for
heparin. Interestingly, some of the residues, which show significant 1H-15N chemical shift
perturbations are located in β-strand G and constitute the FGF binding interface.
Effect of mutations on the D2-SOS interaction: The 1H-15N HSQC of W214G in the presence of
SOS (fig. 4.16) shows a significant number of chemical shifts. The residues that show significant
chemical shift perturbations in the presence of SOS include K161, K176 and K208. However,
residues R210 and H213 that provide interactions to SOS in D2 (wt) are not visibly perturbed in
the W214G mutant. The lower affinity of the W214G mutant to SOS/heparin is plausibly caused
due to increased flexibility of the amino acid segment involved in SOS binding. Interestingly, the
lower binding of the W214G mutant is corroborated by ITC results.
Overlay of 1H-15N HSQC spectra of the D225H mutant on that of the D2 (wt) reveals
moderate perturbations in the D225H mutant (fig. 4.17). The chemical shift perturbation plot of
D225H reveals the most perturbed residues are located in the central and -terminal portions of
the D2 structure. The amino acid sequence spanning residues H245-L249 are significantly
perturbed and located in the FGF binding site of the D2 domain. These residues are located in the
βG strand, which is adjacent to the βD stand where the D225H mutation is located. Additionally,
residues in the amino acid segment Y207 – H213 are also prominently perturbed. These residues
occur in the flexible loop portion of D2. It appears that the D225H disrupts structural interactions
with the Y207 – H213 segment also.
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Superposition of 1H-15N HSQC spectra of D225H in the presence of SOS is shown in
figure 4.17. Minor perturbations occur at the N-terminal and central regions of the D2 structure.
The most perturbed residues include E160, K161, M162 and K176. The residues of D2 (wt) that
form the heparin-binding site include K208, K161, R210, H213 and K176. Residues K208, R210
and H213 are not significantly perturbed in the D2 domain. Additionally, the 1H-15N HSQC of
the D225H mutant shows moderate perturbations in the amino acid sequence Y207-H213.
Residues K208 and R210 are in the perturbed regions of D225H and contribute to the binding
site of heparin. The lack of chemical shifts during the 1H-15N HSQC titration of D225H using
SOS suggests the flexibility in this region may decreases the interaction of K208 and R210 with
SOS.
1

H-15N HSQC spectrum of G238D overlaid on wild type shows moderate perturbations

across the D2 domain (figure 4.19). The D2 G238D mutation occurs at the turn between strands
βF-βG strands. 1H-15N HSQC spectrum of the G238D mutation reveals the aspartic acid
mutation causes the most significant perturbations in the amino acid segment E236 –S239.
Residues in this segment are situated in close proximity to the G238 mutation site. Additionally,
moderately perturbed residues extend down the β-strand G. The βG- strand extends to the Cterminus of the D2 domain and constitutes a significant portion of the FGF binding site.
Therefore, perturbations in β-strand G likely causes local structural change that plausibly leads to
loss-of-binding to the ligand, FGF-1. The loss of FGF-1 binding is supported by the ITC data.
The G238D mutation prominent changes observed in the 1H-15N HSQC spectrum of G238D
suggest that native β-sandwich structure of the D2 domain is significantly disrupted.
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A.

B.

C.

Figure 4.14– Panel A shows an 1H-15N HSQC spectrum of D2 C179S (blue) mutant overlaid on
wild type D2 (red). Panel B The weighted average (of 1H and 15N) chemical-shift perturbation
[∆δ = √((δH)2 + 0.2(δ15N)2)] of residues in the C179S mutant compared to wild type D2. The
blue bars indicate crosspeaks in the C179S mutant of D2 that were significantly shifted and
could not be unambiguously identified. The horizontal line arbitrarily set at 0.1 ppm to highlight
residues which show significant chemical-shift perturbations. Panel C is a structural stereo-view
representation (pdb -1wvz) of the D2 domain highlighting the residues (blue) which show 1H-15N
chemical perturbation greater than 0.10 ppm. The site of the C179S mutation is colored in red.
Most perturbed residues resulting from the C179S mutation is located on β-strand F and the Cterminal beta strand G.
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A.

B.

C.

Figure 4.15– Panel A shows an 1H-15N HSQC spectrum of W214G (blue) mutant overlaid on
wild type D2 (red). Panel B The weighted average (of 1H and 15N) chemical-shift perturbation
[∆δ = √((δH)2 + 0.2(δ15N)2)] of residues in the W214G mutant compared to wild type D2. The
blue bars indicate crosspeaks in the W214G mutant of D2 that were significantly shifted and
could not be unambiguously identified. The horizontal line arbitrarily set at 0.1 ppm to highlight
residues, which show significant chemical-shift perturbations. Panel C is a structural stereo-view
representation (pdb -1wvz) of the D2 domain highlighting the residues (blue) which show 1H-15N
chemical perturbation greater than 0.10 ppm. The site of the W214G mutation is colored in red.
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A.

B.

C.

Figure 4.16 – Panel A shows the 1H-15N HSQC of D2 W214G + SOS (blue) overlaid on wild
type D2 W214G (red). Panel B The weighted average (of 1H and 15N) chemical-shift
perturbation [∆δ = √((δH)2 + 0.2(δ15N)2)] of residues in the W214G mutant of D2 compared to
wild type D2. The horizontal line arbitrarily set at 0.1 ppm to indicate the significant chemicalshift perturbations from those that show insignificant chemical perturbations (< 0.1 ppm). Panel
C is a structural stereo view representation (pdb -1wvz) of D2 highlighting the residues (blue)
with chemical perturbations greater than 0.1 ppm. The site of the W214G mutation is colored in
red. Many of the most perturbed residues resulting from the addition of SOS to the W214G
mutation of D2 is located at the residues (K161, H167, K176 and K208) responsible for
interacting with heparin on the wild type D2 domain.
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A.

B.

C.

Figure 4.17– Panel A shows an 1H-15N HSQC spectrum of D225H (blue) mutant overlaid on
wild type D2 (red). Panel B The weighted average (of 1H and 15N) chemical-shift perturbation
[∆δ = √((δH)2 + 0.2(δ15N)2)] of residues in the D225H mutant compared to wild type D2. The
blue bars indicate crosspeaks in the D225H mutant of D2 that were significantly shifted and
could not be unambiguously identified. The horizontal line arbitrarily set at 0.1 ppm to highlight
residues which show significant chemical-shift perturbations. Panel C is a structural stereo-view
representation (pdb -1wvz) of the D2 domain highlighting the residues (blue) which show 1H-15N
chemical perturbation greater than 0.10 ppm. The site of the D225H mutation is colored in red.
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A.

B.

C.

Figure 4.18 – Panel A shows the 1H-15N HSQC of D2 D225H + SOS (blue) overlaid on D225H
(red). Panel B The weighted average (of 1H and 15N) chemical-shift perturbation [∆δ = √((δH)2
+ 0.2(δ15N)2)] of residues in the D225H mutant with SOS compared to D225H. The horizontal
line arbitrarily set at 0.1 ppm to indicate the significant chemical-shift perturbations from those
that show insignificant chemical perturbations (< 0.1 ppm). Panel C is a structural stereo view
representation (pdb -1wvz) of D2 highlighting the residues (blue) with chemical perturbations
greater than 0.1 ppm. The site of the G238D mutation is colored in red. Many of the most
perturbed residues resulting from the D225H mutation of D2 is located on charged residues
(K161, K176, K208 and R210) responsible or interacting with SOS.
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A.

B.

C.

Figure 4.19– Panel A shows an 1H-15N HSQC spectrum of G238D (blue) mutant overlaid on
wild type D2 (red). Panel B The weighted average (of 1H and 15N) chemical-shift perturbation
[∆δ = √((δH)2 + 0.2(δ15N)2)] of residues in the G238D mutant compared to wild type D2. The
blue bars indicate crosspeaks in the G238D mutant of D2 that were significantly shifted and
could not be unambiguously identified. The horizontal line arbitrarily set at 0.1 ppm to highlight
residues which show significant chemical-shift perturbations. Panel C is a structural stereo-view
representation (pdb -1wvz) of the D2 domain highlighting the residues (blue) which show 1H-15N
chemical perturbation greater than 0.10 ppm. The site of the G238D mutation is colored in red.
Most perturbed residues resulting from the G238D mutation is located on β-strand F and the Cterminal beta strand G.
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Discussion
Kallmann’s syndrome may be associated numerous mutations that occur in the fibroblast
growth factor receptor 1. The FGFR1 loss-of-function theory has been postulated for mutations
in the receptor resulting in Kallmann’s syndrome. The mutations C179S, W214G, D225H and
G238D of D2 showed many different biophysical changes with some specific similarities.

C179S Mutation of D2 shows a significant change in the thermodynamic stability and it
interactions with heparin and FGF-1. Disruption of the disulfide bond formed by C179 and
C230 resulted in very significant changes in the stability of the D2 domain. The increased
flexibility upon disruption of the disulfide bond is most notably observed by the rapid cleavage
during the limited trypsin digestion and the low melting temperature (Tm ~28 ºC) determined
using differential scanning calorimetry. Despite these significant stability changes in the D2
structure the secondary structure appears not to be significantly changes. The circular dichroism
measurements of the C179S mutant of D2 suggest the mutation does not disrupt the native ßsheet structure observed in wild type D2. Additionally, this data is supported by the steady-state
fluorescence maximum wavelength that very closely matches the maximum wavelength of wild
type D2. The steady-state fluorescence suggests the only subtle structural changes result from the
C179S mutant. The isothermal titration calorimetry data supports ligand binding experiments
suggest the C179S mutant significantly hinders the interaction with both FGF-1 and heparin. The
isothermal titration thermogram supports negligible binding occurs between the C179S mutant of
D2 and heparin. Additionally, results of the isothermal titration calorimetry experiments support
that the ligand, FGF-1, binding is lost upon disruption of the disulfide bond. Although it is no
yet known if heparin is required for signaling, the D2 domain must interact with FGF for signal
transduction to occur. 1H-15N HSQC perturbation plots of the C179S mutant of D2 shows
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significant perturbations occurring at the c-terminal domain of ß-strand G. Additionally,
significant structural perturbations result across the middle portion of the D2 domain and
between the two ß-sheets that form the ß-sandwich of D2. This data plausibly supports a partial
opening of the D2 domain structure, separating the positively charged residues responsible for
the interaction with heparin. The perturbation of the central portion of the structure of the D2
domain as well as the perturbations of the C-terminal domain residues supports the loss-ofbinding of the D2 domain to heparin and FGF.

W214G mutation of D2 results in a significant reduction in its interaction with FGF. The
W214 is located between strands ßD – ßE in the structure of the D2 domain. In Addition, W214
has several residues which are located in lose vicitinity. The W214G mutation of D2 results in
very little changes in secondary structural as supported by the circular dichroism data. The
steady-state fluorescence shows a signficant shift in the wavelength maximum of 339 nm
observed in wild type D2 to 308 nm for the W214G mutant of D2. Although the maximum
wavelength shift is very large the shift may be a result of the removal of one of the three
tryptophans in D2. The decrease in the stability of the D2 domain as a result of the W214G
mutation can be inferred from the differential scanning calorimetry and limited trypsin digestion
experiments. The limited trypsin digestion experiment support an increase in the backbone
flexibility. The differential scanning calorimetry data support a moderate decrease in the stability
of the D2 domain (decrease in Tm ~ 5 ºC). The isothermogram shows the ligand binding
interactions of the W214G mutant results in a 25-fold decrease in the binding interaction with
heparin. Additionally, results of the isothermal titration calorimetry experiment of the W214G
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mutant of D2 with FGF-1 shows no significant binding interactions. 1H-15N chemical shift
perturbation plots of the W214G mutant shows significant perturbations in the heparin binding
region, surrounding the W214 as well as in the C-terminal region of the D2 molecule. The Cterminal domain is responsible for the hydrophobic interactions required for FGF binding.
Significant 1H-15N chemical shift perturbations in the c-terminal domain support the loss-ofbinding to FGF. The 1H-15N HSQC spectrum of W214G in the presence of SOS shows
prominent perturbations at residues K208, K176 and K161. However, significant perturbations
are not observed at residues R210 and H213 which are located in the heparin binding site of wild
type D2. The close proximity of these residues to the W214G mutation appears to weaken
interactions with heparin due to increase flexibility or moderate structural perturbations.

D225H mutant of D2 results in a significant decrease in affinity to FGF. D225H does not
cause significant change in the secondary structure. The circular dichroism and steady-state
fluorescence closely resemble the data acquired on wild type D2. The limited trypsin digestion
data suggests there is an increase in the backbone flexibility as a result of the D225H mutant of
D2. Although there is increased flexibility, differential scanning calorimetry experiments
suggests that the stability of the D225H mutant is comparable to wild type (∆Tm ~ 1 ºC). The
minor decrease in melting temperature of the D225H mutant of D2 does not support a significant
charge-charge interaction with R203. The isothermal titration calorimetry data suggests the
heparin binding affinity of D225H is decreased seven-fold compared to wild type D2.
Additionally the isothermal titration calorimetry indicate that binding interaction of the D225H
mutant of D2 with FGF-1 is completely inhibited. 1H-15N HSQC perturbation plot of the D225H
mutant of D2 compared to wild type suggests the mutation most signficantly perturbs the strand
ßD-ßE and at the C-terminal ßG strand. The hydrophobic FGF binding pocket formed by the ßA’
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and ßG strands. The loss of FGF binding by the D225H mutant of D2 is further supported by the
pertrubations occuring in the ßG strand.

G238D mutant of D2decreases the stability of the D2 domain and also reduces the binding
interaction with FGF: Pitteloud et al. previousy proposed that the lowered expression of the
G238S mutant of D2 results from the retention of the misfolded protein in the endoplasmic
reticulum(23). Circular dichroism and steady-state fluorescence structural studies suggest the ßsheet formation and the tertiary structure formation of the D2 domain are not due to the G238D
mutation. Limited trypsin digestion and ANS titration experiments suggest the D238G mutation
increases the backbone flexibility and the exposure of hydrophobic residues. Additionally, the
differential scanning calorimetry experiments suggest the mutation results in a significant
decrease in the stability of the D2 domain (∆Tm ~12 ºC). Isothermal titration calorimetry binding
experiments suggest the G238D mutant of D2 significantly reduces the interaction with heparin
by 25-fold. Additionally, ITC rsults suggests that the G238D mutantion causes a loss-of-binding
to FGF-1. 1H-15N HSQC chemical perturbation plots of the G238D mutation of D2 compared to
wild type suggest the most prominent structural peturbations occur at ß-strands F and G. The
perturbation of ß-strand G is centered at the FGF binding site on the D2 domainIt appears that
introduction of a negatively charged residue in the middle of β-strand F cuases a subtle
conformations changes which causes loss-of-binding to the lignad, FGF-1.
In conclusion, Kallmann syndrome mutations appear to induce critical local structural
changes at the heparin and FGF-1 binding sites, which in turn effect the FGF-signalling process.
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Pfeiffer syndrome mutations have been suggested to result in an increased signaling. A172F
mutation did not cause major changes in the stability of the D2 domain. Steady-state
fluorescence and circular dichroism data suggests that the A172F mutation retains most of the
native secondary structural interactions. Additionally, ANS titration and limited trypsin digestion
support a minor increase in the backbone flexibility and a greater exposure of the solventexposed non-polar surfaces. Interestingly the ligand binding interaction of the A172F mutant of
D2 and heparin is decreased 7-fold compared with the wild type. Heparin plays an important role
in the formation of the 2: 2: 2 ternary signaling complex composed of heparin: D2: FGF.
Destabilization of the interaction of the D2 domain with heparin would also be expected to
decrease the signaling of the receptor. Therefore, the results of this study are not consistent with
the gain-of-function proposed for the Pfeiffer syndrome mutations. Results of phosphorylation
assays of the A172F mutant of D2 reported by Ibrahami et. al showed that A172F mutation
enhances the tyrosine phosphorylation activity(26). These results suggest that pfeiffer mutation
cause increased activation of the FGF receptor.

Crystal structure of the D2-D3 homodimer of

FGFR shows that phenylalanine 172 in one monomeric unit of the D2 domain is involved in a
positive pi-stacking interaction with the complementary monomeric unit of the D2 domain. This
pi-stacking interaction acts to stabilize the dimeric structure of the FGF receptor and
consequently activates the FGF receptor even in the absence of the ligand, FGF (26).
Interestingly, ITC results obtained in this study do not support the hypothesis proposed by
Ibrahimi et al. ITC data suggests that the A172F mutant has ~45-fold lower affinity to FGF than
the wild type D2 domain. At the present juncture, the reasons for the observed disparity in the
results between this study and the published report is not clear. More detailed experiments
including tyrosine kinase assays comparing the autophosphorylation potency of the wild type and
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the A172F need to be performed in the future to understand the structure-function relationship of
the A172F Pfeiffer sydrome mutation.
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Structure and Functional Characterization of the R203C Mutation of D2 Commonly
Found in Breast Cancer

Abstract:
Fibroblast growth factor signaling mediates key cellular processes including cell
differentiation, mitogenesis, angiogenesis, neuron development and tumor growth. Mutations
found in the FGF receptor are associated with 5- 10% of human breast cancer cases (1-3).
Associated with these single nucleotide polymorphisms is the R203C mutation located in the
FGF receptor D2 domain (3). Using a variety of biophysical methods including multidimensional
NMR techniques we have shown that the R203C mutation in the D2 domain of FGFR2 decreases
the binding affinity between FGF and heparin. The loss-of-binding suggests a decrease in the
FGF induced activation of the R203C mutant of FGFR2.
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Introduction:

Cancerous cells are the combination of accumulated mutations and/or the overexpression
of proteins resulting in a malignancy (4). Characterization of malignant cells shows six
properties required to maintain tumor growth. Malignant cancer cells require: insensitivity of
anti-growth signals, self-sufficiency in growth signals, unlimited replicative potential,
uncontrolled cell proliferation, invasive metastasis of distant tissues and sustained supply to
nutrients and oxygen to promote growth (4). Cancer cells often have a significant number of
mutations that have accumulated over a prolonged period of time. Among the many cell growth
and regulatory genes, receptor tyrosine kinases are highlighted as protein accumulating
mutations that may result in changes in the cellular regulations (4).

Fibroblast growth factors (FGFs) are approximately 16 kDa heparin-binding proteins that
regulate key cellular processes such as angiogenesis, cell differentiation, morphogenesis, wound
healing and tumor growth (5, 6). FGF receptors consist of three extracellular ligand binding
domains (D1, D2, D3), a single transmembrane helix, and cytoplasmic tyrosine kinase domain.
Cell surface-bound HSPGs (heparan sulfate proteoglycans) that support dimerization or
oligomerization of FGFRs, which are activated during cellular processes (7). The D2 domain of
the FGF receptor is suggested to bind with both HSPGs and FGFs to form a ternary complex (8).
The dimerization complex of the FGFR has been well characterized by Platnikov et. al to include
FGF: FGFR: heparin in a 2: 2: 2 complex (8). Formation of the dimeric complex results in
autophosphorylation of seven-conserved cytoplasmic tyrosine residues (9). Subsequently,
autophosphorylation of the tyrosine residues recruits SH2 domain containing proteins allowing
for downstream signaling (10). FRS2 (FGF receptor substrate 2) is an SH2 domain containing
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protein that docks on the FGF receptor. Phosphorylation of FRS2 results in downstream
signaling and the activation of the MAPK (mitogen activated protein kinase) pathway mediating
proliferation, gene expression, differentiation, apoptosis and other cellular events (11). Fibroblast
growth factor receptors act as a point of activation for the MAPK pathway allowing for
mutations in the FGF receptor to result in disease states (12, 13).
The R203C mutant of the FGF receptor D2 domain has been indicated as a mutation
occurring in breast cancer tumors (14, 15). Fibroblast growth factor receptor 2 activated
proliferation and invasion of terminal end buds of the developing breast in mice (16). Single
nucleotide polymorphisms have been located in the FGFR2 gene and associated with the
increased risk of breast cancer (17). FGF receptor 2 shows increased expression in breast cancer
cell lines and in tumoral breast tissue (18, 19). SNPs associated with breast cancer commonly
occur in the intron 2 of the FGF receptor 2 (3). Additionally, the R203C mutant of the D2
domain has been determined to be associated with breast cancer (14, 15). The R248C (bladder
cancer), S249C (cervical cancer) and W290C (lung cancer) mutations result in ligandindependent

dimer

formations

(20-23).

The

autodimerization

and

subsequent

autophosphorylation result from intermolecular disulfide bonds formed between adjacent FGF
receptors (24-26). The cell takes up phosphorylated fgf receptors so the protein may be recycled
through proteolytic degredation in the lysosome following endocytosis (27). The enhanced
stability of the interdisulfide bond inhibits protein degradation in the lysosome (28). The added
lifetime of the phosphorylated FGF receptor is postulated to result in reinsertion into the
membrane to continue signaling (29, 30). In this study we use multidimensional nmr and
biophysical techniques to characterize the structural properties of the R203C mutant of the D2
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domain. Additionally, mutants R203E, R203L and R203K were assessed to determine the wild
type interactions formed by R203.

Materials and Methods
Mutagenesis, overexpression and protein purification: The R203 mutations on the FGFR2 D2
domain (residues, 145-255) was generated using the Quikchange kit (Stratagene). The mutation
was confirmed by automated DNA sequencing. Wild type and the R203 mutants of the D2
domain were overexpressed and purified from Escherichia coli [BL21 (pLysS) strain] according
to the method reported previously [18].
Far UV Circular Dichrosim (CD): Data on the wild type D2 and the R203 mutants were
acquired using a Jasco J-710 spectropolarimeter. Protein solutions (90-100 μM) were prepared in
10 mM phosphate buffer containing 100 mM NaCl and 50 mM ammonium sulfate (pH 6.5).
Wavelength scans were set to 250-190 nm. CD measurements were made using a 0.1 cm
pathlength cuvette. A total of 10 scans were averaged for each sample.
Fluorescence spectroscopy: Measurements were made using a Hitachi F-2500 fluorimeter.
Fluorescence measurements were made using a 1.0 cm path length and the concentration of each
protein sample was adjusted to ~50 µM. Excitation wavelength was set to 280 nm and intrinsic
tryptophan emission was measured from 300 nm to 450 nm. 8-anilino-1-napthalene sulphonate
(ANS) binding experiments were performed using an excitation wavelength of 390 nm and an
emission wavelength range of 450 nm- 600 nm. In the ANS titration experiments, protein
samples were titrated with 3 μl aliquots of 10 mM ANS in 10 mM phosphate buffer containing
100 mM NaCl and 50 mM ammonium sulfate at pH 6.5.
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Differential scanning calorimetry (DSC): DSC measurements were performed using a N-DSC
III calorimeter. Protein concentration used was in the range of 1.0 – 1.5 mg/ml in 10 mM
phosphate buffer containing 50 mM ammonium sulfate and 100 mM NaCl (pH ~6.5). The scan
rate was set to 1 °C/min and protein samples were heated from 10 °C - 90°C. Data were analyzed
using the CpCalc software provided by the manufacturer.
Isothermal titration caolorimetry (ITC): ITC measurements were performed using Microcal VP
titration calorimeter (Northhampton, MA, USA). Titrations consisted of 5-10 μl injections of 0.5
mM sucrose octasulfate (a heparin analog) delivered into 0.050 mM concentration of the D2
domain. Injections were delayed for 1.5 - 3.5 minutes to allow the titration peak to return to the
baseline prior to additional injections. The titrations curves were analyzed using Origin software
supplied by Microcal Inc.
NMR spectroscopy: 1H-15N HSQC data were acquired at 298 °K using 0.5 mM

15

N labeled D2

domain in 10 mM phosphate buffer (prepared in 95% H2O + 5 %D2O, pH 6.5) containing 50
mM ammonium sulfate and 100 mM NaCl. All experiments were performed using Bruker
Avance 700 MHz and 500 MHz NMR spectrometers equipped with cryoprobes. NMR data were
referenced to the 1H resonance frequency of 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS).

Results:
Structure and sequence analysis shows R203 to be conserved in FGF receptors 1 – 4. Analysis of
the 3D x-ray and NMR structure of the D2 domain reveal differences in the structural
interactions involving R203. The x-ray crystal structure shows the side chain of R203 is directed
towards the interior of the structure. The side chain non-covalent interactions formed by R203
includes a charge-charge interaction with aspartic acid 225, which is located on beta strand F.
210

Figure 5.1 shows the x-ray crystal stereo view structure of the D2 domain (pdb – 1ev2) (31).
Aspartic acid 225 is oriented towards R203 allowing for an electrostatic interaction between side
chains.

The distance of the interacting side chains of D225 and R203 are less than 5 Å. However, the
NMR solution structure of the D2 domain does not place R203 – D225 within close spatial
proximity to allow for an electrostatic interaction. The distance of separation between the side
chain residues of R203 and D225 is approximately 12 Å(32). The distance of separation is too
large for an effective electrostatic interaction. Additionally, the mutational studies support the
formation of a cation-π interaction with W191 in the absence of a ligand (Supporting information
in chapter 1).
The R203 mutation of D2 only causes subtle tertiary changes in the D2 domain. Intrinsic
fluorescence serves as a useful and sensitive spectral probe to monitor tertiary structural changes
in proteins. D2 domain has three well-conserved tryptophan residues that are partially buried in
the interior of the protein. The microenvironment of the tryptophan is obvious from the emission
maximum of the wild type D2 domain at 339 nm (fig. 5.3). The emission maximum of the R203
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Figure 5.2 Stereoview of the NMR solution structure of the D2 domain (pdb: 1wvz)
(32).Labeled residues include R203, W191 and D225. Side chain of aspartic acid 225 shown to
be projected towards the exterior of the D2 structure. Additionally, the sidechain of R203 is
displaced vertically to be in close proximity to the indole ring of W191.
mutant of D2 is a modest red shift by 2-3 nm (λmax – 339 nm – 342 nm) indicating the mutation
causes only a subtle tertiary conformational change (fig. 5.3). The red shift in wavelength
maximum suggests an increased solvent exposure of the tryptophan indole rings of tryptophan
residues found in the D2 domain.

Tertiary structural changes: ANS is a popular fluorescent hydrophobic dye, which is commonly
used to monitor solvent-exposed hydrophobic surfaces in proteins. ANS in the presence of the
wild type D2 domain shows weak emission with an emission maxima centered at 510 nm (Fig.
5.4). However, the emission maximum of the dye shows a red shift of 4 nm (508 nm to 512 nm)
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Figure 5.3 The steady-state fluorescence spectrum of the R203 mutants of the D2 domain. The
wavelength of maximum emission of the mutants of D2 show a slight red shift when compared
to that of wild type D2.
with a concomitant 6-fold increase in the emission intensity. These fluorescence characteristics
suggest that substitution of R203 with lysine and glutamic acid results in significant increase in
the solvent exposure of hydrophobic residues.
The R203C and R203L mutants of D2 showed significant increases in relative
fluorescence intensity (at 510 nm), but were considerably less than the glutamic acid and lysine
mutants of D2. These results suggest that a mutation at the R203 site results in the moderate to
significant solvent exposure of hydrophobic residues.

213

Figure 5.4 ANS titration of the mutants of D2 and wild type. The maximum fluorescence of
R203E and R203K mutants of D2 is eight fold than that of the wild type. The relative
fluorescence measurements were recorded at 510 nm.

The R203 mutation significantly decreases the thermodynamic stability and increase in the
conformational flexibility of the FGF receptor domain: Differential scanning calorimetry is a
versatile technique to directly probe the themodynamic stability of proteins. Melting
thermograms of wild type D2 show a relatively sharp melting transition (Tm~52 ºC), from the
folded to the unfolded state. (Fig. 5.5) These results suggest that mutations R203E (Tm ~39 °C),
R203L (Tm ~42 °C) and R203K (Tm ~42 °C) result in a significant decrease in the stability of the
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Figure 5.5 shows an overlay of the differential scanning calorimetry thermograms of the wild
type and R203 mutants of the D2 domain.
D2 domain. Additionally, the R203C mutant of D2 showed the greatest decrease in melting
temperature (Tm ~34 °C). The thermogram suggests the R203C mutant of D2 is moderately less
stable that the other R203 mutants.
Limited trypsin digestion is a useful technique to obtain information on the backbone
flexibility of proteins. Lysine and arginine residues located in flexible and solvent-accessible
regions of the protein are more susceptible to trypsin cleavage than when these residues are
located in the rigid portions of protein molecules. Therefore, differences in the susceptibility to
trypsin cleavage can be expected to provide valuable information on the changes in the backbone
flexibility due to conformational changes in the protein.
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Figure 5.6 Panel A - shows the 15% SDS PAGE of the limited-trypsin digestion of the wild type
and R203E, R203C and R203K mutants of D2 after 0, 2, 4, 6, 8, 10, 15, 20, 30 and 40 min.). The
arrow indicates the protein band. Panel B – shows the densitometric scan of the limited-trypsin
digestion of the mutants of D2 and wild type.

D2 domain of FGFR2 contains

nine lysine residues and six arginine residues. The wild type

protein is rapidly cleaved by trypsin in the initial few minutes of initiation of the cleavage
reaction (Fig. 5.6). About 45% of the D2 parent band (MW~13.7 kDa) corresponding to the
intact D2 domain remains after 10 minutes of cleavage. (Fig. 5.6) Interestingly, more than 80%
of the R203K mutant protein and 90% of the R203C and R203E mutants are cleaved within the
same time period (of 5 minutes; Fig. 5.6). These results in conjunction with those obtained using
the far UV CD and fluorescence data suggest that the lysine substitution at position 203 only
causes subtle conformational changes.
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Figure 5.7 – Far UV circular dichroism spectral overlay for the R203 mutants of D2. Wild-type
D2 (black) and mutants R203C (red), R203E (grey), R203K (green) and R203L (blue).
Heparin is polydisperse and therefore, it is challenging to obtain an accurate estimation of
their binding to proteins. In this context, we used sucrose octasulfate (SOS) to represent heparin
binding interactions with the D2 domain. In addition, sucrose octasulfate, unlike heparin, is
monodisperse and can be obtained in the pure form (>99% purity). SOS has been demonstrated
to be a good structural and functional mimic of heparin.
Isothermogram representing the binding of wild type D2 domain to SOS is sigmoidal and
the binding consistent (Kd) characterizing the SOS-D2 domain interactions is ~ 2.2 uM (Fig.
S5.1). SOS and D2 domain bind to each other in a 1:1 stoichiometry. Interestingly, results of the
ITC experiments performed under similar conditions show that the binding affinity of the R203C
mutant for SOS is about 15 times lower than that of the wild type D2 protein. The lowering of
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the heparin binding is unexpected because the mutation site (R203) is remote from the heparinbinding site in the D2 domain. However, R203 is shown to stabilize the interaction with heparin
through the cation-π interaction formed with W191.

Figure 5.8 – Binding isotherm representing the titration of D2 and D2 R203C, R203L and
R203E with SOS. The top panel shows the raw data from the titration. The bottom panel shows
the integrated data derived from the raw data.
The ITC experiments show the R203L and R203E mutations in D2 significantly reduce
the binding interaction with SOS (fig. 5.8). The binding affinity of the R203L mutant for SOS is
about 15 times lower than that of the wild type D2 protein. Additionally, the binding affinity of
the R203E mutant of D2 for SOS is about 25 times lower than the interaction with D2 wild type.
Wild type D2 domain binds strongly (Kd~ 2 µM) to FGF-1. The binding affinity (Kd) of
the isolated D2 domain is in the same range as that of the intact extracellular portion of FGFR
suggesting that D2 domain is critical for FGF binding (fig. 5.9). Interestingly, the R203C mutant
of the D2 domains exhibits a 45-fold decrease in affinity for FGF-1. These results suggest that
loss-of-function from the R203C mutation.
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Figure 5.9 - Binding isotherm representing the titration of the wild type and the R203C mutant
of the D2 domain with FGF. The top panel shows the raw data of the titration. The bottom panel
shows the integrated data derived from the raw data. Panels A and B show the titration of the
wild type and the R203C mutant of the D2 domain with FGF.

Loss of ligand binding affinity occurs due to subtle conformational changes to the D2 domain:
Two-dimensional 1H-15N HSQC spectrum is a finger-print of the backbone conformation of
proteins. Each crosspeak in the 1H-15N HSQC spectrum represents an amino acid in a particular
backbone conformation of the protein. In this context, we monitored the backbone
conformational changes induced due to the breast cancer related R203C mutant of D2. The 1H15

N HSQC spectrum overlaid on wild type shows a significant amount of overlay. However, the

amino acids in close proximity to the R203C mutation site show significant perturbations. The
1

H-15N chemical shift perturbation plot (fig 5.9) shows the most significant perturbations

occurring on the C-terminal β-strand G (which is the binding site of FGF). Additionally, the
structural view of the 3D structure of the D2 domain of FGFR shows that residues such as F198,
K193 and K196 are also significantly perturbed in the R203C mutant. Loss-of-binding of the
cation-π interactions formed by R203 and W191 appears to result in the increased flexibility of
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A.

Amino Acid
Figure 5.10 - Panel A shows an overlay of 1H-15N HSQC spectra of D2 R203C (blue) on that of
wild type D2 (red). Panel B The weighted average (of 1H and 15N) chemical-shift perturbation
[∆δ = √((δH)2 + 0.2(δ15N)2)] of residues in the R203C mutant of D2 compared to wild type D2.
The horizontal line arbitrarily set at 0.1 ppm to indicate the significant chemical-shift
perturbations from those that show insignificant chemical perturbations (< 0.1 ppm). Panel C:
3D structural depiction of D2 (pdb -1wvz) highlighting the residues (blue) with chemical
perturbations greater than 0.1 ppm. The site of the R203C mutation is colored in red. Most of
the most perturbed residues resulting from the R203C mutation of D2 is located on the Cterminal beta strand G.
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the βC’ – βC strands. In addition, the 1H-15N chemical shift perturbation plot of the R203C
mutant also suggests that residues in β-strands F and G are also significantly perturbed due to the
R203C mutation.

Conclusion
Results of the biophysical experiments on the R203C mutant do not fully support R203C
is a gain-of-function mutation. The R203 side-chain extends into a hydrophobic pocket
consisting of residues in β-strand C and C’. The side-chain of arginine 203 form a cation-π
interaction with the indole group of W191 (chapter 2). The R203E, R203L and R203K mutants
showed a consistent decrease in the melting temperature (Tm ~9 –ll °C).

The mutations at the

203 site produce similar structural changes. All the R203 mutants appear to lack the cation-π
interaction observed between R203 and W191. Results of ANS titration reveal that both R203E
and R203K enhanced solvent –exposed non-polar surfaces. Introduction of negatively charged
glutamic acid residue plausibly disrupts the potential cation-π with W191. Similarly, introduction
of a lysine side-chain (R203K) may not be favorable for the formation of a cation-π interaction
with W191. It appears that disruption of the native R203-W191 interaction in the R203E and
R203K mutants slightly opens-up the 3D structure of the D2 domain. In this context the
increased solvent exposed non-polar surfaces results in R203E and R203K is supported by the
ANS binding data. The R203L and R203C mutations also showed a significant decrease in
melting temperature. ANS titration also suggests that there are significant solvent-exposed nonpolar surfaces due to conformational change induced by these mutations (R203L and R203C).
The conformational change induced in the R203L and R203C appears to be likely due to the
disruption of the native cation-π interaction.
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The isothermal titration calorimetry binding study shows a 15-25-fold decrease in the
interaction of the mutants with heparin. This significant decrease in binding affinity to heparin
suggests the heparin interaction partially is stabilized by the r203 cation-π interaction.
Additionally, results from the isothermal titration calormetry characterization of the binding of
R203C with FGF-1 show a 45-fold decrease in the binding affinity. The significant loss-ofinteraction with both FGF-1 and heparin is further supported by the 1H-15N HSQC chemical shift
perturbation data obtained on he R203C mutant. The R203C mutation resulted in significantly
perturbed residues across both the heparin and FGF-1 binding regions. The location of the
perturbed residues corroborates the significant decrease in binding affinity of both heparin and
FGF-1.
Most cancers linked to the FGF receptor are believed to be due to enhanced activation of
the receptor-ligand (FGF) binding. Although, R203C mutation is associated with breast cancer
the same mechanism does not appear to be valid for breast cancer associated with the R203C
mutation in the D2 domain of the FGF receptor. The results obtained with the R203C mutants
clearly show that the mutants exhibit significantly decreased binding affinity to both heparin and
FGF. Based on these results, it is reasonable to assume that the R203C mutation linked breast
cancer is not due to enhanced FGF-mediated cell signaling events. Alternatively, it appears that
substitution of arginine with cysteine at position 203 (R203C) induces dimerization of adjacently
placed FGF receptors through formation of intermolecular disulfide bonds involving cysteine at
position 203. Dimerization of FGF receptor causes its activation, triggering a sequence of down
stream events resulting in unregulated proliferation of cells. However, in the absence of
experimental evidence supporting dimerization of the FGF receptor through intermolecular
disulfide bond formation, this mechanism should be considered as largely speculative.

222

Literature Cited
1. Gelsi-Boyer, V., B. Orsetti, N. Cervera, P. Finetti, F. Sircoulomb, C. Rouge, L. Lasorsa, A.
Letessier, C. Ginestier, F. Monville, S. Esteyries, J. Adelaide, B. Esterni, C. Henry, S.P.
Ethier, F. Bibeau, M.J. Mozziconacci, E. Charafe-Jauffret, J. Jacquemier, F. Bertucci, D.
Birnbaum, C. Theillet and M. Chaffanet 2005. Comprehensive profiling of 8p11-12
amplification in breast cancer. Mol. Cancer. Res. 3, 655-667.
2. Chin, K., S. DeVries, J. Fridlyand, P.T. Spellman, R. Roydasgupta, W.L. Kuo, A. Lapuk,
R.M. Neve, Z. Qian, T. Ryder, F. Chen, H. Feiler, T. Tokuyasu, C. Kingsley, S. Dairkee, Z.
Meng, K. Chew, D. Pinkel, A. Jain, B.M. Ljung, L. Esserman, D.G. Albertson, F.M.
Waldman and J.W. Gray 2006. Genomic and transcriptional aberrations linked to breast
cancer pathophysiologies. Cancer. Cell. 10, 529-541.
3. Letessier, A., F. Sircoulomb, C. Ginestier, N. Cervera, F. Monville, V. Gelsi-Boyer, B.
Esterni, J. Geneix, P. Finetti, C. Zemmour, P. Viens, E. Charafe-Jauffret, J. Jacquemier, D.
Birnbaum and M. Chaffanet 2006. Frequency, prognostic impact, and subtype association of
8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer.
6, 245.
4. Hanahan, D. and R.A. Weinberg 2000. The hallmarks of cancer. Cell. 100, 57-70.
5. Colvin, J.S., Green, R.P., Schmahl, J., Capel, B. and Ornitz, D.M. 2001. Male-to-female sex
reversal in mice lacking fibroblast growth factor 9. Cell. 104, 875-889.
6. Feldman, B, Poueymirou, W., Papaioannou, V.E., DeChiara, T.M. and Goldfarb, M. 1995.
Requirement of FGF-4 for postimplantation mouse development. Science. 267, 246-249.
7. Thornton, S.C., Mueller, S.N. and Levine, E.M. 1983. Human endothelial cells: Use of heparin
in cloning and long-term serial cultivation. Science. 222, 623-625.
8. Plotnikov, A. N., J. Schlessinger, S.R. Hubbard and M. Mohammadi 1999. Structural basis for
FGF receptor dimerization and activation. Cell. 98, 641-650.
9. Mohammadi, M., I. Dikic, A. Sorokin, W.H. Burgess, M. Jaye and J. Schlessinger 1996.
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1
and elucidation of their importance in receptor activation and signal transduction. Mol. Cell.
Biol. 16, 977-989.
10. Martinez, N., C.A. Garcia-Dominguez, B. Domingo, J.L. Oliva, N. Zarich, A. Sanchez, S.
Gutierrez-Eisman, J. Llopis and J.M. Rojas 2007. Sprouty2 binds Grb2 at two different
proline-rich regions, and the mechanism of ERK inhibition is independent of this
interaction. Cell. Signal. 19, 2277-2285.
11. Beenken, A. and M. Mohammadi 2009. The FGF family: Biology, pathophysiology and
therapy. Nat. Rev. Drug Discov. 8, 235-253.

223

12. Turner, N. and R. Grose 2010. Fibroblast growth factor signalling: From development to
cancer. Nat. Rev. Cancer. 10, 116-129.
13. Wesche, J., K. Haglund and E.M. Haugsten 2011. Fibroblast growth factors and their
receptors in cancer. Biochem. J. 437, 199-213.
14. Stephens, P., S. Edkins, H. Davies, C. Greenman, C. Cox, C. Hunter, G. Bignell, J. Teague,
R. Smith, C. Stevens, S. O'Meara, A. Parker, P. Tarpey, T. Avis, A. Barthorpe, L.
Brackenbury, G. Buck, A. Butler, J. Clements, J. Cole, E. Dicks, K. Edwards, S. Forbes, M.
Gorton, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, D. Jones, V. Kosmidou, R.
Laman, R. Lugg, A. Menzies, J. Perry, R. Petty, K. Raine, R. Shepherd, A. Small, H.
Solomon, Y. Stephens, C. Tofts, J. Varian, A. Webb, S. West, S. Widaa, A. Yates, F.
Brasseur, C.S. Cooper, A.M. Flanagan, A. Green, M. Knowles, S.Y. Leung, L.H. Looijenga,
B. Malkowicz, M.A. Pierotti, B. Teh, S.T. Yuen, A.G. Nicholson, S. Lakhani, D.F. Easton,
B.L. Weber, M.R. Stratton, P.A. Futreal and R. Wooster 2005. A screen of the complete
protein kinase gene family identifies diverse patterns of somatic mutations in human breast
cancer. Nat. Genet. 37, 590-592.
15. Easton, D. F., K.A. Pooley, A.M. Dunning, P.D. Pharoah, D. Thompson, D.G. Ballinger, J.P.
Struewing, J. Morrison, H. Field, R. Luben, N. Wareham, S. Ahmed, C.S. Healey, R.
Bowman, SEARCH collaborators, K.B. Meyer, C.A. Haiman, L.K. Kolonel, B.E.
Henderson, L. Le Marchand, P. Brennan, S. Sangrajrang, V. Gaborieau, F. Odefrey, C.Y.
Shen, P.E. Wu, H.C. Wang, D. Eccles, D.G. Evans, J. Peto, O. Fletcher, N. Johnson, S. Seal,
M.R. Stratton, N. Rahman, G. Chenevix-Trench, S.E. Bojesen, B.G. Nordestgaard, C.K.
Axelsson, M. Garcia-Closas, L. Brinton, S. Chanock, J. Lissowska, B. Peplonska, H.
Nevanlinna, R. Fagerholm, H. Eerola, D. Kang, K.Y. Yoo, D.Y. Noh, S.H. Ahn, D.J.
Hunter, S.E. Hankinson, D.G. Cox, P. Hall, S. Wedren, J. Liu, Y.L. Low, N. Bogdanova, P.
Schurmann, T. Dork, R.A. Tollenaar, C.E. Jacobi, P. Devilee, J.G. Klijn, A.J. Sigurdson,
M.M. Doody, B.H. Alexander, J. Zhang, A. Cox, I.W. Brock, G. MacPherson, M.W. Reed,
F.J. Couch, E.L. Goode, J.E. Olson, H. Meijers-Heijboer, A. van den Ouweland, A.
Uitterlinden, F. Rivadeneira, R.L. Milne, G. Ribas, A. Gonzalez-Neira, J. Benitez, J.L.
Hopper, M. McCredie, M. Southey, G.G. Giles, C. Schroen, C. Justenhoven, H. Brauch, U.
Hamann, Y.D. Ko, A.B. Spurdle, J. Beesley, X. Chen, kConFab, AOCS Management
Group, A. Mannermaa, V.M. Kosma, V. Kataja, J. Hartikainen, N.E. Day, D.R. Cox and
B.A. Ponder 2007. Genome-wide association study identifies novel breast cancer
susceptibility loci. Nature. 447, 1087-1093.
16. Lu, P., A.J. Ewald, G.R. Martin and Z. Werb 2008. Genetic mosaic analysis reveals FGF
receptor 2 function in terminal end buds during mammary gland branching morphogenesis.
Dev. Biol. 321, 77-87.
17. Hunter, D. J., P. Kraft, K.B. Jacobs, D.G. Cox, M. Yeager, S.E. Hankinson, S. Wacholder, Z.
Wang, R. Welch, A. Hutchinson, J. Wang, K. Yu, N. Chatterjee, N. Orr, W.C. Willett, G.A.
Colditz, R.G. Ziegler, C.D. Berg, S.S. Buys, C.A. McCarty, H.S. Feigelson, E.E. Calle, M.J.
Thun, R.B. Hayes, M. Tucker, D.S. Gerhard, J.F. Fraumeni Jr, R.N. Hoover, G. Thomas and

224

S.J. Chanock 2007. A genome-wide association study identifies alleles in FGFR2 associated
with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874.
18. Tannheimer, S. L., A. Rehemtulla and S.P. Ethier 2000. Characterization of fibroblast growth
factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast
Cancer Res. 2, 311-320.
19. Adnane, J., P. Gaudray, C.A. Dionne, G. Crumley, M. Jaye, J. Schlessinger, P. Jeanteur, D.
Birnbaum and C. Theillet 1991. BEK and FLG, two receptors to members of the FGF
family, are amplified in subsets of human breast cancers. Oncogene. 6, 659-663.
20. Munro, N. P. and M.A. Knowles 2003. Fibroblast growth factors and their receptors in
transitional cell carcinoma. J. Urol. 169, 675-682.
21. Black, P. C. and C.P. Dinney 2008. Growth factors and receptors as prognostic markers in
urothelial carcinoma. Curr. Urol. Rep. 9, 55-61.
22. Lajeunie, E., S. Heuertz, V. El Ghouzzi, J. Martinovic, D. Renier, M. Le Merrer and J.
Bonaventure 2006. Mutation screening in patients with syndromic craniosynostoses
indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of
pfeiffer syndrome. Eur. J. Hum. Genet. 14, 289-298.
23. Robertson, S. C., A.N. Meyer, K.C. Hart, B.D. Galvin, M.K. Webster and D.J. Donoghue
1998. Activating mutations in the extracellular domain of the fibroblast growth factor
receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like
domain. Proc. Natl. Acad. Sci. U. S. A. 95, 4567-4572.
24. Dutt, A., H.B. Salvesen, T.H. Chen, A.H. Ramos, R.C. Onofrio, C. Hatton, R. Nicoletti, W.
Winckler, R. Grewal, M. Hanna, N. Wyhs, L. Ziaugra, D.J. Richter, J. Trovik, I.B. Engelsen,
I.M. Stefansson, T. Fennell, K. Cibulskis, M.C. Zody, L.A. Akslen, S. Gabriel, K.K. Wong,
W.R. Sellers, M. Meyerson and H. Greulich 2008. Drug-sensitive FGFR2 mutations in
endometrial carcinoma. Proc. Natl. Acad. Sci. U. S. A. 105, 8713-8717.
25. Pandith, A. A., Z.A. Shah and M.A. Siddiqi 2013. Oncogenic role of fibroblast growth factor
receptor 3 in tumorigenesis of urinary bladder cancer. Urol. Oncol. 31, 398-406.
26. Pollock, P. M., M.G. Gartside, L.C. Dejeza, M.A. Powell, M.A. Mallon, H. Davies, M.
Mohammadi, P.A. Futreal, M.R. Stratton, J.M. Trent and P.J. Goodfellow 2007. Frequent
activating FGFR2 mutations in endometrial carcinomas parallel germline mutations
associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 26, 71587162.

27. Haugsten, E. M., J. Malecki, S.M. Bjorklund, S. Olsnes and J. Wesche 2008. Ubiquitination
of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its
endocytosis. Mol. Biol. Cell. 19, 3390-3403.
225

28. Belleudi, F., L. Leone, M. Maggio and M.R. Torrisi 2009. Hrs regulates the endocytic sorting
of the fibroblast growth factor receptor 2b. Exp. Cell Res. 315, 2181-2191.
29. Haugsten, E. M., J. Malecki, S.M. Bjorklund, S. Olsnes and J. Wesche 2008. Ubiquitination
of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its
endocytosis. Mol. Biol. Cell. 19, 3390-3403.
30. Haugsten, E. M., V. Sorensen, A. Brech, S. Olsnes and J. Wesche 2005. Different
intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. J.
Cell. Sci. 118, 3869-3881.
31. Schlessinger, J., A.N. Plotnikov, O.A. Ibrahimi, A.V. Eliseenkova, B.K. Yeh, A. Yayon, R.J.
Linhardt and M. Mohammadi 2000. Crystal structure of a ternary FGF-FGFR-heparin
complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell. 6,
743-750.
32. Hung, K. W., T.K. Kumar, Y.H. Chi, I.M. Chiu and C. Yu 2004. Molecular cloning,
overexpression, and characterization of the ligand-binding D2 domain of fibroblast growth
factor receptor. Biochem. Biophys. Res. Commun. 317, 253-258.

226

Fluorescence Quenching Mechanism of Fibroblast Growth Factor 1

227

Introduction: Tryptophan serves as a critical chromophore in biological fluorescence
experiments that is sensitive to the surrounding electrostatic environment (1, 2). Tryptophan
residues exhibit the largest fluorescence quantum yields of the naturally occurring amino acids.
These characteristics allow tryptophan to be an excellent intrinsic fluorophore to probe the
structural properties of proteins. The properties of a protein commonly monitored by
fluorescence include folding/unfolding, ligand binding and external quencher accessibility. (3-6)
Many fluorescence experiments take advantage of changes in fluorescence intensity, wavelength
maximum (λmax), fluorescence lifetimes, band shape and energy transfers. Tryptophan
fluorescence experiments monitoring wavelength maximum and fluorescence intensity
experiments are particularly sensitive to the microenvironment of the tryptophan residue. The
fluorescence sensitivity of tryptophan to the local electrostatic environment is further explained
by the Stokes shift.
The Stokes-shift is the difference between the wavelength of the maximal absorbance
and maximal emission. Changes in the Stokes-shift are attributed to the rearrangement of dipoles
around the tryptophan residue upon excitation of the tryptophan. Both the solvent and the protein
environment may influence the Stokes-shift (7). Fluorescence intensity is determined by the
excited state electron density shift from the indole ring to the electron acceptor (adjacent side
chain, solvent or amide backbone).(8) The electron build-up on the tryptophan residues have two
excited states, 1La and 1Lb. The 1La is the fluorescing state of tryptophan residues. (9) Rapidly
quenched tryptophan residues results in a decrease in the electron build-up on the benzene ring
of tryptophan. As a result, it is possible for proteins to contain a tryptophan but display
diminished tryptophan fluorescence. Tryptophan fluorescence quenching mechanisms are critical
towards understanding the fluorescence intensity of proteins.
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Tryptophan fluorescence quenching may occur through both radiative and non-radiative
mechanisms. The non-radiative contributors towards fluorescence quenching include intersystem
crossing, solvent quenching, excited-state proton transfer and excited-state electron transfer (1016). The quenching mechanism of buried tryptophan residues in proteins is commonly achieved
though excited-state electron transfer. Tryptophan excited-state electron transfer occurs by the
excited-state electron transferring from the indole ring to the benzene ring on the tryptophan
residue (17). The electron may then be transferred to an electron acceptor of nearby amino acid
side chain or to the peptide backbone of the protein. The side chains capable of quenching an
excited state electron from tryptophan residues are limited. The electron-accepting amino acids
include cysteine (oxidized and reduced), thiolate (deprotonated cysteine), histidine , glutamic
acid (pH <5), aspartic acid (pH <5), N-acylated glutamine and asparagine (18). The efficiency of
the excited-state electron transfer may be enhanced by the angle of the tryptophan relative to the
electron acceptor as well as charges surrounding the tryptophan side chain (18).
The angle of the tryptophan relative to the electron acceptor changes the energy required
for the electron transfer. The rotameric state of the tryptophan depends on the χ1 and χ2 angle.
Rotation about χ1 and χ2 provide nondegenerate states of electron transfer (19). Tryptophan
residues confined to angles decreasing the efficiency of electron transfer may lead to a build-up
of excited-state electron population allowing for increased fluorescence. Likewise, tryptophan
side chains allowed to freely rotate will be capable of allowing for efficient electron transfer to
an electron acceptor. The second contributing factor to fluorescence lifetime is the charge
distribution of amino acid side chains surrounding the tryptophan side chain.
Following excitation of the tryptophan residue, the excited-state electron is transferred
from the indole ringe to the benzene ring of tryptophan. The excited-state electrons that do not
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undergo radiative relaxation will be transferred to a side chain or to the peptide backbone of the
protein. The rate of excited-state electron transfer is accelerated by placement of positively
charged near the benzene ring of tryptophan (20-22). Accelerating the transfer of the excitedstate electron to an electron acceptor prevents the build-up of excited-state electrons on the
benzene ring of tryptophan side chains (23). Decreasing this population of excited state electrons
decreases the fluorescence lifetime. Conversely, placement of negatively charged residues
surrounding the benzene portion of a tryptophan can act to inhibit the transfer of the excited-state
electrons to an electron acceptor (24).
This rare phenomenon of highly decreased tryptophan fluorescence may further be
masked by tyrosine fluorescence (25-28). The occurrence of this phenomenon is observed in
proteins azurin and fgf-1. Azurin has been highly studied, but the FGF-1 fluorescence has been
given little explanation for the observed fluorescence.
Fibroblast growth factor-1 (fgf-1) is a critical tyrosine kinase binding protein that
regulates key cellular functions. Interactions of fgf-1 with the fibroblast growth factor receptor
domain D2 act to regulate angiogenesis, cell differentiation, neurogenesis and tumor growth. In
addition to the FGF receptor the fgf protein binds to heparin. The heparin-fgf-1 interaction is
believed to inhibit proteolysis of the fgf-1 protein on the cell surface. The fgf-1 protein is a 16kDa protein composed of 12 antiparallel β-sheets in trefoil architecture. The fgf-1 protein
sequence contains a single tryptophan residue and 8 tyrosine residues. The fluorescence
spectrum of fgf-1 shows a wavelength maximum of ~307 nm.
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Materials and Methods
Mutagenesis, overexpression and protein purification: The mutations on the FGF domain
(residues, 145-255) were generated using the Quikchange kit (Stratagene). The mutation was
confirmed by automated DNA sequencing. Wild type and the FGF mutants were overexpressed
and purified from Escherichia coli [BL21 (pLys) strain] according to the method reported
previously.
Far UV Circular Dichrosim (CD): data on the wild type FGF and the FGF mutants were
acquired using a Jasco J-710 spectropolarimeter. Protein solutions (90-100 uM) were prepared in
10 mM phosphate buffer containing 100 mM NaCl and 50 mM ammonium sulfate (pH 6.5).
Wavelength scans were set to 250-190 nm. CD measurements were made using a 0.1 cm
pathlength cuvette. A total of 10 scans were averaged for each sample.
Fluorescence spectroscopy: measurements were made using a Hitachi F-2500 fluorimeter.
Fluorescence measurements were made using a 1.0 cm pathlength and the concentration of each
protein sample was adjusted to ~50 µM. Excitation wavelength was set to 280 nm and intrinsic
tryptophan emission was measured from 300 nm to 450 nm. 8-anilino-1-napthalene sulphonate
(ANS) binding experiments were performed using an excitation wavelength of 390 nm and an
emission wavelength range of 450 nm- 600 nm. In the ANS titration experiments, protein
samples were titrated with 3 μl aliquots of 10 mM ANS in 10 mM phosphate buffer containing
100 mM NaCl and 50 mM ammonium sulfate at pH 6.5.
Differential scanning calorimetry (DSC): DSC measurements were performed using a DASM1M calorimeter. Protein concentration used was in the range of 1.0 – 1.5 mg/ml in 10 mM
phosphate buffer containing 50 mM ammonium sulfate and 100 mM NaCl (pH ~6.5). The scan
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rate was set to 1 °C/min and protein samples were heated from 10 °C - 90°C. Data were analyzed
using the Origin DSC software provided by Microcal Inc.
Isothermal titration caolorimetry (ITC): ITC measurements were performed using Microcal VP
titration calorimeter (Northhampton, MA, USA). Titrations consisted of 5-10 μl injections of 0.5
mM sucrose octasulfate (a heparin analog) delivered into 0.050 mM concentration of the D2
domain. Injections were delayed for 3.5 minutes to allow the titration peak to return to the
baseline prior to additional injections. The titrations curves were analyzed using Origin software
supplied by Microcal Inc.
NMR spectroscopy: 1H-15N HSQC data were acquired at 298 °K using 0.5 mM

15

N labeled D2

domain in 10 mM phosphate buffer (prepared in 95% H2O + 5 %D2O, pH 6.5) containing 50
mM ammonium sulfate and 100 mM NaCl. All experiments were performed using Bruker
Avance 700 MHz and 500 MHz NMR spectrometers equipped with cryoprobes. NMR data were
referenced to the 1H resonance frequency of 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS).

Results
The secondary structure of the FGF-1 domain is a 16 kDa protein that includes 12 antiparallel βstrands arranged in a trefoil fold to form a β-barrel structure (fig. 6.1). Tryptophan 121 is the
only tryptophan residue in the FGF-1 structure. This tryptophan is highly conserved in the fgfs.
Tryptophan 121 is placed between β-strand 9 and β-strand 10. The fgf-1 residues responsible for
binding to heparin include Arg-20, Asn-94, Asn-116, Gln-117, Val-122, Lys-126, Gln-131, Lys132 and Thr-133.
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Figure 6.1 – Stereo-view of the Ribbon structure of FGF-1. Tryptophan 121 is located centrally
between residues P135 and H117.

Nearby strong quenching residue His-117 is placed ~3.7 Å in distance from Trp-122. Histidine is
considered to be a strong fluorescent quenching side-chain. Additionally, placed adjacent to His117 is Lys-120 that is only 4 Å in distance from the tryptophan side-chain. Positively charged
residues placed near a fluorescent quenching side chain aids in the excited state electron transfer
from the tryptophan to an electron-accepting residue. Additionally, the backbone of proline 135
is located ~3.75 Å in distance from the side chain of tryptophan. Proline 135 has been cited by
Blaber et. al. as the quenching residue of tryptophan 121 (29) Located directly behind Pro-135 is
Arg-133 that could aid in the excited-state electron transfer from the tryptophan residue to the
backbone of Pro-135. This diversity of fluorescence quenching side chain residues surrounding
Trp-122 has required the synthesis of multiple mutants to determine characterize the quenching
mechanism. In order to address this multiple fluorescence quenching mechanisms we have made
FGF H117A, K120E, W122Y, FGF P135G and FGF H117A/P135G.
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The steady-state fluorescence the mutants His-117 and P135G of fgf-1 contribute to the
quenching mechanism in fgf-1. The steady-state fluorescence of wild type fgf-1 shows a
wavelength maximum at ~306 nm. The fluorescence spectrum of wild-type fgf-1 in 6M urea
results in a wavelength maximum of 346 nm. The shift in the maximum wavelength suggests the
tryptophan side chain is efficiently quenched in the native fgf-1 structure. The W122L mutant of
fgf-1 shows a wavelength maximum of ~306 nm. This spectrum suggests the fluorescence
observed in fgf-1 is tyrosine fluorescence and not tryptophan fluorescence.

Figure 6.2 – steady-state fluorescence of fgf-1 (wt), fgf W122L and fgf-1 (3M urea). The steady
state fluorescence excitation wavelength was 280nm and emission was measured from 300nm –
450nm.
The steady-state fluorescence spectrum (fig. 2) includes the mutants of fgf-1. The K120E mutant
of fgf-1 exhibits only a slight red shift in the wavelength maximum. Mutants H117A and P135G
both result in a wavelength maximum (~306 nm). However, the H117A and P135G mutants
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show a moderate shoulder peak occurring near 350 nm. The H117A/P135G mutant shows the
same maximum wavelength maximum as wild type fgf-1. However, the H117A/P135G mutant
shows a significant shoulder peak occurring at ~347 nm. The increased fluorescence occurring at
347 nm suggests an increase in tryptophan fluorescence.

However, the fluorescence spectrum of the H117A/P135G mutant of fgf-1 does not reflect the
denatured (3m urea) sample fluorescence. This data suggests the tryptophan fluorescence
quenching mechanism is partially impaired by the H117A/P135G mutant.

Figure 6.3 – Steady-state fluorescence spectrum of each of the mutants of fgf-1. The excitation
wavelength was 280nm.
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The H117A and P135G mutations do not significantly perturb the backbone conformations of
FGF-1. Far UV CD spectrum of the wild type FGF-1 domain shows a strongly negative
ellipticity band around 220 nm and a positive ellipticity peak centered at 205 nm. These features
of the far UV CD spectrum are typical of β-sheets arranged in a β-sandwich structure.
Interestingly, the far UV CD spectrum of the H117A and P135G mutants superimpose quite well
with that of the wild type of the D2 domain suggesting that these mutations causes no or minimal
perturbations in the secondary structure of the receptor domain. Maintaining a wild type fold is
critical to understand the fluorescence quenching mechanism of FGF-1. The CD suggests the
secondary structure of the FGF-1 mutants is not significantly changed from that of wild type.

The FGF-1 mutations do not significantly affect the stability of the FGF domain: Differential
scanning calorimetry is a versatile technique that can be used to directly probe the
thermodynamic stability of proteins. The melting thermogram of the wild type FGF domain
shows a relatively sharp melting transition (Tm~48 ºC), from the folded to the unfolded state. The
Tm value does not appear to significantly change due to the W122L, P135G or K120E mutations.
The W122L mutation resulted a decrease in Tm value by 5 °C. The K120E and P135G mutants of
FGF-1 resulted in a decrease of Tm value of ~3°C compared to wild type. These results suggest
that the thermodynamic stability of the receptor domain is not significantly affected by the
mutation.
Differential scanning calorimetry was also used to determine the thermodynamic
properties of the each of the FGF-1 mutants in the presence of SOS. The ligand SOS binds to
wild type FGF-1 with relatively high affinity (KD ~ 7 μM). The DSC experiment of wild type
FGF in the presence of SOS reflects the high affinity interaction through increased Tm values.
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The change in the wild type Tm value with the addition of SOS results in an increase by 6 °C.
Each of the mutants of FGF-1 resulted in similar increases in Tm value when compared to wild
type. However, the K120E mutant of FGF-1 resulted in a 10 °C increase in Tm value in the
presence of SOS. This data suggests the K120E mutant of FGF-1 may stabilize the interactions
formed with SOS. Additionally, the W122L and P135G DSC Tm values suggest the mutations do
not significantly change the interactions with heparin.

Figure 6.4 – Shows the dsc scans for each of the mutants of FGF-1. The mutants W122L
(Tm~37°C) and W122Y (Tm~45°C) show a significant decrease in stability when compared to
FGF-1 wild-type (Tm~49°C).
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FGF-1 mutation decreases heparin-binding affinity: FGF-1 is forms binding interactions with
both fibroblast growth factor receptor and heparin. Isothermal titration calorimetry (ITC)
experiments were performed to examine the effect(s) of the mutation of FGF on the affinities
with heparin. ITC is a useful technique to characterize the protein/ligand interactions as it relies
on the heat evolved or absorbed during binding interactions.
Heparin is polydisperse and therefore it is challenging to obtain an accurate estimation of
its binding affinity to proteins. In this context, we used polyanionic sucrose octasulfate (SOS) to
represent heparin binding interactions with the FGF domain. Sucrose octasulfate, unlike heparin,
is monodisperse and can be obtained in the pure form (>99% purity). In addition, SOS has been
demonstrated to be a good structural and functional mimic for heparin.

Isothermogram representing the binding of wild type FGF domain to SOS is sigmoidal
and the binding constant (Kd) characterizing the SOS-D2 domain interaction(s) is ~ 7.2 µM.
SOS and D2 domain bind to each other in a 1:1 stoichiometry. Interestingly, each of the mutants
show very similar binding affinities when compared to wild type interactions with SOS. This
data suggests each of the mutation in the FGF-1 domain do not significantly change the binding
interactions with SOS.

Structural changes resulting from the mutants in the FGF-1 domain: The changes in
fluorescence quenching were further investigated for any structural changes resulting from the
mutations. In this context, multidimensional NMR experiments were performed to assess the
plausible structural changes induced by the FGF mutations and also understand the consequences
of the conformational change. Two-dimensional 1H-15N HSQC spectrum is a finger-print of the
backbone conformation of proteins. Each crosspeak in the 1H-15N HSQC spectrum represents an
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Figure 6.5 – Panel A shows the 1H-15N HSQC of FGF K119E (blue) overlaid on FGF-1 wild
type (red). Panel B shows the chemical shift perturbation of the K119E residues shown in the 1H15
N HSQC. Panel C highlights the most perturbed residues (green) on the structure of FGF-1.
The tryptophan (red) and mutated residue K119E are shown on the structure of FGF-1.
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amino acid in a particular backbone conformation of the protein. In this context, we monitored
the backbone conformational changes induced due to the FGF-1 mutations using the 1H-15N
chemical shift perturbation () observed in the HSQC spectra.
The 1H-15N HSQC of the K119E mutant of FGF-1 overlays the peaks of FGF-1 wild type
very closely. The minor perturbations increase in residues neighboring the K119E mutation. The
location of the most perturbed residues (K114, K132, G134 and V45) are located near K119, but
they are not in the hydrophobic pocket containing W121. This data suggests the structural
perturbations resulting from the K119E mutant do not change the chemical environment directly
surrounding W121.
The 1H-15N HSQC of the P135G mutant of FGF-1 is shown in figure X. Panel B shown
in figure x highlights the most perturbed residues in the 1H-15N HSQC. The most perturbed
residues encircle the P135G residue. Interestingly, of the six most perturbed residues (T83, G84,
L87, K132, G134 and T137) only the side chain of L87 is located in the hydrophobic pocket
containing tryptophan 121. However, residues K132 – T137 are all located on the same β-sheet.
The location of this β-sheet encloses the hydrophobic box that contains W121. The P135G
mutant may significantly reduce the turn induced by proline 135. The current tryptophan
fluorescence quenching mechanism suggests this the backbone of P135 acts as the excited-state
electron acceptor. Perturbations in this β-sheet may then act to reduce the quenching efficiency.
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Figure 6.6 – Panel A shows the 1H-15N HSQC of FGF P135G (red) overlaid on FGF-1 wild type
(blue). Panel B shows the chemical shift perturbation of the mutant FGF-1 residues shown in the
1
H-15N HSQC. Panel C highlights the most perturbed residues (green) on the structure of FGF-1.
The tryptophan (blue) and mutated residue P135G (green) are shown on the structure of FGF-1.
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Conclusion
Tryptophan fluorescence of FGF-1 has previously studied, but the efficient fluorescence
quenching mechanism is not yet fully understood (29). The first mechanism proposed by Blaber
et al. suggests the backbone of P135 acts to quench tryptophan 121 (29). Site-directed
mutagenesis suggests mutant K119E may not significantly contribute to the steady-state
fluorescence quenching mechanism. However, mutant FGF H117A, P135G and H117A/P135G
show minor and significant changes in the steady-state fluorescence intensity of tryptophan 121.
FGF P135 residue caused minor increases in the steady-state fluorescence of tryptophan.
Thermal denaturation experiments suggest only minor decreases in protein stability result from
the P135G mutant of FGF-1. 1H-15N HSQC perturbation plots show perturbations centered at the
residues adjacent to P135. 1H-15N HSQC suggests no significant perturbation of the W121
residues as a result of the P135G mutant. The stead-state fluorescence of the P135G mutant
shows a minor increase in relative fluorescence occurring near 350 nm. However, the observed
tryptophan steady-state fluorescence is significantly less than the tryptophan fluorescence of
denatured FGF-1. This suggests the fluorescence quenching mechanism of tryptophan 121 may
be supplemented by additional tryptophan quenching mechanisms. Similar to P135, the H117
side chain is in close distance to W121 and capable of quenching tryptophan.
The H117 residue of FGF-1 is approximately 4 Å from the side chain of tryptophan 121.
The close proximity of H117 to W121 makes it a possible quenching agent of tryptophan. The
differential scanning calorimetry results suggest the H117A mutation does not significantly
change the stability of the FGF domain. This data suggests the H117A mutant does not
significantly destabilize the structure of the FGF domain. The H117A mutant of FGF-1 resulted
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in minor increases in the fluorescence of W121. Steady-state fluorescence data of the H117A
mutant shows a minor increase in relative fluorescence near a wavelength of 350 nm. This minor
increase in relative fluorescence suggests the H117A mutant causes minor changes in the
efficiency of the tryptophan fluorescence quenching mechanism. The role of both H117A and
P135G mutants of FGF-1 were determined by introducing the double mutant into FGF.
The H117A/P135G mutant of FGF-1 shows the greatest increase in tryptophan
fluorescence. This data suggests the H117 and P135 residues both play a role in the fluorescence
quenching mechanism of FGF-1. However, unlike the single mutants the H117A/P135G mutant
significantly destabilized the FGF-1 domain. The fluorescence denaturation curve suggests the
Tm value is reduced from 48 °C (FGF-1 wt) to ~29 °C for the H117A/P135G mutant of FGF. The
denaturation data suggests that in each of these residues plays a significant role in the stability of
the FGF domain. The distance of H117 (4 Å) and P135 (3.75 Å) from W121 and might allow for
efficient electron transfer from the tryptophan to the backbone of P135 or side chain of H117.
Additionally, the position of R134 and K119 are surrounding the electron acceptors (H117 and
P135). The position of R134 and K119 introduces an electrostatic environment surrounding
W121 that may stabilize excited-state electron transfer from the benzene ring to the electron
acceptors. However, single mutation at the K119 residue is not sufficient to increase tryptophan
intensity. This may be the result of electron transfer to P135 backbone or to H117.
Mutants P135G and H117A of FGF-1 are implicated in this study as significant
contributors of the quenching of tryptophan 121. Two considerations that remain to be answered
by this study include the structural changes of FGF-1 that result from each of the mutants and the
degree of contribution residues H117A and P135G make toward the quenching of W121. The
individual role of amino acids H117 and P135 may contribute toward the quenching of W121
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has not been fully elucidated by this study. Steady-state fluorescence may indicate significant
changes in the quenching of W121. However, the contribution H117A, P135G and
H117A/P135G make individually to the overall rate of electron transfer (Ket) (quenching of
W121) requires time resolved fluorescence experiments. Time-resolved fluorescence will
provide the fluorescence lifetimes and the rate of electron transfer for each of the mutants.
Additionally, structural information of the FGF-1 protein is required to determine if significant
structural changes occurred as a result of the mutations.
The steady-state fluorescence of tryptophan side chains is sensitive to the chemical
environment. Mutations made at amino acids known to make significant contributions to the
backbone angles (Proline) are also most likely to result in structural changes in the secondary
and possibly tertiary structure of FGF-1. Tryptophan-121 sits within a hydrophobic pocket
allowing for efficient fluorescence quenching. Mutations resulting in significant structural
perturbations of FGF-1 may expose W121 to the solvent and/or remove it from the native
tryptophan-quenching environment. The structural changes resulting from a mutation might
decrease fluorescence-quenching contributions of amino acids that were not mutated. As a result,
the fluorescence quenching changes of FGF-1 that result from mutations must be shown not to
significantly change the structure of FGF-1.
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Summary Conclusions:
Signaling through the fibroblast growth factor receptor is important for maintaining
normal cellular functions and development. Critical receptor functions are modulated through
non-covalent forces within the FGF receptor and between the D2 domain and FGF or heparin.
Non-covalent interactions supported by disease-linked mutation sites emphasize the role many
amino acids contribute to the function of the FGF receptor. The disease-linked mutation sites
alter cation-π bonds, hydrogen bonds and hydrophobic binding sites.
R203 and W191 are engaged in a cation-π bond that contributes to the stability of the D2
domain. The R203C mutation within the D2 domain is also linked to breast cancer. We have
shown mutations R203E, R203L, R203K and R203C in the D2 domain act to destabilize the
FGF receptor. Additionally, point at the aromatic pi residue W191A and double mutation
W191L/R203L result in decreased stability of the D2 domain. The biophysical characteristics of
the W191 mutants reflect the results of the R203 mutations. These results support the NMR
solutions structure (pdb: 1wvz). The electrostatic interaction formed by R203 and D225,
supported by all published x-ray structures, within the D2 domain was not supported through
site-directed mutagenesis data. Our site-directed mutagenesis and multidimensional NMR
experiments provide a clarified structural picture of the D2 domain in solution and a new
understanding for the contributions cation-π bonds provide to the structure of the FGF receptor.
The non-covalent interactions of Kallmann Syndrome-linked mutants of the FGF receptor
are important for the stability and ligand-binding sites of the D2 domain. Differential scanning
calorimetry, limited trypsin digestion and ANS titration experiments of KS-linked mutants
C179S, W214G, and G238D show a significant decrease in stability and increased backbone
flexibility. The increase flexibility of the D2 domain results in a significant decrease in binding
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with both heparin and FGF-1. Mutants C179S, W214G and G238D show a loss-of-binding with
FGF-1. KS-linked mutants A168S and D225H do no result in a significant decrease in stability
of the D2 domain. The A168S and D225H mutants result in a moderate decrease in binding
interaction with heparin and a loss-of-binding with FGF-1. The A168 residue forms critical
hydrophobic interactions with FGF-1. The A168S mutation replaces a critical hydrophobic
residue with a hydrophilic residue, causing a loss-of-binding with FGF-1. 1H-15N HSQC suggests
the D225H mutant of D2 causes moderate perturbations at the C-terminus. The C-terminus of D2
forms a critical hydrophobic pocket required for FGF-1 binding. The D225H mutant results in a
loss-of-binding with FGF-1.
The critical non-covalent interactions formed by cation and aromatic-π residues as well
KS-linked mutation sites are critical for the ligand-binding and normal function of the FGF
receptor.
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